Li-Tzong Chen, M.D., Ph.D.
National Institute of Cancer Research, National Health Research Institutes
2F, No. 367, Sheng-Li Road, 70456 Tainan, Taiwan
Phone No.: 06-2083422 ext. 65110
Fax No.: 06-2083427
E-mail: leochen@nhri.org.tw
Web: http://english.nhri.org.tw/facprofile2007/
Education
1975 ~ 1982
1992 ~ 2001
M.D., Kaohsiung Medical University, Kaohsiung, Taiwan
Ph.D., Post-graduate School, Kaohsiung Medical University, Taiwan
Research and Professional Positions Held in Chronological Sequence
1981 ~1982
Internship, Kaohsiung Medical University Hospital (KMUH)
1982 ~ 1984
Military service
1984 ~ 1987
Resident, Department of Internal Medicine, KMUH
1987 ~ 1988
Chief Resident, Division of Gastroenterology, Department of Internal
Medicine, KMUH
1988 ~
Attending Physician, Division of Gastroenterology, Depepartment of
Internal Medicine, KMUH
1988 ~ 1990
Fellowship of Medical Oncology Training Program Institute of Biomedical
Science, Academia Sinica, Taipei
1992 ~ 2005
Lecturer of Internal Medicine, Kaohsiung Medical University
1995 ~
Attending Physician, National Institute of Cancer Research, National Health
Research Institutes (NHRI), Taiwan
2002 ~ 2006
Associate Investigator, National Institute of Cancer Research, NHRI
2006 ~
Investigator, National Institute of Cancer Research, NHRI
2008 ~
Deputy Director, National Institute of Cancer Research, NHRI
Research Interests
As a qualified gastroenterologist and oncologist, personal research interests focus on the development of
innovative strategies for treating prevalent digestive tract cancers through clinical trials and translational
research.
Major Honors and Awards
1999
Excellence Award of Poster Presentation, 4th Annual Joined Meeting of
Taiwan Oncology Societies. “Dose-escalation study of weekly docetaxel
plus cisplatin and 24-hour infusion of high-dose fluorouracil and leucovorin
in advanced gastric cancer”
2000
Excellence Award of Poster Presentation, 5th Annual Joined Meeting of
Taiwan Oncology Societies. “Anti-Helicobater pylori therapy in early-stage
low-grade & high-grade MALT lymphoma of the stomach”
2001
Excellence Award of Poster Presentation, 6th Annual Joined Meeting of
Taiwan Oncology Societies. “Phase I and PK study of thalidomide in
advanced hepatocellular carcinoma”
2003
Clinical Research Award, the 8th Annual Meeting of Joint Taiwan Oncology
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
Biographical Sketch Format Page
2004
2005
2005
2006
2007
2007
2008
2008
2009
2009
2009
Societies. “Medical therapy in gastrointestinal cancer: the NHRI studies”,
Taipei, Taiwan
Invited speaker for the International Symposium “The Cooperation in Asia”,
“The review and prospect of gastric cancer chemotherapy in Taiwan” in the
76th Annual Meeting of Japanese Gastric Cancer Association (JGCA),
Yonago, Japan, March 4-6.
Invited speaker for the “Controversy of adjuvant chemotherapy for gastric
cancer” in the 18th Asian-Pacific Cancer Conference (APCC), Seoul, Korea,
September 7-9
Outstanding Research Award, Kaohisung Medical University
Outstanding Research Award, Kaohsiung Medicial University
“What is the optimal combination in treating advanced CRC?” in the 2007
World Congress on GI Cancer: Asian Perspectives at Beijing, China,
August 24th-25th
Invited speaker for the “Clinical trials for hepatobiliary and pancreatic in
Taiwan” in the 1st Taiwan and Japan Oncology Joint Meeting, Kanazawa,
Japan, 12th-13th October
Invited speaker for the “The current status of chemotherapy for gastric
cancer in Taiwan” in the Asian Symposium “Can we collaboration for
gastric cancer chemotherapy in Asia” in the 46th Annual Meeting of Japan
Society of Clinical Oncology (JSCO), Nagoya, Japan, 1st November
Invited speaker for the “The 1st-line imatinib in GIST: relationship to
genotype and response – a retrospective study from Taiwan” in the 2008
Korean GIST multidiscipline symposium, Seoul, Korea, November 29th
Invited speaker for the “Molecular targeted therapy in hepatocellular
carcinoma” in the Consensus Workshop at the Asian Oncology Summit,
Singapore, April 5th
Invited speaker for the “Investigator-initiated Phase III trials for
hepatocellular carcinoma in Taiwan” in Asian Symposium-II: “Phase III
studies in Asia” in the 47th Annual Meeting of Japan Society of Clinical
Oncology (JSCO), Yokohama, Japan, 23rd October
Invited speaker for the “Eradication of Helicobacter pylori in the treatment
of GI diffuse large B cell lymphoma” in the Annual Meeting of European
Gastrointestinal Lymphoma Society, London, United Kingdom, 20th
November
2010
2010
2010
Invited speaker for the “Molecular basis for resistance to tyrosin kinase
inhibitors in double mutated c-kit protein: a computer assisted virtual
modeling study” in the 7th International Symposium for Chinese Medicinal
Chemists (ISCMC-2010) Kaohsiung, Taiwan, 3rd February
Invited speaker for the “New drug development for pancreatic cancer in
Taiwan” in the 4th Annual Conference in Japan for Asian New Drug
Development (DIA), Tokyo, Japan, 13th-14th, April
2010 National Health Research Institute Research Achievement Award
Page 2
Principal Investigator/Program Director (Last,
First, Middle):
Shen, Chia-Ning (沈家寧)
NAME
POSITION TITLE
CHIA-NING SHEN
Assistant Research Fellow/Assistant Professor
COMMONS USER NAME
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and
include postdoctoral training.)
DEGREE
INSTITUTION AND LOCATION
YEAR(s)
FIELD OF STUDY
(if applicable)
University of Bath, Bath, U.K.
PhD
2002
Developmental Biology
National Yang-Ming University, Taipei, Taiwan
MSc
1997
Biotechnology
National Sun Yet-San University, Kaoushiung,
BSc
1992
Marine Biotechnology
Taiwan
Page 3
A. Positions
Academic Appointments:
2004-present
2005-present
2009-present
2005-present
2004
2002-2004
1999-2001
1997-1998
1994-1995
Assistant Research Fellow, Genomics Research Center, Academia Sinica, Taipei, Taiwan
Adjunct Assistant Professor, Department of Biotechnology & Laboratory Science in
Medicine, National Yang-Ming University, Taiwan
Adjunct Assistant Professor, Institute of Clinical Medicine, Taipei Medical University,
Taiwan
Joint appointed Assistant Professor, Institute of Bioscience and Biotechnology, National
Taiwan Ocean University, Taiwan
Visiting scholar, Dept. of Pathology and Dept. of Microbiology & Immunology, University of
Texas Medical Branch, Galveston, Texas, United States
Research officer, Centre for Regenerative Medicine, University of Bath, United Kingdom
Practical demonstrator on the course of Developmental Biology & Molecular Biology, Dept.
of Biology & Biochemistry, University of Bath, United Kingdom
Research assistant, Institute of Biotechnology in Medicine, National Yang-Ming University,
Taiwan
Research assistant, Department of Education and Medical Research, Taipei Veterans General
Hospital, Taiwan
Reviewers &Other Positions:
Journal Reviewer:
2005-present Reviewer of Journal of Biomedical Sciences
2006-present Reviewer of Differentiation
2007-present Reviewer of Vaccine
2010-present Reviewer of Acta Pharmacologica Sinica
2010-present Reviewer of Molecular Nutrition and Food Research
2010-present Reviewer of Biomacromolecules
Grant Reviewer:
2005-present Grant Reviewer, Department of Life Science, National Science Council
2005-present Grant Reviewer, Department of Health, Taipei City Government
Others:
2010
Member of grant rebuttal committee, Section of basic medical research, Department of Life
Science, National Science Council
2007-present Member of advisory committee, Stem cells and Tissue Engineering Center,
Ministry of Education Advisory Office
2007--present Member of Director Board. Taiwan Society for Stem Cell Research
2007-2008
Chair of the management committee, Academia Sinica Residential Complex for New Blood
2005-2007
Secretary in General, Taiwan Society for Stem Cell Research
B. Honors and Awards:
2007
2002
2001
2001
2000
2000
1999-2002
Travel award of Japan Society for the promotion of science for attending NPG Nature
Asia-Pacific network meeting
Scholarship of International Society of Differentiation for attending the 12th International
Conference of ISD at Lyon, France
Travel Grant of British Society of Developmental Biology for attending 2001 Wellcome Trust
Advanced Courses at Cambridge, England)
Entrant of January 2001 Santa Cruz Investigator Award
Scholarship of International Federation of Cell Biology for attending International Congress on
Differentiation, Cell and Molecular Biology at Gold Coast, Australia
Travel Grant of British Society of Developmental Biology for attending BSDB 2000 Spring
Symposium at Coventry, England
Overseas Research Student Award, Committee of vice-chancellors and principals of the
Page 1
Universities of the United Kingdom
C. Publications (in chronological order).
(Cited by 645 according to Scopus database).
1.
2.
3.
4.
Choo K.B., C.M. Chen, C.N. Shen, L.C. Au. 1995 Resolution of uncertainties in restriction maps of
cosmid clones by "sequencing stitching". (IF=3.287, 19/67 in Biochemical method, 10/70 in analytical
chemistry.)Anal Biochem. 228:355-7.
Shen, C.N., J.M.W. Slack, and D. Tosh. 2000. Molecular basis of transdifferentiation of pancreas to liver.
Nature Cell Biol. 2: 879-887. (Highlight by Nature Reviews Molecular Cell Biology 01 Dec 2000)
(IF=19.527, 6/161 in Cell Biol.) Times Cited: 210
Tosh, D., C.N. Shen, and J.M.W. Slack 2002. Conversion of pancreatic cells to hepatocytes. Biochem.
Soc.Trans. 30: 51-5. (IF=3.378, 98/283 in Biochem. & Mol. Biol.) Times Cited: 18
Tosh, D., C.N. Shen, and J.M.W Slack 2002. Differentiated properties of hepatocyte-like cells induced
from the pancreatic cell. Hepatology 36:534-543. (IF=10.840, 2/65 in Gastro. & Hepatol.) Times Cited:
40
5.
6.
Shen C.N., M.E.Horb, J.M.W. Slack and D. Tosh 2003. Transdifferentiation of pancreas to liver. Mech.
Dev. 120: 107-116. (IF=2.827, 16/35 in Dev. Biol.) Times Cited: 54
Horb, M.E., C.N. Shen, D. Tosh, and J.M.W. Slack 2003 Experimental conversion of liver to pancreas.
Curr. Biol. 13(2): 105-115. (Highlight by Nature Reviews Molecular Cell Biology 01 Mar 2003) Times
Cited: 164
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Shen, C. N., J.R. Seckl, J.M.W. Slack, and D. Tosh. 2003. Glucocorticoid suppresses beta cell
development and induces hepatic metaplasia in embryonic pancreas. Biochem. J. 375(1): 41-50. (Front
cover of the issue) (IF=5.155, 50/283 in Biochem. & Mol. Biol.) Times Cited: 51
Kurash, J.K1., Shen C.N1., and D. Tosh 2004. Induction and expression of acute phase proteins in
transdifferentiated hepatocyte. Exp. Cell Res. 292(2): 342-358. (1Authors contribute equally, Front cover)
(IF=3.589, 70/161 in Cell Biol.) Times Cited: 24
Burke, Z.D., C.N. Shen, and D. Tosh. 2004. Bile Ducts as a Source of Pancreatic  cells? BioEssays 26:
932-937. (IF=5.125, 5/73 in Biol.) Times Cited: 12
Shen, C.N., Z.D. Burke, and D. Tosh. 2004. Transdifferentiation, metaplasia and tissue regeneration.
Organogenesis 1(2): 36-44. Times Cited: 4
Wang, R.Y.L., C.N. Shen, M.H. Lin, D. Tosh and C.H. Shih. 2005. Hepatocyte-like cells
transdifferentiated from pancreatic origin can support hepatitis B virus. J. Virol. 79: 13116-13128.
(IF=5.150, 4/30 in Virol.) Times Cited: 7
Burke, Z.D., C.N. Shen, K.L. Ralphs, and D. Tosh. 2006. Characterization of liver function in TD
hepatocytes. J. Cell. Physiol. 206:147-159. (IF=4.586, 7/75 in Physiol.) Times Cited: 21
Tosh. D., C.N. Shen, M.R. Alison, C.E. Sarraf, and J.M.W. Slack 2007. Copper deprivation in rats
induces islet hyperplasia and hepatic metaplasia in the pancreas. Biol. Cell. 99: 37-44. (IF=3.974,
63/161 in Cell Biol.) Times Cited: 4
Shen, C.N., A. Petiot, C.Y. Chien, C. Dickson, J. M.W. Slack, and D. Tosh. 2007. All-trans Retinoic
Acid suppresses exocrine differentiation and branching morphogenesis in the embryonic pancreas.
Differentiation 75: 62-74. (Editor chosen for online open) (IF=3.311, 9/35 in Dev. Biol.) Times Cited: 9
Susanto, J., Y.H. Lin, Y.N. Chen, C.R.Shen, Y.T.Yan, S.T. Tsai, C.H Chen, and C.N. Shen*. 2008.
Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of embryonic stem cells. PLoS
ONE 3(12): e4023. (*corresponding author) (IF=4.351, 9/73 in Biol.) Times Cited: 8
Huang Y.H ., C. C. Chin, H.N. Ho, C.K. Chou, C.N. Shen, H.C. Kuo, T.J Wu, Y.C. Wu, Y.C. Hung, C.C.
Chang,, T.Y Ling. 2009. Pluripotency of Mouse Spermatogonial Stem Cells Requires IGF-1. FASEB J.
23(7): 2076-87. (IF=6.401, 3/73 in Biol.) Times Cited: 9
Huang Y.C., T.L. Hwang, C.S. Chang,Y.L. Yang, C.N. Shen, W.Y. Liao, S.C. Chen, and C.C. Liaw. 2009.
Anti-inflammatory flavonoids from the rhizomes of Helminthostachys zeylanica. J. Nat. Prod.
72(7):1273-8. (IF=3.159, 12/46 in Chem, Medicinal, 23/172 in Plant Sci) Times Cited: 1
Yang Y.L., W.Y. Liao, W.Y. Liu, C.C. Liaw, C.N. Shen, Z.Y. Huang, and S.H.Wu. 2009. Discovery of
New Natural Products by Intact-Cell Mass Spectrometry and LC-SPE-NMR:Malbranpyrroles, Novel
Polyketides from Thermophilic Fungus Malbranchea sulfurea. Chemistry-A European Journal.
15(43):11573-80. (IF=5.382, 16/138 in Chem, Multidisciplinary )
Yang, C-J1., Liu, Y-K1., Liu, C-L., C.N. Shen, M.L. Kuo, C.C.Su, C.P.Tseng, T.C.Yen, and C.R.Shen*.
2009. Inhibition of acidic mammalian chitinase by RNA interference suppresses ovalalbumin-sensitized
Page 2
allergic asthma. Human Gene Therapy 20:1597–1606. (IF=4.202, 22/150 in Biotech.) Times Cited: 6
20. Tsai H.A., R.R.Wu, I.C. Lee, H.Y.Chang, C.N. Shen* and Y.C.Chang*. 2010. Selection, enrichment and
maintenance of Self-Renewal Liver Stem/Progenitor Cells utilizing Polypeptide Polyelectrolyte
Multilayer Films. Biomacromolecules 11:994-1001 (*corresponding author). (IF=4.502, 6/76 in
Polymer; 61/283 in Biochem. & Mol. Biol.) Times Cited: 1
21. Wu, S.Y., C.C. Hsieh, R.R. Wu, J. Susanto, T.T. Liu, C.R. Shen,Y. Chen, I.F. Cheng, C.C. Su, F.P. Chang,
H.M. Chang, D. Tosh, and C.N. Shen* 2010. Differentiation of pancreatic acinar cells to hepatocytes
requires an intermediate cell type. Gastroenterology 138:2519-2530. (*corresponding author, Editor
chosen as an issue- highlight article). (IF=12.899, 1/65 in Gastro. & Hepatol.) Times Cited: 3
22. Al-Adsani A., Z.D. Burke, D. Eberhard, K. L. Lawrence, C.N. Shen, A K. Rustgi, H. Sakaue, J. M.
Farrant and D Tosh. 2010. Dexamethasone treatment induces the reprogramming of pancreatic acinar
cells to hepatocytes and ductal cells. PLoS One 5(10): e13650. (IF=4.351, 9/73 in Biol.)
23. C.F.Chen, C.Y. Chu, T.H. Chen, S.J. Lee, C.N. Shen*, and C.D. Hsiao*. 2011. Establishment of a
Transgenic Zebrafish Line for Superficial Skin Ablation and for Functionally Validation of
Anti-Apoptotic Pathways in vivo. PLoS One (Accepted *corresponding author) (IF=4.351, 10/76 in
Biol.)
24. Liaw C.C*., W.Y.Liao, C.S.Chen, Y.C.Wu, S.C. Jao, C.N. Shen*,and S.H. Wu. 2011. Calcium-Chelating
Capability of Tetrahydrofuranic Moieties Modulates Cytotoxicity of Annonaceous Acetogenins.
Angewandte Chemie Intl Ed (Accepted , *corresponding author) (IF=11.829, 5/140 in Chem,
Multidisciplinary)
25. W.Y.Liao, C.C. Liaw, C.S. Chen, G.H. Wang, Y.C.Huang, J.Susanto, S.C.Kuo*, and C.N. Shen* 2011.
Disruption of porphyrin homeostasis by inhibiting ABCG2 with cyclohexylmethyl flavonoids suppresses
propagation of breast cancer stem cells. Chemistry & Biology (In revision,*corresponding author)
(IF=6.523; 32/283 in Biochem. & Mol. Biol.)
26. C.Y. Chu, C.F. Chen; R.S. Rajendran, C.N. Shen, T.H. Chen, C.C. Yen, C.K. Chuang, D.S. Lin and C.D.
Hsiao. 2011 Overexpression of Akt1 Enhances Adipogenesis and Leads to Lipoma Formation in
Zebrafish. PLoS One (Under review)
27. Lee I.C., C.Y. Chien, H.A. Tsai, H.S. Lee, Y.C. Chang* and C.N. Shen*. 2011. Propagation of liver
stem/progenitor cells on Polyvinyl alcohol substrates. Tissue Engineering Part A (Manuscript in
preparation, *corresponding author) (IF=4.582., 19/152 in Biotech.).
28. Su, C.C1., I.M.Shyu, H.Y. Chang, C.C.Hsieh, T.H. Chen, W.Y. Liao, C.C. Liaw, C.F. Shyu, M. Hsiao,
and C.N. Shen* 2011. Glucocorticoids enhance development of pancreatic intraepithelial neoplasia
driven by Kras. (Manuscript in preparation *corresponding author).
29. Hsieh, C.C1., W.Y.Liao1, M. Hsiao, T.H. Chen, C.F. Shyu, C.C.Liaw, S.Y.Sung, I.M.Shyu*and C.N.
Shen* 2011. Identification of metastatic cancer stem cells in pancreatic ductal adenocarcinoa.
(Manuscript in preparation *corresponding author).
30. Chen, J.L., Y.T. Yan, H.C. Kuo, J. Yu, S. M. Hwang, H. L. Su, C. H. Chen, and C. N. Shen* 2011Cyclin
D negatively regulates the progression of intermediates to fully-reprogrammed pluripotent cells in a
p21-dependent manner. (Manuscript in preparation *corresponding author).
Patent
1. Kuo, H.C., Y.L.Chen, Y.T. Yan, C.N.Shen, S.H. Chen, J.Yu, C.Y. Chuang. Method of deriving pluripotent
stem cells from a single blastomere. (USPTO Application #: 20070298496; U.S. provisional patent
application Ser. No. 60/815,842, filed on Jun. 23, 2006)
Thesis , Book chapters & other publications
1. Slack, J.M.W., A.C. Percival, P.A. Seymour, C.N. Shen, W. Bennett, M. Horb, and D. Tosh. 2001.
Pancreatic stem cells. Seoul Symposium on Stem Cells & Therapeutic Cloning.
2. Shen, C.N., 2002. Molecular basis of hepatic metaplasia of the pancreas. PhD Thesis of University of
Bath.
3. Shen, C.N., J.M.W. Slack, and D. Tosh. 2002. Regulation of epithelia morphogenesis in hepatic
transdifferentiation of pancreas. Differentiation 70: 363. (Conference abstract)
4. 沈家寧
2007. 人造幹細胞 科學發展 414: 34-39. ( *corresponding author)
5. 沈家寧、林宇星、張曉旻、陳志龍、簡皎芸 2008.第三章: 胚幹細胞體外培養與誘導分化 幹細胞學 幹
細胞與組織工程教學資源中心主編.
Page 3
6. Yang, C.J., C.R. Shen, M.L.Kuo, C.N. Shen and Y.K. Liu. 2008. RNA interference-mediated inhibition of
acidic mammalian chitinase suppresses OVA-sensitized allergic asthma. Clinical Immunology 127:
S44-S45. (Conference abstract)
7. 沈家寧、謝綺哲、廖紋瑩 2009. 腫瘤幹細胞與癌症治療 科學月刊 40(7): 535-539. ( *corresponding
author)
8. C.N. Shen* and D. Tosh and 2010 Chapter 14: Transdifferentiation of pancreatic cells to hepatocytes.
Hepatocyte: Methods and Protocols. Humana Press (Edited by Patrick Maurel. ISBN
978-1-60761-687-0, DOI 10.1007/978-1-60761-688-7_14) (also in Methods in Molecular Biology
640: 273-280). ( *corresponding author)
9. 沈家寧、陳志龍 2010. 體細胞重新編程技術與應用前景 中榮醫訊 142: 9-11 (*corresponding
author)
10. 沈家寧主編 2011 圖解幹細胞科技
五南圖書公司 (In preparation,*corresponding author)
International Symposium Abstract (Since 2004)
1. Shen, C. N., A. Petiot, C. Dickson, J.M.W. Slack, and D. Tosh. 2004. All-trans retinoic acid induces islet
formation and suppresses exocrine differentiation in the embryonic pancreas. 2nd Annual Meeting of
International Society of Stem Cell Research. Boston Seaport Hotel, Boston, Massachusetts, United states of
America.
2. Burke, Z., C.N. Shen, and D. Tosh. 2004. Transdifferentiated hepatocytes from pancreatic AR42J-B13
progenitor cells. FASEB Summer Research Conference. Snowmass Village, Colorado, United states of
America.
3. Shen, C.N., H.-Y. Chang, C.-Y. Chien, and C.-R. Shen. 2005. Pancreatic Reprogram of multipotent
progenitors isolated from liver. 3rd Annual Meeting of International Society of Stem Cell Research. San
Francisco Marriott, San Francisco, California, United states of America.
4. Kuo, H.C., Y.L. Chen, Y.T. Yan, C.N. Shen, S.H. Chen, C.Y. Chuang, J. Yu, and D.P. Wolf. 2006.
Derivation of pluripotent stem cells from single blastomeres of mouse four and eight stage embryos. 4th
Annual Meeting of International Society of Stem Cell Research, Toronto, Canada.
5. Shen, C.N., T.T. Liu, Cheng I. F., H.Y. Chang, C.R. Shen. 2006. Bipotential side-population progenitors
derived from hepatic transdifferentiation. 4th Annual Meeting of International Society of Stem Cell
Research, Toronto, Canada.
6. Shen, C.N., H.M. Chang, K.W. Cheng, H.Y. Chang, E.C. Chan. 2006. Maintenance of the differentiation
capability of mouse hair follicle stem cells with embryonic fibroblast feeders. 4th Annual Meeting of
International Society of Stem Cell Research, Toronto, Canada.
7. Chien, C.Y., R.R. Wu, Y.H. Lin, J.L. Chen and C.N. Shen. 2007. Islet vascularization elevated by retinoic
acid signaling promotes pancreatic progenitor cells to differentiate into mature beta cells. 5th Annual
Meeting of International Society of Stem Cell Research, Cairns, QLD, Australia.
8. Shen, C.N., Y.N. Chen, Y.H. Lin, J Susanto. 2007. Involvement of PI3K/Akt signaling and multidrug
transporter ABCG2 in regulating pluripotency of embryonic stem cells. 5th Annual Meeting of International
Society of Stem Cell Research, Cairns, QLD, Australia.
9. Liao, W.Y., C.C. Su, C.C. Hsieh, S.C. Chen, C.C. Liaw, and C.N. Shen 2008. Nestin-positive
stem/progenitor cells derived from pancreatic neoplastic transformation. Keystone Symposia on Stem Cells,
Cancer and Aging. Biopolis, Singapore, Singapore.
10. Shen, C.N., J. Susanto, Y.H. Lin, Y.N. Chen, Y.T. Yan, S.T. Tsai, C.H. Chen 2008. The genetic integrity of
embryonic stem cells maintained by ABCG2-dependent defense machinery. Keystone Symposia on Stem
Cells, Cancer and Aging. Biopolis, Singapore, Singapore.
11. S.T. Tsai, C.N. Shen, C.C. Tsou, W.Y. Mao, W.C. Chang, W.L Hsu, and C.H. Chen 2009. Comparative
proteomic analysis of liver cancer stem cells. 57th ASMS Conference on Mass Spectrometry. Philadelphia,
Pennsylvania, United states of America.
12. Shen, C.N., Liao, W.Y., C.C. Su, C.C. Hsieh, S.C. Chen, C.C. Liaw. 2009. ABCG2-positive multipotent
tumor-initiating cells isolated from pancreatic ductal adenocarcinomas. 7th Annual Meeting of International
Society of Stem Cell Research, Barcelona, Spain.
13. R.R. Wu, S.Y. Wu, J. Susanto, C.C. Hsieh, Susanto, D. Tosh, and C.N.Shen. 2010. Reprogramming of
pancreatic acinar cells to multipotent progenitor cells. 43rd annual meeting of Japan Society of
Developmental Biology. Kyoto, Japan.
Page 4
14. W.Y.Liao, J. Susanto, S.H.Wu, L.H.Lin, Y.C.Huang, S.C.Kuo, C.C. Liaw., and C.N. Shen 2010.
Cyclohexylmethyl flavonoids downregulates self-renewal expansion of ABCG2+CD24low/-CD44+ Breast
Cancer Stem Cells. 8th Annual Meeting of International Society of Stem Cell Research. San Francisco
Marriott, San Francisco, California, United states of America.
15. H.Y. Hen, C.N.Shen, H.K.Liu 2010 Evaluation for the Impact of Penta-O-galloyl-glucopyranose Isoforms
(PGG) on Each Stages of Adipocyte Life Cycle. 9th Annual Meeting of CGCM, Hong Kong Convention
and Exhibition Centre, Wan Chai, Hong Kong.
16. Shen, C.N., T.A. Yuan, C.Y. Chien, R.R. Wu, and H.S. Lee. 2011. Retinoic acid ameliorates type I diabetes
mellitus by increasing regulatory T cells and by promoting beta-cell differentiation. 9th Annual Meeting of
International Society of Stem Cell Research, Toronto, Canada.
17. Chang, F.P., R.R. Wu, H.K. Sytwu, and C.N. Shen. 2011. Neuogenin3 promotes proliferation of
transdifferentiated beta cells. 9th Annual Meeting of International Society of Stem Cell Research, Toronto,
Canada.
Invited lecture at conference (Since 2004)
1. Shen, C.N. 2004. Plasticity of Pancreatic Differentiation. Centre for Molecular Medicine Symposium on
Endoderm formation, Biopolis, Singapore.
2. Shen, C.N. 2005. Molecular Basis of the plasticity of pancreatic cells and the hepatic transdifferentiation
differentiation. Joint Meeting of 3rd NHRI conference on Signal Transduction & 4th NHRI Conference on
Developmental Biology, NHRI, Hsichu, Taiwan.
3. Shen, C.N. 2005. Reprogramming of somatic cells and stem cell plasticity. 21st Summer Camp of Biology
Rui-Li, Chia-Yi, Taiwan.
4. Shen, C.N. 2005. Somatic cells plasticity and Transdifferentiation. The symposium on Recent Advances in
Medical Biotechnology, National Yang-Ming University, Taipei, Taiwan.
5. Shen CN. 2006. Derivation of multipotent progenitors from pancreas-to-liver transdifferentiation. 14th
Symposium on recent advance in cellular and molecular biology. Pintung, Taiwan.
6. Shen, C.N. 2006. Bipotential stem/progenitor cells and pancreatic metaplasia. Annual symposium on
plasticity and application of stem cells.Chinese Medical Association, Taipei, Taiwan.
7. Shen, C.N. 2006. Role of retinoids in pancreas development. Taiwan-Scotland Bilateral Developmental
Biology Symposium. Taipei, Taiwan.
8. Shen, C.N. 2007. Bipotential stem/progenitor cells and transdifferentiation in pancreas. Japan-Taiwan
Bilateral Symposium on Cell and Developmental Biology. Academia Sinica, Taipei, Taiwan.
9. Shen, C.N., 2007. Involvement of PI3k/Akt Signaling in Derviation of Multipotent Stem/Progenitor Cells
From Pancreas-to-Liver Transdifferentiation. The Sixth Cross Strait Symposium on Biomedical and
Bioengineering Research. China Academy of Science, Shanghai, China.
10. Shen, C.N. 2007. Isolation of multipotent stem cells from skin. Annual Symposium on autologous stem
cell therapy. Taiwan Mesotherapy Research Society, Taipei, Taiwan
11. Shen, C.N., 2007. Role of Multipotent Stem/Progenitor Cells in Ductal Neopplasia & Hepatic Metaplasia
of Pancreas. Special Seminars in Cancer stem cells. Taiwan Medical Week, Taipei, Taiwan.
12. Shen, C.N. 2008. Isolation and application of skin stem cells. Annual Symposium on modern trend of
autologus stem cell therapy in microplasty.Taiwan Mesotherapy Research Society. NTUH International
Conference Center, Taipei, Taiwan.
13. Shen, C.N. 2008. Isolation and application of dermal stem cells. Annual meeting of Taiwan Academy of
liposuction surgery. Taipei, Taiwan.
14. Shen, C.N., 2008. Transdifferentiation, a potential solution for diabetic and pancreatic cancer therapy.
Special Seminars in Cell Therapy. Joint symposium of Taiwan Surgical Society, Kaohsiung, Taiwan
15. Shen, C.N., 2008. Generation of ABCG2-positive multipotent precursor cells in pancreatic neoplastic
transformation. International Symposium on Stem cells, epigenetic and Development. NTUH International
Conference Center, Taipei, Taiwan.
16. Shen, C.N., 2009. ABCG2-positive plastic progenitor generated from pancreatic transdifferentiation and
intraepithelial neoplasia. International Symposium of Stem cells and Bioengineering. NCKU Medical
College, Tainan, Taiwan.
17. Shen, C.N. 2009. Therapeutic potential of stem cells in skin repair and regeneration. The Symposium of
Integrated Aesthetic Medicine. NTUH International Conference Center
18. Shen, CN., 2009 Generation of insulin-producing cells from pluripotent reprogramming and lineage
reprogramming of somatic cells. Regenerative Medicine 2009: From stem cells to disease models. National
Page 5
Yang-Ming University, Taipei, Taiwan
19. Shen, CN., 2009 Generation of insulin-producing cells from pluripotent reprogramming and lineage
reprogramming of somatic cells. Biotechnology Taiwan 2009: International Symposium of Stem cells,
Vaccine, and molecular Medicine. Chang Yung-Fa Foundation International Convention Center, Taipei,
Taiwan.
20. Shen CN., 2010 Reprogramming of pancreatic acinar cells into multipotent progenitor cells. Academia
Sinica-Kumamoto University Joint conference on Organogenesis. B1C Auditorium, Institute of Biomedical
Sciences, Academia Sinica, Taipei, Taiwan
21. Shen, C.N., 2010. Porphyrin homeostasis maintained by ABCG2 transporter regulates self-renewal of
embryonic stem cells and cancer stem cells. The international conference of Stem cells and regenerative
medicine for neurodegenerative diseases. Buddhist Tzu-Chi General Hospital, Hualien, Taiwan
22. Shen, C.N., 2010. Activation of glucocorticoid pathway in chronic pancreatitis promotes development of
pancreatic neoplasm. Inflammation, Stem cell and Carcinogenesis Symposium. Kaohsiung Medical
University, Kaohsiung, Taiwan.
23. Shen, C.N., 2010. Application of epidermal stem cells for healing diabetic wound 5th Annual Meeting of
Taiwanese Society for Investigative Dermatology. National Defense Medical Center, Taipei, Taiwan
24. Shen, C.N., 2010. Reprogramming of pancreatic acinar cells to multipotent progenitor cells. 43rd annual
meeting of Japan Society of Developmental Biology. Kyoto, Japan.
25. Shen, CN., 2010. Generation of insulin-producing cells from pluripotent reprogramming and lineage
reprogramming of somatic cells. Millipore Asia Bioforum on “Recent Advances in Stem Cell &
Epigenetics”. Taipei, Taiwan
26. Shen, CN., 2010. In search of cancer stem cells from pancreatic ductal adenocarcinoma. Asia-Pacific
Congress on Pancreas and Biliary Tract Cancer (In conjunction with the 14th Annual Meeting of the Taiwan
Cooperative Oncology Group). Taipei, Taiwan.
Page 6
CURRICULUM VITAE
May, 2011
NAME:
Tsann-Long Hwang
SEX:
Male.
BIRTH DAY:
Oct. 22, 1952.
CITIZENSHIP:
TAIWAN.
CHINESE PERMANENT REGISTRATION NO.: A102336755
LANGUAGE: Chinese
SPONSE:
Her Meei-Meei,
Birth Day: Nov. 24, 1952.
EDUCATION: M.B. (Equivalent to M.D. in U.S.A.)
September 1970 - June 1977.
School of Medicine, National Taiwan University, Taipei, Taiwan.
POST-GRADUATE EDUCATION:
Research Fellow, Department of Surgery
Apr. 1985 - Feb. 1986.
Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA., U.S.A.
ACADEMIC APPOINTMENT:
Professor of Surgery (1994),
Associate Professor (1991)
Approved by Chang Gung Memorial Hospital & Medical College, Taipei,
Taiwan.
Professor of Surgery (1994),
Associate Professor (1991)
Approved by Educational Administration of Taiwan.
EMPLOYMENT RECORD:
1976-1977
Intern, National Taiwan University Hospital, Taipei, Taiwan, (The Best Intern)
1977-1978
First year surgical resident, Chang Gung Memorial Hospital, Taipei, Taiwan.
1978-1982
Complete surgical residency, National Taiwan University Hospital, Taipei, Taiwan.
1982-1983
Page 7
Fellow, General surgery, Chang Gung Memorial Hospital, Taipei, Taiwan.
1983-present
Attending staff, General surgery, Chang Gung Memorial Hospital, Taipei, Taiwan.
1984-2000
Director, Nutritional Support Service, Chang Gung Memorial Hospital, Taipei.
1986-1988
Section Chief, General surgery, Chang Gung Memorial Hospital at Keelong.
1993-2003
Director, Experimental surgery, Chang Gung Memorial Hospital, Taipei, Taiwan.
1994-2000
Chief, Department of Nutritional Therapy, Chang Gung Memorial Hospital, Taipei.
1995-2000
Chairman, Department of Surgery, Chang Gung Memorial Hospital, Taipei,Taiwan.
2000-2008
Dean, School of Medicine, Chang Gung University, Tau-Yuan, Taiwan.
Vice President, Chang Gung Memorial Hospital, Taipei, Taiwan.
2008-2009
Chairman, Trauma Center, Chang Gung Memorial Hospital, Taipei, Taiwan.
2010-Present
Chairman, Committee of Enteral and Parenteral Nutrition, Chang Gung Memorial
Hospital, Taipei, Taiwan
2010-Present
Chairman, Committee of Stem Cells and Tissue Engineering Research , Chang Gung
Memorial Hospital, Taipei, Taiwan
BOARD CERTIFICATION:
1. Diplomate Medicine of Republic of China (Physician License, November 1977)
2. Educational Commission for Foreign Medical Graduate (ECFMG, March 1983)
3. Surgical Board of Republic of China. (Surgical Board certified, Sept. 1982)
4. International College of Surgeon, section of R.O.C., 1988.
5. Fellow of American College of Surgeons (FACS) Oct. 1993.
LICENSURES: Chinese (Taiwan) License No. 007503.
PROFESSIONAL AFFILIATIONS:
Page 8
1. Collegium Internationale Chirugiae Digestivae.
2. International Hepato-Biliary Pancreatic Association.
3. American Society for Parenteral and Enteral Nutrition.
4. American College of Surgeons
5. American Society for Alimentary Surgeons
6. European Society for Parenteral and Enteral Nutrition.
7. Shock Society
8. Western Pacific Association of Critical Care Medicine.
9. The association of Surgeon of South East Asia.
10. The Taiwan Surgical Association.
11. Surgical Society of Gastroenterology, R.O.C.
12. The Gastroenterological Society of the Republic of China.
13. Formosan Medical Association.
14. Chinese Nutrition Society.
15. Taipei Physician Society.
16. Ultrasound in Medicine of Republic of China
17. Taiwan Society for Parenteral and Enteral Nutrition.
18.Chinese Society of Free Radicals
19.Taiwan Trauma Society
20.Taiwan Pancreas Society
PROFESSIONAL ACTIVITIES
1. Chairman of Educational committee of Chang Gung Memorial Hospital.(2001-2003)
2. Chief of Department of Nutritional Therapy of Chang Gung Memorial Hospital. (1994-2000)
3. Chief of Experimental Surgery of Chang Gung Memorial Hospital. (1993-2003)
4. Chairman of Department of Surgery, Chang Gung Memorial Hospital. (1995-2000)
5. President, Chinese Society of Parenteral and Enteral Nutrition. (1997-2001)
6. President, Asian Pacific Association of PBL. (2003-2004)
7. Dean, School of Medicine, Chang Gung University. (2000-2008)
8. Vice Superintent, Chang Gung Memorial Hospital. (2000-2008)
9. Chairman, Trauma Center, Chang Gung Memorial Hospital. (2008-present)
10. Director of Pancreatic Cancer Team, Chang Gung Memorial Hospital. (2006-presnet)
10. President, Taiwan Pancreatic Society. (2006-present)
EDITOR OF INTERNATIONAL JOURNAL
Page 9
1. Regional Editor in Asia:
“Nutrition”
2. Editor: “World Journal of GI Oncology”
3. Ediotr: “Asian Journal of Surgery”
4. Ediotr: “Formosal Journal of Surgery”
PUBUBLICATIONS:
More than 250 peer-review papers.
Page 10
BIBLIOGRAPHY OF TASANN-LONG HWANG, M.D. (2006-2011)
Tsann-Long Hwang, MD, FACS
(A) Publications in Journals:
1. Chang HJ,, Liu YU, Wang HP, Chiu YF, Chang MC, Tsann-Long Hwang, Chen LT:
(Corresponding author)
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-FU / leukovorin followed by
chemoradiotherapy in patients with locally advanced pancreatic cancer – A Taiwan
cooperative oncology group phase II study
Int J Radiation Oncology 2011; (In press) (SCI)
2. Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Tse- Chen, Tsann-Long Hwang, Ta-Shen Yeh,
Ja-Sung Yu:
Secretome based identification of ULBP2 as a novel marker for pancreatic cancer detection
Clinical Laboratory, 2011; (In press) (SCI)
3. Tsann-Long Hwang, Che-Hung Lo, Ying Liang, Kuan-Yi Chien, Jau-Song Yu：
The effects of knock down phosphoglycerate kinase 1 on pancreatic ductal
adenocarcinoma – From proteomic and SiRNA study to micro-PET evidence
(Submitted), 2011
4. Tsann-Long Hwang, Ying-Liang, Je-Hong Lao:
The prognostic association of p16, p53, EGFR, and VEGF protein expression with pancreatic
carcinoma.
(Submitted), 2011
5. Tsann-Long Hwang, Chi-Yi Chen:
Gender different responses of immunonutrition for liver cirrhosis in sepsis.
(Submitted), 2011
6. Tsann-Long Hwang, LY Lee, CC Wang, Y Liang, SF Huang, CM Wu:
Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in
gastric cancer
Experimental & Therapeutic Medicine 1:789-797, 2010.
7. KD Chakravarty JT Hsu, KH Liu, CN Yeh, TS Yeh, Tsann-Long Hwang,, YY Jan, MF Chen:
(Corresponding author)
Prognosis and feasibility of en-bloc vascular resection in stage II pancreatic adenocarcinoma
World J Gastroenterol. Feb 28;16(8):997-1002, 2010. (SCI)
8. Tsann-Long Hwang:
The prognosis of small pancreatic adenocarcinoma – Is it a real early cancer?
Page 11
Formosan J Surgery 43:273-277, 2010
9. HP Yu, YT Lau, Tsann-Long Hwang:
Resveratrol prevents endothelial dysfunction and aortic superoxide production following
trauma hemorrhage through estrogen receptor-dependent hemeoxygenase-1 pathway
Critical Care Medicine 38:1147-54, 2010 (SCI)
10. JF Fang, LY Shih, KC Yuan, KY Fang, Tsann-Long Hwang, SY Hsieh:
Proteomic analysis of post-hemorrhagic shock mesenteric lymph Shock 34:291-298, 2010
(SCI)
11. Tsann-Long Hwang,
Potential use of albumin administration in severe sepsis. J Chin Med Assoc 72:225-226, 2009
12. Tsann-Long Hwang,
Surgical treatment of acute pancreatitis.
Formosan J Surgery 42:7-11, 2009
13. Tsann-Long Hwang:
Modern diagnosis and treatment for sepsis
Proceeding of Traditional & Modern Medicine Dialogue Forum 14:51-55, 2009
14. KC Chiang, CN Yeh, WC Lee, YY Jan, Tsann-Long Hwang:
Prognostic analysis of patients with pancreatic heand cancer less than 2 cm undergoning
resection World J Gastroenterol. Sept 14;15(34):4305-4310, 2009.(SCI)
15. KH Liu, TS Yeh, Tsann-Long Hwang, YY Jan, MF Chen:Surgical management of
gallbladder sarcomatoid carcinoma World J Gastroenterol 15, 1876-9, 2009. (SCI)
16. KC Chiang, JT Hsu, HY Chen, SC Jwo, Tsann-Long Hwang, YY Jan, MF Chen:
Multifocal intraductal papillary mucinous neoplasm of the pancreas--a case report
World J
Gastroenterol. Feb 7;15(5):628-32, (SCI)
17. Tsann-Long Hwang, Yu-Mei Yang:
Gender dimorphic responses of immunonutrition in sepsis.
Nutrition 24:761-66, 2008. (SCI)
18. Li-Yu Lee, CM Wu, CC Wang, JS Yu, Y Liang, KH Huang,CH Lo, Tsann-Long Hwang:
(Corresponding author)Expression of MMP-2 and MMP-9 in gastric cancer and their relation
to claudin-4 expression. Histology and Histopathology 23:515-521, 2008. (SCI)
19. Huang-Ping Yu, JC Hsu, Tsann-Long Hwang, CH Yen, YT Lau:
Reserveratrol attenuates hepatic injury after trauma-hemorrhage via estrogen
receptor-related pathway. Shock 30:324-8, 2008. (SCI)
20. Wen-Chian Lai, Jen-Fong Fang, Tsann-Long Hwang: (Corresponding author)
Clinical significance of portal venous gas in ischemic bowel. Surgery Today 38:656-60, 2008.
(SCI)
Page 12
21. Hsu JT, Chen HM, Liao CH, Yeh CN, Yeh TS, Tsann-Long Hwang, Jan YY, Chen MF:
(Corresponding author) Clinicopathologic features and predictors for survival of Mucinous
and nonmucinous appendiceal adenocarcinoma Digestive Surgery 25:369-75, 2008. (SCI)
22. Hsu JT, Chen HM, Wu RC, Yeh CN, Yeh TS, Tsann-Long Hwang, Jan YY, Chen MF:
(Corresponding author) Clinicopathologic features and outcomes following surgery for
pancreatic adenosquamous carcinoma. World J Surg Oncology 6:95, 2008. (SCI)
23. Yeh CN, Lee HL, Liu YY, Chiang KC, Tsann-Long Hwang, Jan YY, Chen MF:
(Corresponding author) The role of parenteral glutamine supplement for surgical; patient
perioperatively: result of a single center, prospective and controlled study. Lang Arch Surg
393:849-55, 2008. (SCI)
24. Kuo KN, Tsann-Long Hwang, Chen PJ: Physician-scientist: Attitude of Graduates of clinical
medicine graduate schools. J Formosan Med Assoc 107:519-26, 2008. (SCI)
25. Fu CY, Yeh CN, Hsu JT, Jan YY, Tsann-Long Hwang: (Corresponding author)
Mortality in severe acute pancreatitis: Experience from a single institute. World J
Gastroenterology 13:1966-1969, 2007. (SCI)
26. Hsu JT, Ueng SH, Tsann-Long Hwang, Chen HM, Jan YY, Chen MF: Primary
angiosarcoma of the spleen in a child with long term survival. Pediatr Surg Int 23:807-10, 2007.
(SCI)
27. Yu CC, TsengJH, Yeh CN, Tsann-Long Hwang, Jan YY: Clinicopathological study of solid
and pseudopapillary tumor of pancreas: emphasis on MRI finding. World J Gastroenterol
28:1811-15, 2007. (SCI)
28. Chi-Chang Yu, JH Tseng, CN Yeh, Tsann-Long Hwang, YY Jan: Clinicopathological study of
solid and pseudopapillary tumor of pancreas: Emphasis of MRI finding. World J
Gastroenterol 13:1811-1815, 2007. (SCI)
29. Tsann-Long Hwang, Ying Liang, Kuan-Yi Chien, Jau-Song Yu ： Over-expression and
elevated serum level of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma
Proteomics 6:2259-2272, 2006. (SCI)
30. Tsann-Long Hwang:The current medical education system in Taiwan. APBN (Asia Pacific
BioTech) 10:812-814, 2006.
31. Chi-Ming Wu, YS Lee, TH Wang, LY Lee, WH Kong, ES Chen, ML Wei, Ying Liang ,
Tsann-Long Hwang: (Corresponding author) Identification of differential gene expression
between intestinal and diffuse gastric cancer using a cDNA microarray. Oncology Report
15:57-64, 2006. (SCI)
32. Wen-Ling Kuo, Li-Yu Lee, Chi-Ming Wu, CC Wang, JS Yu, Ying Liang , CH Lo, KH Huang,
Tsann-Long Hwang: (Corresponding author) Differential expression of claudin-4 between
Page 13
intestinal and diffuse-type gastric cancer. Oncology Report 16:729-734, 2006. (SCI)
33. Waitzberg DL, Saito H, Palnk LD, Jamieson GG, Jagannath P, Tsann-Long Hwang ,Mijares
JM, Bihari D: Postsurigal infection are reduced with special nutritional support.
World J. Surgery 30:1592-1604, 2006 (SCI)
34. Luo JD, Chan EC, Shih CL, Chen TL, Liang Y, Tsann-Long Hwang, Chiou CC:
Detection of rare mutant K-ras DNA in a single tube reaction using nucleic acid as both PCR
clamp and sensor probe.
Nucleic Acids Research 34:e12, 2006. (SCI) Huang-Ping Yu, Lui PW, Tsann-Long Hwang,
Yen CH, Ying-Tung Lau: Propofol improved endothelial dysfunction and attenuates vascular
superoxide production in septic rats.
Critical Care Medicine 34:453-460, 2006. (SCI) Chang CC, Hsu JT, Tseng JH, Tsann-Long
Hwang, Chen HM, Jan YY: Combined resection and multi-agent adjuvant chemotherapy for
desmoplastic small round cell tumor arising in the abdominal cavity: report of a case.
World J Gastroenterol 12:800-3, 2006. (SCI)
35. Hsu JT, Yeh CN, Hung CF, Chen HM, Tsan-Long Hwang, Jan YY, Chen MF:
Management of the transdermal delivery of catechins by liposomes incorporating anionic
surfactants and ethanol.
BMC Gastroenterol 6:3, 2006. (SCI)
36. Wu TJ, Lee LY, Yeh CN, Wu PY, Chao TC, Tsann-Long Hwang, Jan YY, Chen MF:
Surgical treatment and prognostic analysis for GIST of the small intestine: before the era of
imatinib mesylate. BMC Gastroenterology 2006 6:29. (SCI)
Page 14
Curriculum Vitae
Kenoki Ohuchida, M.D., Ph.D.
Office address:
Department of Surgery and Oncology
Graduate School of Medical Sciences, Kyushu University
3-1-1, Maidashi, Fukuoka 812-8582, Japan
Telephone: +81-92-642-5440, Facsimile: +81-92-642-5458
E-mail: kenoki@surg1.med.kyushu-u.ac.jp
Birth date: September 30, 1971
Citizenship: Japan
Education: 1997 M.D., Kyushu University, Fukuoka, Japan
Professional Training, Research Experience and Employment:
2007-present; Assistant professor in the Dept. of Surgery and Oncology and Dept. of
Advanced medical initiatives, Graduate School of Medical Sciences,
Kyushu University, Fukuoka, Japan
2006-2007; Research Fellow of the Japan Society for the Promotion of Science,
Department of, Faculty of Medicine, Kyushu University, Fukuoka, Japan,
2003-2005; Postgraduate Student of Ph.D. Course at the Department of Anatomic
Pathology, Pathological Sciences, Faculty of Medicine, Kyushu University,
Fukuoka, Japan
2002-2003; Staff in the Dept. of Surgery, Kyushu University Hospital, Fukuoka, Japan
Medical licensure: Medical License of Japan, No. 386488
Membership: Japan Pancreas Society (JPS)
Japanese Surgical Society (JSS)
The Japanese Society of Gastroenterological Surgery (JSGS)
The Japan Society for Endoscopic Surgery (JSES)
The Japan Esophageal society (JES)
The Japanese Society of Gastroenterology (JSG)
Japan Society of Clinical Oncology (JSCO)
Japanese Cancer Association (JCA)
Japanese Board of Cancer Therapy (JBCT)
Quantifications: Board Certified Surgeon (by JSS)
Board Certified Surgeon in Gastroenterology (by JSGS)
General Clinical Oncologist (by JBCT)
Editorial Board member; Global Journal of Surgery
Page 15
Associate Editor: BMC Cancer Editorial Board 2010-2012
Honors/Prizes
1. The Commendation for Science and Technology by the Minister of Education,
Culture, Sports, Science and Technology, The Young Scientists’ Prize, 2007
2. Inoue Research Award for Young Scientists, Inoue Foundation for Science, 2006
3. Poster of Distinction: American Pancreatic Association, Poster, 2010, Chicago,
USA.
Bibliography (English Only):
Original Article
1. Kurata Nobuaki, Hayato Fujita, Kenoki Ohuchida, Kazuhiro Mizumoto, Prawej
Mahawithitwong,
Hiroshi Sakai, Manabu Onimaru, Tatsuya Manabe, Takao Ohtsuka, and Masao Tanaka
Predicting the
chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes
associated
with the metabolism of gemcitabine and 5-fluorouracil International Journal of Oncology, in
press
2. Tadashi Kayashima, Kohei Nakata, Kenoki Ohuchida*, Hayato Fujita, Cui Lin, Kazuhiro
Mizumoto,
Masao Tanaka Insig2 is overexpressed in pancreatic cancer and its expression is induced by
hypoxia
Cancer Science, in press
3. Kenoki Ohuchida*, Kazuhiro Mizumoto, Tadashi Kayashima, Midori Sato, Hayato Fujita,
Taiki
Moriyama, Takao Ohtsuka, Junji Ueda, Shunichi Takahata, Makoto Hashizume, and Masao
Tanaka
MicroRNA expression as a predictive marker for gemcitabine response after surgical
resection
of pancreatic cancer Annals of Surgical Oncology, in press
4. Hiroshi Sakai, Kenoki Ohuchida*, Kazuhiro Mizumoto, Lin Cui, Nobuaki Kurata, Kouhei
Nakata,
Yoshihiro Miyasaka, Norihiro Sato, Hiroki Toma, Eishi Nagai, and Masao Tanaka Inhibition of
p600 expression suppresses both invasiveness and anoikis resistance of gastric cancer,
Annals of
Surgical Oncology, in press
5. Kohei Nakata, Eishi Nagai, Yoshihiro Miyasaka, Kenoki Ohuchida, et al Indication of
gastrectomy
Page 16
and endoscopic submucosal dissection for mucosal gasric carcinoma
Hepatogastroenterology, in
pressKohei Nakata, Kenoki Ohuchida, Shinichi Aishima, Yoshihiko Sadakari, Tadashi
Kayashima,
Yoshihiro Miyasaka, Eishi Nagai, Kazuhiro Mizumoto, Masao Tanaka, Masazumi
Tsuneyoshi,
Yoshinao Oda Invasive carcinoma derived from intestinal-type intraductal papillary mucinous
neoplasm is associated with minimal invasion, colloid carcinoma and less invasive behavior,
leading
to better prognosis. Pancreas, 40:581-7, 2011
6. Takaharu Yasui, Kenoki Ohuchida*, Ming Zhao, Lin Cui, Manabu Onimaru, Takuya
Egami, Takao
Ohtsuka , Kazuhiro Mizumoto, Kunio Matsumoto, Masao Tanaka Adenoviral therapy is more
effective in gemcitabine-resistant pancreatic cancer cells than in gemcitabine-sensitive cells
Anticancer Research, 31:1279-87, 2011
7. Kosuke Tsutsumi, Norihiro Sato, Cui Lin, Kazuhiro Mizumoto, Yoshihiko Sadakari, Hayato
Fujita,
Kenoki Ohuchida, Shunichi Takahata, and Masao Tanaka Expression of Claudin-4 (CLDN4)
mRNA in intraductal papillary mucinous neoplasms of the pancreas Modern Pathology,
24:533-41,
2011
8. Takaharu Yasui, Kenoki Ohuchida, Chou Mei, Manabu Onimaru, Takuya Egami, Takao
Ohtsuka,
Kazuhiro Mizumoto, Masao Tanaka Tumor-stromal interactions prevent efficacy of adenoviral
therapy via HGF-MET pathway Cancer Science, 102:484-91, 2011
9. Hayato Fujita, Kenoki Ohuchida*, Kazuhiro Mizumoto, Soichi Itaba, Tetsuhide Ito, Kohei
Nakata,
Jun Yu, Tadashi Kayashima, Akifumi Hayashi, Ryota Souzaki, Tatsuro Tajiri, Manabu
Onimaru,
Tatsuya Manabe, Takao Ohtsuka, Masao Tanaka High EGFR mRNA Expression Level is a
Prognostic Factor for Reduced Survival in Pancreatic Cancer after Gemcitabine-based
Adjuvant
Chemotherapy International Journal of Oncology, 38; 629-41, 2011
10. Hayato Fujita, Kenoki Ohuchida*, Kazuhiro Mizumoto, Kohei Nakata, Jun Yu, Tadashi
Page 17
Kayashima, Manabe Tatsuya, Ohtsuka Takao, Masao Tanaka α-SMA expressing stroma
promotes an
aggressive tumor-biology in pancreatic ductal adenocarcinoma . Pancreas, 39, 8: 1254-62,
2010
11. Naoki Ikenaga, Kenoki Ohuchida*, Kazuhiro Mizumoto, Jun Yu, Tadashi Kayashima,
Hayato
Fujita, Kohei Nakata and Masao Tanaka MicroRNA-203 expression is a new prognostic
marker of
pancreatic cancer. Annals of Surgical Oncology,17:3120-8, 2010
12. Sadakari Y, Ohtsuka T, Ohuchida K, Tsutsumi K, Takahata S, Nakamura M, Mizumoto K,
Tanaka
M. MicroRNA Expression Analyses in Preoperative Pancreatic Juice Samples of Pancreatic
Ductal
Adenocarcinoma. JOP. 11:587-92, 2010
13. Jun Yu, Kenoki Ohuchida*, Kazuhiro Mizumoto, Hayato Fujita, Kouhei Nakata and
Masao Tanaka
MicroRNA miR-17-5p is overexpressed in pancreatic cancer, and its upregulation enhances
cancer
cell proliferation and invasion in vitro, Cancer Biology & Therapy, 10:748-57, 2010
14. Hayato Fujita, Kenoki Ohuchida*, Kazuhiro Mizumoto, Soichi Itaba, Tetsuhide Ito, Kohei
Nakata,
Jun Yu, Tadashi Kayashima, Ryota Souzaki, Tatsuro Tajiri, Tatsuya Manabe, Takao Ohtsuka,
Masao
Tanaka Gene Expression levels as Predictive Markers of Outcome in Pancreatic Cancer after
Gemcitabine-based adjuvant Chemotherapy, Neoplasia, 12: 801-17, 2010
15. Lin Cui, Kenoki Ohuchida*, Kazuhiro Mizumoto, Taiki Moriyama, Manabu Onimaru,
Kohei
Nakata, Toshinaga Nabae, Takashi Ueki, Norihiro Sato, Yohei Tominaga, Masao Tanaka
Prospectively isolated cancer-associated CD10+ fibroblasts have more strong interaction with
CD133+ colon cancer cells than CD133- colon cancer cells PLos One 12;5:e12121, 2010
16. Naoki Ikenaga, Kenoki Ohuchida*, Kazuhiro Mizumoto, Lin Cui, Tadashi Kayashima,
Katsuya
Morimatsu, Taiki Moriyama, Kohei Nakata, Hayato Fujita, and Masao Tanaka CD10+
pancreatic
Page 18
stellate cells enhance the progression of pancreatic cancer Gastroenterology, 139; 1041-51,
2010
17. Jun Yu, Kenoki Ohuchida*, Kazuhiro Mizumoto*, Norihiro Sato, Tadashi Kayashima,
Hayato
Fujita, Kouhei Nakata , and Masao Tanaka MicroRNA hsa-miR-200c is an independent
prognostic
factor in pancreatic cancer, and its upregulation inhibits pancreatic cancer invasion, but
increases cell
proliferation. Molecular Cancer 28;9:169, 2010
18. Naoki Ikenaga, Kenoki Ohuchida*, Kazuhiro Mizumoto, Jun Yu, Tadashi Kayashima,
Akifumi
Hayashi, Kohei Nakata, and Masao Tanaka Characterization of CD24 expression in
intraductal
papillary mucinous neoplasms and pancreatic cancer. Human Pathology, 41:1466-74, 2010
19. Kohei Nakata, Eishi Nagai, Kenoki Ohuchida, Shinichi Aishima, Akifumi Hayashi,
Yoshihiro
Miyasaka, Jun Yu, Kazuhiro Mizumoto, Masao Tanaka, and Masazumi Tsuneyoshi S100P is
a novel
marker to identify invasive lesion in intraductal papillary mucinous neoplasms, Human
Pathology,
41; 824-31, 2010
20. Ieiri S, Nakatsuji T, Higashi M, Akiyoshi J, Uemura M, Konishi K, Onimaru M, Ohuchida
Kenoki,
Hong J, Tomikawa M, Tanoue K, Hashizume M, Taguchi T Effectiveness of basic endoscopic
surgical skill training for pediatric surgeons. Pediatr Surg Int. 26:947-54, 2010.
21. Yoshihiko Sadakari, Kenoki Ohuchida, Kohei Nakata, Tadashi Kayashima, Shinichi
Aishima,
Shunichi Takahata, Masafumi Nakamura, Kazuhiro Mizumoto, and Masao Tanaka, Invasive
carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the
pancreas has a poorer prognosis than that derived from the intestinal type Surgery, 147;
812-7, 2010
22. Taiki Moriyama, Kenoki Ohuchida*, Kazuhiro Mizumoto, Lin Cui, Naoki Ikenaga, Norihiro
Sato,
and Masao Tanaka Enhanced cell migration and invasion of CD133+ pancreatic cancer cells
Page 19
cocultured with pancreatic stromal cells Cancer, 116; 3357-68, 2010
23. Manabu Onimaru, Kenoki Ohuchida*, Takuya Egami, Kazuhiro Mizumoto, Eishi Nagai,
Lin Cui,
Hiroki Toma, Kunio Matsumoto, Makoto Hashizume, and Masao Tanaka Gemcitabine
synergistically enhances the effects of adenovirus gene therapy via activation of the CMV
promoter
in pancreatic cancer cells Cancer Gene Therapy, 17; 541-9, 2010
24. Manabu Onimaru, Kenoki Ohuchida*, Eishi Nagai, Kazuhiro Mizumoto, Takuya Egami,
Lin Cui,
Norihiro Sato, Junji Uchino, Koichi Takayama, Makoto Hashizume, Masao Tanaka
Gemcitabine
synergistically enhances cytotoxicity of hTERT promoter-dependent conditionally replicative
adenovirus in pancreatic cancer cells Cancer Letter, 294; 178-86, 2010
25. Onimaru Manabu, Ohuchida Kenoki*, Mizumoto Kazuhiro, Nagai Eishi, Cui Lin, Toma
Hiroki,
Takayama Koichi, Matsumoto Kunio, Hashizume Makoto, Tanaka Masao hTERT-promoter
dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of
replication-defective adenovirus vectors in pancreatic cancer cells Cancer Science
101:735-42, 2010
26. Kei Miyoshi, Norihiro Sato, Kenoki Ohuchida, Kazuhiro Mizumoto and Masao Tanaka
SPARC
mRNA Expression as a prognostic Marker for pancreatic adenocarcinoma patients,
Anticancer
Research, 30:867-71, 2010
27. Hayato Fujita, Kenoki Ohuchida*, Kazuhiro Mizumoto, Takuya Egami, Kei Miyoshi, Taiki
Moriyama, Cui Lin, Jun Yu, Tatsuya Manabe, Masao Tanaka Tumor-stromal interactions with
direct
cell contacts enhance proliferation of human pancreatic carcinoma cells; Evaluation with
direct and
indirect co-culture system Cancer Science 100:2309-17, 2009
28. Tanoue K, Uemura M, Kenmotsu H, Ieiri S, Konishi K, Ohuchida Kenoki, Onimaru M,
Nagao Y,
Kumashiro R, Tomikawa M, Hashizume M. Skills assessment using a virtual reality simulator,
LapSim, after training to develop fundamental skills for endoscopic surgery.Minim Invasive
Page 20
Ther
Allied Technol1, 9:24-9, 2010.
29. Yoshihiro Miyasaka, Eishi Nagai, Kenoki Ohuchida, Kohei Nakata, Akifumi Hayashi,
Kazuhiro
Mizumoto, Masazumi Tsuneyoshi, Masao Tanaka CD44v6 Expression in Intraductal Papillary
Mucinous Neoplasms of the Pancreas Pancreas 39:31-5, 2010
30. Noshiro H, Kenoki Ohuchida, Kawamoto M, Ishikawa M, Uchiyama A, Shimizu S,
Tanaka M
Intraabdominal Roux-en-Y reconstruction with a novel stapling technique after laparoscopic
distal
gastrectomy. Gastric Cancer. 2009;12:164-9. 2009
31. Taiki Moriyama, Kenoki Ohuchida*, Kazuhiro Mizumoto, Jun Yu, Toshinaga Nabae,
Shunichi
Takahata, Norihiro Sato, Hiroki Toma, Eishi Nagai, and Masao Tanaka MicroRNA-21
(miR-21)
modulates biologic functions of pancreatic cancer cells including their proliferation, invasion
and
chemoresistance, Molecular Cancer Therapeutics 8: 1067-74, 2009
32. Naoki Ikenaga, Kenoki Ohuchida*, Kazuhiro Mizumoto, Jun Yu, Takuya Egami,
Toshinaga Nabae,
Junji Ueda, Norihiro Sato, Eishi Nagai, and Masao Tanaka S100A4 mRNA is a diagnostic and
prognostic marker in pancreatic carcinoma Journal of Gastrointestinal Surgery 13:1852-8,
2009
33. Takuya Egami, Kenoki Ohuchida*, Takaharu Yasui, Kazuhiro Mizumoto, Manabu
Onimaru,
Hiroki Toma, Norihiro Sato, Kunio Matsumoto, and Masao Tanaka Upregulation of integrin ß3
in
Radio-Resistant Pancreatic Cancer impair Adenovirus Gene Therapy, Cancer Science
100:1902-7,
2009
34. Kenoki Ohuchida, Hajime Kenmotsu, Atsuyuki Yamamoto, Kazuya Sawada, Taketo
Hayami,
Kenichi Morooka, Shinichiro Takasugi, Kozo Konishi, Satoshi Ieiri, Kazuo Tanoue, Yukihide
Iwamoto, Masao Tanaka, Makoto Hashizume The frontal cortex is activated during learning of
Page 21
endoscopic procedures Surg Endosc. 23:2296-301, 2009
35. Kohei Nakata, Kenoki Ohuchida, Eishi Nagai, Akifumi Hayashi, Yoshihiro Miyasaka, Jun
Yu,
Naoko Kinukawa, Kazuhiro Mizumoto, Masao Tanaka, and Masazumi Tsuneyoshi. LMO2 is a
unique marker that correlates with carcinogenesis, angiogenesis, cell proliferation and good
prognosis in pancreatic cancer Neoplasia 11:712-9, 2009
36. Takuya Egami, Kenoki Ohuchida*, Kei Miyoshi, Kazuhiro Mizumoto, Manabu Onimaru,
Hiroki
Toma, Kunio Matsumoto, and Masao Tanaka Chemotherapeutic Agents Enhance Adenoviral
Gene
Therapy in Pancreatic Cancer, Cancer Science 100: 722-9 2009
37. Kenoki Ohuchida, Hajime Kenmotsu, Atsuyuki Yamamoto, Kazuya Sawada, Taketo
Hayami,
Kenichi Morooka, Hiroshi Hoshino, Munenori Uemura, Kozo Konishi, Daisuke Yoshida,
Takashi
Maeda, Satoshi Ieiri, Kazuo Tanoue, Masao Tanaka, Makoto Hashizume CyberDome, a
novel
3-dimensional dome-shaped display system, improves procedures for laparoscopic surgery
International Journal of Computer Assisted Radiology and Surgery, 4: 125-32, 2009
38. Kohei Nakata, Eishi Nagai, Kenoki Ohuchida, Shinich Aishima, Akifumi Hayashi,
Yoshihiro
Miyasaka, Jun Yu, Kazuhiro Mizumoto, Masao Tanaka, and Masazumi Tsuneyoshi REG4 is
associated with carcinogenesis in the ‘intestinal’ pathway of intraductal papillary mucinous
neoplasms Modern Pathology 22: 460-8, 2009
39. Jun Yu, Kenoki Ohuchida*, Kohei Nakata, Kazuhiro Mizumoto, Hayato Fujita, Hiroshi
Yamaguchi,
Takuya Egami, Hidehisa Kitada, and Masao Tanaka LIM only 4 is overexpressed in
pancreatic cancer
but not at the early stages of pancreatic carcinogenesis Molecular Cancer 7: 93, 2008
40. Hayato Fujita, Kenoki Ohuchida*, Kazuhiro Mizumoto, Takuya Egami, Yoshihiro
Miyasaka,
Hiroshi Yamaguchi, Jun Yu, Lin Cui, Manabu Onimaru, Shunichi Takahata, Masazumi
Tsuneyoshi,
Masao Tanaka Quantitative analysis of hTERT mRNA levels in cells microdissected from
Page 22
cytological
specimens Cancer Science 99: 2244-51 2008
41. Seiji Ohhashi, Kenoki Ohuchida*, Kazuhiro Mizumoto, Takuya Egami, Jun Yu, Cui Lin,
Hiroki
Toma, Shunichi Takahata, Toshinaga Nabae, and Masao Tanaka Midkine mRNA is
Overexpressed in
Pancreatic Cancer Digestive Disease and Science 54:811-5 2008
42. Seiji Ohhashi, Kenoki Ohuchida*, Kazuhiro Mizumoto, Hayato Fujita, Takuya Egami, Jun
Yu,
Hiroki Toma, Shoko Sadatomi, Eishi Nagai, and Masao Tanaka Down-regulation of
Deoxycytidine
Kinase Specifically Enhances Acquired Resistance to Gemcitabine in Pancreatic Cancer
Cells
without affecting Proliferation Anticancer Research 28: 2205-12, 2008
43. Nagai S, Nakamura M, Yanai K, Wada J, Akiyoshi T, Nakashima H, Ohuchida K, Sato N,
Tanaka
M, Katano M. Gli1 contributes to the invasiveness of pancreatic cancer through matrix
metalloproteinase-9 activation Cancer Science 99: 1377-84, 2008
44. Yamagi Y. Yoshida S, Ishikawa K, Sengokku A, Sato K, Yoshida A, Kuwahara R, Kenoki
Ohuchida, Oki E, Enaida H, Fujisawa K, Kono T, Ishibashi T TEM7 (PLXDC1) in
Neovascular
Endothelial Cells of Fibrovascular Membranes from Patients with Proliferative Diabetic
Retinopathy.
Invest Ophthalmol Vis Sci. 49: 3151-7, 2008
45. Takuya Egami, Kenoki Ohuchida*, Kazuhiro Mizumoto, Manabu Onimaru, Hiroki Toma,
Shoko
Nishio, Eishi Nagai, Kunio Matsumoto, Toshikazu Nakamura, and Masao Tanaka Radiation
Enhances Adenoviral Gene Therapy in Pancreatic Cancer via Activation of CMV Promoter
and
Increased Adenovirus Uptake Clin Cancer Res 14: 1859-67, 2008
46. Kenoki Ohuchida*, Kazuhiro Mizumoto, Yoshihiro Miyasaka, Yu Jun, Cui Lin, Hiroshi
Yamaguchi, Hiroki Toma, Shunichi Takahata, Norihiro Sato, Eishi Nagai, Koji Yamaguchi,
Masazumi Tsuneyoshi, and Masao Tanaka Overexpression of S100A2 in pancreatic cancer
is
correlated with tumor progression and poor prognosis Journal of Pathology 213: 275-82,
Page 23
2007
47. Kenoki Ohuchida, Kazuhiro Mizumoto, Seiji Ohhashi, Hiroshi Yamaguchi, Hiroyuki
Konomi,
Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. Twist, a novel
oncogene,
is up-regulated in pancreatic cancer; Clinical implication of Twist expression in pancreatic
juice. Int
J Cancer, 120:1634-40, 2007
48. Kenoki Ohuchida, Kazuhiro Mizumoto, Yu Jun, Hiroshi Yamaguchi, Hiroyuki Konomi,
Eishi
Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. S100A6 is increased in a
stepwise manner during pancreatic carcinogenesis: Clinical value of expression analysis in
93
pancreatic juice samples. Cancer Epidemiology, Biomarkers & Prevention, 16:649-54
2007
49. Yoshihiro Miyasaka, Eishi Nagai, Hiroshi Yamaguchi, Kei Fujii, Takahiro Inoue, Kenoki
Ohuchida, Tomomi Yamada, Kazuhiro Mizumoto, Masao Tanaka, Masazumi Tsuneyoshi.
The role
of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the
pancreas.
Clin Cancer Res. 13:4371-7. 2007
50. Hiroshi Yamaguchi, Takahiro Inoue, Takashi Eguchi, Yoshihiro Miyasaka, Kenoki
Ohuchida,
Kazuhiro Mizumoto, Yamada Tomomi, Koji Yamaguchi, Masao Tanaka, and Masazumi
Tsuneyoshi
Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline
neoplasms,
and carcinomas) of the pancreas, correlated with increased histological grade. Modern
Pathology,
20;552-61 2007
51. Daisuke Yamada, Kenoki Ohuchida, Kazuhiro Mizumoto, Seiji Ohhashi, Jun Yu, Takuya
Egami,
Hayato Fujita, Eishi Nagai, and Masao Tanaka. Increased expression of ADAM 9 and ADAM
15
Page 24
mRNA in pancreatic cancer. Anticancer Research, 27:793-800, 2007
52. Kenoki Ohuchida, Kazuhiro Mizumoto, Daisuke Yamada, Kei Fujii, Nami Ishikawa,
Hiroyuki
Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi and Masao Tanaka.
Quantitative
analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of
pancreatic
cancer. Int J Cancer,118:405-11, 2006
53. Kenoki Ohuchida, Kazuhiro Mizumoto, Daisuke Yamada, Hiroshi Yamaguchi, H Konomi,
Eishi
Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. Quantitative analysis of
human
telomerase reverse transcriptase in pancreatic cancer. Clin Cancer Res;12 2066-9, 2006
54. Kenoki Ohuchida, Kazuhiro Mizumoto, Takuya Egami, Hiroshi Yamaguchi, H Konomi,
Eishi
Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. S100P is an early
developmental
marker of pancreatic carcinogenesis. Clin Cancer Res; 12: 5411-6, 2006
55. Kenoki Ohuchida, Kazuhiro Mizumoto, Hayato Fujita, Hiroshi Yamaguchi, Hiroyuki
Konomi,
Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. Sonic hedgehog is
an early
developmental marker of intraductal papillary mucinous neoplasm: clinical implications of
mRNA
levels in pancreatic juice. Journal of Pathology, 210: 42-48, 2006
56. Kenoki Ohuchida, Kazuhiro Mizumoto, Seiji Ohhashi, Hiroshi Yamaguchi, Hiroyuki
Konomi,
Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. S100A11, a
putative tumor
suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res; 12:
5417-22, 2006
57. Yasuhiro Ogura, Kazuhiro Mizumoto, Masao Tanaka, Kenoki Ohuchida, Mitsuhiko
Murakami,
Daisuke Yamada, Nami Ishikawa, Eishi Nagai. Strategy for prevention of local recurrence of
Page 25
pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin
glue in an
orthotopic nude mouse model. Surgery;140(1):66-71, 2006
58. Jun Yu, Kenoki Ohuchida, Kazuhiro Mizumoto, Nami Ishikawa, Yasuhiro Ogura,
Daisuke Yamada,
Takuya Egami, Hayato Fujita, Seiji Ohashi, Eishi Nagai, Masao Tanaka. Overexpression of
c-met in
the early stage of pancreatic carcinogenesis; altered expression is not sufficient for
progression from
chronic pancreatitis to pancreatic cancer. World J Gastroentero. 12:3878-82, 2006
59. Nami Ishikawa, Takahito Miya, Kazuhiro Mizumoto, Kenoki Ohuchida, Eishi Nagai, Koji
Yamaguchi, Masahiro Amano, Shigeori Takenaka, and Masao Tanaka. Rapid and Sensitive
Assay
of K-ras Mutations in Pancreatic Cancer by Electrochemical Detection with
Ferrocenyl-naphthalene-diimide. Cancer genomics & Proteomics; 3: 47-54, 2006
60. Kenoki Ohuchida, Kazuhiro Mizumoto, Yasuhiro Ogura, Nami Ishikawa, Eishi Nagai,
Koji
Yamaguchi, and Masao Tanaka. Quantitative assessment of telomerase activity and human
telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the
diagnosis
of pancreatic cancer. Clin Cancer Res;11:2285-92, 2005.
61. Kenoki Ohuchida, Kazuhiro Mizumoto, Nami Ishikawa, Kei Fujii, Hiroyuki Konomi, Eishi
Nagai,
Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. The role of S100A6 in
pancreatic
cancer development and its clinical implication as a diagnostic marker and therapeutic target.
Clin
Cancer Res;11:7785-93, 2005
62. Murakami Mitsuhiko, Nagai Eishi, Mizumoto Kazuhiro, Saimura Michiyo, Ohuchida
Kenoki,
Inadome Naoki, Matsumoto Kunio, Nakamura Toshikazu, Maemondo Makoto, Nukiwa
Toshihiro,
Tanaka Masao. Suppression of metastasis of human pancreatic cancer to the liver by
transportal
Page 26
injection of recombinant adenoviral NK4 in nude mice. Int J Cancer.; 117:160-5, 2005
63. Kawin Leelawat, Kenoki Ohuchida, Kazuhiro Mizumoto, C Mahidol, Masao Tanaka.
All-trans
retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation
of
c-met in pancreatic cancer cells. CANCER letters; 224: 303-310, 2005
64. Kenoki Ohuchida, K Mizumoto, M Murakami, Li-Wu Qian, N Sato, E Nagai, K
Matsumoto, T
Nakamura, and Masao Tanaka. Radiation to stromal fibroblasts increases invasiveness of
pancreatic
cancer cells through tumor-stromal interactions. Cancer Research; 64: 3215-3222, 2004
65. Kenoki Ohuchida, Kazuhiro Mizumoto, Nami Ishikawa, Norihiro Sato, Eishi Nagai, Koji
Yamaguchi, Hideki Takaishi, Toshinori Ide, and Masao Tanaka. A highly-sensitive and
quantitative
telomerase activity assay with pancreatic juice is useful for diagnosis of pancreatic cancer
without
problems due to PCR inhibitors. Cancer;101:2309-17, 2004
66. Hirokazu Noshiro, Shuji Shimizu, Eishi Nagai, Kenoki Ohuchida, and Masao Tanaka.
Laparoscopy-assisted distal gastrectomy for early gastric cancer. Is it beneficial for patients of
heavier weight? Annals of Surgery; 238: 680-685, 2003
67. Li-wu Qian, Kazuhiro Mizumoto, Naoki Maehara, Kenoki Ohuchida, Inadome N, Saimura
M,
Nagai E, Matsumoto K, Nakamura T, Tanaka M. Co-cultivation of pancreatic cancer cells with
orthotopic tumor-derived fibroblasts: fibroblasts stimutate tumor cell invasion via HGF
secretion
whereas cancer cells exert a minor regulative effect on fibroblasts HGF production Cancer
Letters
190 105-112, 2003
Page 27
Masao Tanaka, MD, PhD, FACS
1974 Graduated from Kyushu University, Fukuoka, Japan
1981 Assistant Professor, Kyushu University, 1985-1987 Research Fellow in Gastroenterology Unit,
Mayo Clinic, Rochester, Minnesota, U.S.A., 1987-1988 Research Fellow in Department of Surgery,
University of Heidelberg, Germany, 1989-1992, Assistant Professor in Kyushu University,
1992-Professor and Chairman of Department of Surgery and Oncology, Graduate School of Medical
Sciences, Kyushu University
1983 Ph.D., Kyushu University, 1988 Doctor medicinae (German Ph.D.), University of
Heidelberg
President, Japan Pancreas Society, Auditor, Japanese Surgical Society, Japanese Society of
Gastroenterology, Councilor, International HepatoPancreatoBiliary Association, International
Association of Pancreatology (Past President), Asian-Paciffic HepatoPancreatoBiliary Association
(Former President), Japanese Society of Gastroenterol Endosc, Jap Soc Gastroenterol Endosc Surg,
Asian Surg Assoc, Research Interest, Gastrointestinal and biliary motility, diagnostic and therapeutic
biliary and pancreatic endoscopy, laparoscopic surgery, IPMN, pancreatic cancer
Publication, English originals 522, reviews 34, case reports 88; Japanese originals 45, reviews 401,
case reports 80 (updated May 13, 2011)
Page 28
Name:
Date of Birth:
Place of Birth:
Marital Status:
Yu-Wen Tien (田郁文)
January 26, l959
Taiwan, Taiwan
Married, one son
Education:
1978/08 -1985/07 M.D. in Koashung Medical College
1997/08 - 2001/03 Ph.D.,in Medical Science Graduate Institute of Clinical
Medicine, National Taiwan University.
Postgraduate Training:
1987/08 - 1991/07 Residency in Surgery, National Taiwan University Hospital
1991/08 - 1992/07 Chief Residency in General Surgery, National Taiwan University Hospital
1999/07 - 2000/06 Fellowship in Pancreas Transplantation, Division of Organ
Transplantation, National Cancer Institute of Transplantation, Saint Vincent
Hospital LA, U.S.A.
Speciality:
Pancreatic Surgery, Pancreas Transplantation
Military Service:
Military medical doctor of the Chinese Army.
Licensure and Certification:
l992 Surgical Board of the Republic of China.
Hospital Appointments:
1992/07 – l996/09 House staff in General Surgery, Department of Surgery, Shin-Kong Memorial
Hospital
1997/10 – now
House staff in General Surgery, Department of Surgery, NTUH
Academic Appointments:
2004/08 –2007/07 Assistant Professor of Surgery, Department of Surgery, College of Medicine,
National Taiwan University
2007/08 – now
Associated Professor of Surgery, Department of Surgery, College of
Medicine, National Taiwan University
Professional Societies:
1. Formosan Medical Association
2. Surgical Association, the Republic of China
3. Transplantation Society of the Republic of China
Major Research interests:
1. Mechanism of Metastasis
2. Oncologic study in Pancreatic Cancer.
3. Pancreatic Surgery
Publication lists:
1. Yu-Wen Tien, King-Jen Chang*, Yung-Ming Jeng, Po-Huang Lee, Ming-Shi Wu, Jaw-Town
Lin, Su-Ming Hsu. Tumor Angiogenesis and Its Possible Role in Intravasation of Colorectal
Epithelial. Clin Cancer Res 2001; 7:1627-1632.
2. Jin-De Chen, Ming-Shiang Wu, Yu-Wen Tien, Kuang-Ting Kuo, Ming-Chu Chang, Jaw-Town
Lin. Acinar cell carcinoma with hypervascularity. J Gastroenterol & Hepatol. 2001; 16:
Page 29
107-11.
3. Ming-Chu Chang, Yu-Ting Chang, Ming-Shiang Wu, Chia-Tung Shun, Yu-Wen Tien,
Jaw-Town Lin. K-ras Mutation at Codon 12 in Stage I Pancreatic Adenocarcinoma: Analysis
by Laser Capture Microdissection and Direct Sequencing. J Formos Med Assoc 2001;100:
352-354.
4. Yu-Wen Tien, Po-Huang Lee, Shih-Ming Wang, Su-Ming Hsu, King-Jen Chang*.
Simultaneous Detection of Colonic Epithelial Cells in Portal Venous and Peripheral Blood. Dis
Colon & Rectum 2002; 45: 23-29.
5. Yu-Wen Tien*, King-Jen Chang. Diffuse pancreatic islet cell disease with hyperinsulinism in
adults: problems in recognition and management. Chinese Med. J.2002; 65: 91-92.
6. Yu-Wen Tien, Po-Huang Lee*, Rey-Heng Hu, Su-Ming Hsu, King-Jen Chang. The Role of
Gelatinase in hepatic metastasis of colorectal cancer. Clin Cancer Res 2003; 9: 4891-6.
7. Yu-Wen Tien*, Yung-Ming Jeng, Rey-Heng Hu, Po-Huang Lee, King-Jen Chang.
Intravasation-Reltated metastatic factors in colorectal cancer. Tumor Biology 2004; 25:48-55.
8. Yu-Wen Tien*, Hsien-Li Kao, and Hsiu-Po Wang. Celiac Artery Stenting: A New Strategy for
Patients with Pancreaticoduodenal Artery. J. Gastroenterol. 2004;39:81-85.
9. Chin-Sheng Hung, Peter Lin, Yu-Wen Tien*, Po-Huang Lee. Duodenum-Preserving
pancreatic head resection: Preliminary report on indications and techniques Formos J. Surg.
2004; 37:254-260.
10. Yu-Min Huang, Haw-Tzong Chen, Yao-Jen Chang, Yu-Wen Tien*. Huge Periampullary
Tumors Simulating Hepatic Hilar Tumors---A Report of Three Cases. Tzu-Chi Med. J 2004;
16: 193-6.
11. Yu-Wen Tien*, Kong-Han Ser, , Rey-Heng Hu , Chih-Yuan Lee , Yung-Ming Jeng , Po-Huang
Lee. Solid Pseudopapillary Neoplasms of the Pancreas: is there a pathologic basis for the
gender difference in incidence. Surgery 2005; 137: 591-6.
12. Yu-Wen Tien*, Po-Huang, Chin-Yao Yang, Ming-Chih Ho, Chen-Feng Chiu. Risk factors of
massive bleeding after pancreatic leak following oancreaticoduodenectomy. J of American
College Surgeon 2005, 201:554-9.
13. Ming-Chu Chang, Yu-Ting Chang, Yu-Wen Tien, Chia-Tung Sun, Ming-Shiang Wu,
Jaw-Town Lin. Distinct chromosomal aberrations of ampulla of vater and pancreatic head
cancers detected by laser capture microdissection and comparative genomic hybridization.
Oncology Reports 2005; 14;867-72
14. Yu-Wen Tien*, King-Jen Chang, Yen-Feng Chiu, Kai-Wen Huang, Po-Huang Lee.
Comparison of Angiogenic Factor Levels in Tumor Drainage and Peripheral Venous Blood
from Colorectal Cancer Patients. Ann Surg Oncol, 2006;13:1357-63.
15. Lee TC. Liu KL. Tien YW. Shun CT. Wang HP. Subserosal bullae in pneumatosis intestinalis.
Surgery 2006;139(6):851-3.
16. Lee TC. Liu KL. Lin JT. Tien YW. Mao TL. Wang HP. An unusual cause of
pancreatitis--patient with dominant dorsal pancreatic duct syndrome and intraductal papillary
mucinous neoplasm (IPMN) in the ventral pancreatic duct. Gut 2006;55(2):164, 171.
17. Ming-Chug Chang , Yu-Ting Chang, Chia-Tung Sun, Yen-Feng Chiu, Jaw-Town Lin, and
Yu-Wen Tien*. Differential expressions of cyclin D1 associated with better prognosis of
cancers of ampulla of Vater. World J Surg 2007;30:1-8.
18. Chang MC. Chang YT. Tien YW. Liang PC. Wei SC. Wong JM.. Association of tumour
necrosis factor alpha promoter haplotype with chronic pancreatitis. Gut 2006; 55(11):1674-6.
19. Ji-Shiang Hung, Ming-Chu Chang, Po-Huang Lee, Yu-Wen Tien*. Is surgery indicated for
patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable
hepatic metastases? World J Surg 2007;30:1-8.
20. Ji-Shiang Hung, Ching-Yao Yang, Rey-Heng Hu, Po-Huang Lee, Yu-Wen Tien*. Surgical
treatment of pancreatic serous cystadenoma- Aggressive for operations but limited resections.
Pancreas 2007, 35:358-360.
Page 30
21. Chang MC. Chang YT. Tien YW. Liang PC. Jan IS. Wei SC. Wong JM. T-cell regulatory
gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clinic
Chem 2007; 53(9):1700-5.
22. Chang MC. Chang YT. Su TC. Yang WS. Chen CL. Tien YW. Liang PC. Wei SC. Wong JM.
Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic
pancreatitis. Pancreas 2007;35(1):16-21.
23. Chang MC. Chang YT. Wei SC. Tien YW. Liang PC. Jan IS. Su YN. Wong JM. Spectrum of
mutations and variants/haplotypes of CFTR and genotype-phenotype correlation in idiopathic
chronic pancreatitis and controls in Chinese by complete analysis. Clinical Genetics.
2007;71(6):530-9.
24. Yu-Wen Tien*, Rey-Heng Hu, Ji-Shiang Hung, Hsui-Po Wang, Po-Huang Lee. Noninvasive
pancreatic cystic neoplasms can be safely and effectively treated by limited pancreatectomy.
Ann Surg Oncol 2008; 15:193-198.
25. Yu-Wen Tien*, Yao-Ming Wu , Kao-Lang Liu, Cheng-Maw Ho, Po-Huang Lee. Angiography
is indicated for every sentinel Bleed. Ann Surg Oncol 2008; 15: 1855-1861.
26. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, Tsao PN, Jan IS. Wong JM.
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1
ratio is an independent prognostic marker in pancreatic cancer. Pancreas 2008; 37:145-150.
27. Liu KL. Teng YC. Tien YW. Lin JT. Elevated alpha-fetoprotein and a pancreatic tumour. Gut
2008;57:434.
28. Chen BB, Tien YW, Lin JT, Liu KL. Image of the month. Ectopic spleen in the pancreatic tail.
Arch Surg 2008;143:205-206.
29. Yu-Wen Tien*, Ching-Yao Yang, Yao-Ming Wu, Rey-Heng Hu, Po-Huang Lee. Enteral
Nutrition and Biliopancreatic Diversion Effectively Minimize Impacts of Gastroparesis
after Pancreaticoduodenectomy. J Gastrointest Surg 2009; 13: 929-937.
30. Yu-Wen Tien*, Yao-Ming Wu1, Wei-Chou Lin, Hsuan –Shu Lee, Po-Huang Lee. Pancreatic
carcinoma cells stimulate proliferation and matrix synthesis of hepatic stellate cells. J
Hepatology 200;51:307-14.
31. Yu-Wen Tien*, Chi-Chuan Yeh, Shi-Po Wang, Rey-Heng Hu, Po-Huang Lee. Is Blind
Pancreaticoduodenectomy Justified for Patients With Ampullary Neoplsms? J Gastrointest
Surg 2009; 13: 929-937
32. Yu-Wen Tien*, Chih-Yuan Lee, Chun-Chieh Huang Rey-Heng Hu, Po-Huang Lee. Surgery
for gastrointestinal stroma tumor of the duodenum. Ann Surg Oncol 2010;17:109-114.
33. Yu-Wen Tien*, Kao-Lang Liu, Rey-Heng Hu, Hsiu-Po Wang, King-Jen Chang, Po-Huang Lee.
Risk of varices bleeding after spleen-preserving distal pancreatectomy with excision of splenic
vessels. Ann Surg Oncol 2010, in press.
34. Chi-Chuan Yeh, Yung-Ming Jeng, Cheng-Maw Ho, Rey-Heng Hu, Hsiu-Pi Chang, Yu-Wen
Tien*. Survival after pancreaticoduopdenectomy is not affected by age. World J Surg 2010, in
press.
35. Jin-Ming Wu, Meng-Kun Tsai, Rey-Heng Hu, Kin-Jen Chang, Po-Huang Lee, Yu-Wen Tien*.
Reflux Esophagitis and Marginal Ulcer after Pancreaticoduodenectomy (corresponding author).
J Gastrointest Surg 2010, in press.
Page 31
CURRICULUM VITAE
Name: Ta-Sen Yeh, MD, Ph D
Professor,
Director of Surgical Lab
Chair of Tissue Bank, Chang Gung Memorial Hospital, Taipei
Chief, Division of General Surgery, Chang Gung Memorial Hospital
Sex: Male
Birth Date: Oct. 27, 1958
Citizenship: Chinese
Office Address:
5, Fu-Hsing Street, Kwei-Shan Hsiang, Taoyuan ,Taiwan
Tel. No.: 886-3- 3281200 Ext. 3219,3366 or 2745
FAX: 886-3-3970370 or 886-3-3285818
eMail: tsy471027@adm.cgmh.org.tw
surglab@adm.cgmh.org.tw
surglab@gmail.com
Education:
1. Ph D, Medical College, Chang Gung University
1995- 2001
2. MD, China Medical College
1982 - 1989
3. Bachelor, Power Mechanical Engineering,
National Tsing- Hua University
1976 - 1980
Employment record:
1. Surgical Resident, Chang Gung Memorial Hospital
1989-1993
2. Chief resident, Chang Gung Memorial Hospital
1993-1994
3. Surgical fellow, Beaujon Hospital, Paris, France
1996
4. Surgical fellow, National Nagoya University, Nagoya, Japan
2000
5. Attending Staff, Chang Gung Memorial Hospital, Taipei
1994 – until now
6. Assistant professor, Department of Surgery,
Chang Gung Memorial Hospital, Taipei
1996-2001
7. Associate professor, Chang Gung Nursing School
2005-until now
8. Professor, Department of Surgery,
Chang Gung Memorial Hospital, Taipei
2008- until now
Page 32
Licensure:
1. Republic of China License No.: 018946
2. Board of Surgery, Republic of China No.: 003081
Professional Affiliations:
1. Surgical Association, ROC
2. Formosa Medical Association
3. Surgical Society of Gastroenterology, ROC
4. Surgical Society of Endocrinology, ROC
5. Society of Endoscopic Surgery, ROC
Editorial Board:
Editor of Chang Gung Medical Journal
Editor of World Journal Gastroenterology
Academic interests
1. Hepatobiliary and pancreatic surgery
2. Minimally invasive surgery
3. Basic science in liver regeneration, reversal of cirrhosis and carcinogenesis of hepatobiliary cancer
Research grants:
1. Yeh TS, and Jan YY. Telomerase activity in pancreatic and bile duct cancer.
(NSC86-2314-B182-021)
2. Yeh TS, and Jan YY. Study of K-ras, p53 and nm23 gene mutations in biliary tract malignancies
(NSC87-2314-B182-034)
3. Yeh TS. K-ras, p53 gene mutations and expression of nm23 in exocrine and endocrine pancreatic
adenocarcinoma (1/2) (NSC87-2314-B182-037)
4. Yeh TS. K-ras, p53 gene mutations and expression of nm23 in exocrine and endocrine pancreatic
adenocarcinoma (2/2) (NSC88-2314-182A-109)
5. Chen MF and Yeh TS. Granulocyte colony stimulating factor enhances liver regeneration following
partial hepatectomy--- particular emphasis on kinetics of tumor necrosis factor alfa and interlukin 6
(NSC89-2314-B182-058)
6. Yeh TS. Expression of telomerase activity and its subunits during liver regeneration following
partial hepatectomy induced by granulocyte colony stimulating factor and hyperbaric oxygen in rats
(NSC89-2314-B182A-074)
7. Chen MF and Yeh TS. Dedifferentiation of hepatocellular carcinoma up-regulates telomerase
activity and inhibits apoptosis. (NMRPD9039. NSC89-2314-B182-146)
8. Chen MF, and Yeh TS. The role of NF-kB and HSP70 expressed in kidney of jaundiced rats
Page 33
(CMRP 1265, )
9. Yeh TS. Expression of VEGF in hepatocellular carcinoma inhibits apoptosis through regulation of
Bcl-2 family (CMRP 1092)
10. Jan YY and Yeh TS. Quantitative and morphological evolution of MUC1 and MUC2 from
intraductal portion to invasive portion of cholangiocarcinoma--- correlated with Ki-67. (NMRPD0119.
NSC 90-2314-B-182-082)
11. Yeh TS. Expression of VEGF and bFGF in human hepatocellular carcinoma regulates
apoptosis through p53- dependent pathway --- implication of serum VEGF as a tumor marker of
hepatocellular carcinoma for patients with chronic liver disease (1/2) (NMRPG0091 .
NSC90-2314-B-182A-102)
12. Yeh TS. Expression of VEGF and bFGF in human hepatocellular carcinoma
regulates apoptosis through p53- dependent pathway --- implication of serum VEGF as a tumor
marker of hepatocellular carcinoma for patients with chronic liver disease (2/2) (NMRPG1053 .
NSC91-2314-B-182A-074)
13. Chen MF and Yeh TS. Characterization of maturing hepatocytes derived from embryonic stem
cells of mice in vitro (NMRPD1044 . NSC91-2314-B-182-063)
14. Jan YY and Yeh TS. Expression of matrix metalloproteinases and tissue inhibitors of matrix
metalloproteinases during cholangiocarcinogenesis in rats induced by thioacetamide (NMRPD10745.
NSC91-2314-B-182-064)
15. Yeh TS. Inhibition of angiogenesis-related genes and matrix metalloproteinases genes in
cholangiocarcinoma of rats treated by thalidomide (NMRPG2130. NSC92-2314-B182A-155)
16. Chen MF and Yeh TS. Expression and localization of telomerase reverse transcriptase in common
bile duct-ligated rats--- the possible adaptive mechanism of hepatic stem cells in cholestasis
（NMRPD2075. NSC92-2314-B-182-073）
17. Jan YY and Yeh TS. Expression of epidermal growth factor receptor and apomucins in
progression of intraductal papillary neoplasms of the liver (NMRPD2074. NSC92-2314-B-182-072)
18. Chen MF and Yeh TS. The role of hepsin, a cell membrane-associated serine protease, in
obstructive jaundice. (NMRPD3089. NSC93-2314-B-182-057)
19. Jan YY and Yeh TS. Efficacy of trastuzumab (Herceptin) in combination with paclitaxel to treat
cholangiocarcinoma in rat (NMRPD3088. NSC93-2314-B-182 -056)
20. Yeh TS. Pilot study of celecoxib and thalidomide treating cholangiocarcinoma in rats.
(NMRPG3181. NSC93-2314-B-182A-185)
21. Jan YY and Yeh TS. Efficacy of siRNA based on proteomics to treat murine cholangiocarcinoma
Page 34
(NMRPD140601. NSC94-2314-B-182-037)
22. Yeh TS. Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from
cirrhosis in rats. (CMRPG33154)
23. Yeh TS. Decreased hepatocellular damage in hepsin- deficiency mice with bile duct ligation
--- possible mechanism and clinical application（1/3）(NMRPG340561 . NSC94-2314-B-182A
-079)
24. Chen MF and Yeh TS. The role of serine protease in liver ischemia- reperfusion injury in mice
（1/3）(NMRPD140581 . NSC94-2314-B-182-035)
25. Yeh TS. Audit of new therapeutic targets to reverse liver fibrosis/cirrhosis using functional
proteomics (CMRPG350291).
26. Yeh TS. Decreased hepatocellular damage in hepsin- deficiency mice with bile duct ligation --possible mechanism and clinical application (2/3) (NMRPG340562, NSC95-2314-B-182A -013-)
27. Yeh TS. Target therapy of cholangiocarcinoma using sonic Hedgehog signaling -based siRNA
(NMRPG350391, NSC95-2314-B-182A-093-)
28.Yeh TS. Novel target- therapy for murine hepatocellular carcinoma and cholangiocarcinoma
(Integrated Molecular Image Center grant, No. 6 CMRPG34021)
29.Yeh TS. A phase III study comparing adjuvant chemotherapy consisting of
capecitabine/oxaliplatin versus surgery alone in patients with stage II, IIIA and IIIB gastric
adenocarcinoma (MO17527/L9570, JIRB:05-057-A) (XMRPG350491; IRB NO.95-0059A1).
30. Jan YY and Yeh TS. NFB functions as a neoplasia promoter in inflammation- associated biliary
cancer. (NMRPD150301, NSC95-2314-B-182-026 )
31. Liao LM and Yeh TS. 大專生參與專題研究計畫-廖立民
Thalidomide attenuates tumor growth and prevents cancer cachexia in cholangiocarcinoma rat.
(NZRPG360031, NSC96-2815-C-182A-003-B)
32. Yeh TS. Decreased hepatocellular damage in hepsin- deficiency mice with bile duct ligation --possible mechanism and clinical application（3/3）(NMRPG340563,NSC96-2314-B-182A-004-)
33. Yeh TS. Impaired liver regeneration following portal vein ligation or hepatectomy in cirrhotic
diabetic rats. (1/2) (NMRPG366031, 96-2314-B-182A-008-MY2)
34. Chen MF and Yeh TS. The role of serine protease in liver ischemia- reperfusion injury in mice
（3/3）(NMRPD140583 . NSC96-2314-B-182-002-)
35. Jan YY and Yeh TS. Target therapy of cholangiocarcinoma using siRNA silencing eukaryotic
initiation factor 4E and cyclin D1 (1/3) (NMRPD160391, 96-2314-B-182- 010-MY3)
Page 35
36. Yeh TS. Impaired liver regeneration following portal vein ligation or hepatectomy in cirrhotic
diabetic rats (CMRPG360941)
37. Yeh TS. Novel target- therapy for murine hepatocellular carcinoma and cholangiocarcinoma
(CMRPG340213 )
38. Yeh TS. Volumetric and functional evaluation of liver regeneration for cirrhotic rats following
portal vein ligation using single photon emission computerized tomography (SPECT)
(CMRPG361541 )
39. Yeh TS. Impaired liver regeneration following portal vein ligation or hepatectomy in cirrhotic
diabetic rats (CMRPG360942)
40. Yeh TS. A phase III study comparing adjuvant chemotherapy consisting of
capecitabine/oxaliplatin versus surgery alone in patients with stage II, IIIA and IIIB gastric
adenocarcinoma (MO17527/L9570, JIRB:05-057-A) (XMRPG350493; IRB NO.95-0059A1)
41. Yeh TS. Set-up of molecular imaging navigating system for Helicobacter pylori-affiliated murine
gastric carcinoma model(CMRPG380161)
42. Yeh TS. Hypoxia and glucose metabolism in cholangiocarcinoma: rationale and application of
hypoxia inducing factor-1αsilencing (CMRPG371491)
43. Yeh TS. Establishment of a personalized medicine in cholangocarcinoma patients based on tissue
microarray (NMRPD180501, 98-2314-B-182-026-MY3)
44. Yeh TS. Wnt/ β-catenin signalling in Helicobacter pylori-induced gastric carcinoma in Mongolian
Gerbils - compared with human gastric carcinoma using tissue microarray. (CMRPG390451)
45. Yeh TS. Establishment of orthotopic animal cancer model to survey optimal drugs regimen for
cholangiocarcinoma. (CMRPG391501)
Bibliography:
1.
Yeh TS, Chen RJ, Fang JF. Spontaneous hemoperitoneum secondary to rupture of hepatic
metastasis from primitive neuroectodermal tumor - a case report and review of the literature. J
Surg Assoc, ROC 1994;27:2320-3.
2.
Jeng LB, Lee WC, Yeh TS, et al. Immuno-prophylaxis for hepatitis B virus reinfection after liver
transplantation. Transplantation proceedings 1994;26: 2243-4.
3.
Yeh TS, Jan YY, Chen MF. Roux loop obstruction after pancreatico- duodenectomy. Br J Surg
1997;84:323-4.
4.
Yeh TS, Jan YY, Jeng LB, et al. Pancreaticojejunal anastomotic leak following
pancreaticoduodenectomy. Multivariates analysis of perioperative risk factors. J Surg Res 1997;
67:119-25.
5.
Yeh TS, Jan YY, Jeng LB, et al. Massive extra-enteric gastrointestinal hemorrhage secondary to
Page 36
splanchnic artery aneurysms. Hepatogastroenterology 1997;44:1152-6.
6.
Yeh JT, Yeh TS.* Splenic abscess - a rare sequela following renal abscess caused by staghorn
calculi. Br J Uro1997; 80: 504-5. (Corresponding author)
7.
Wang YC, Yeh TS* Lin JD. Gram-negative thyroid abscess caused by fine-needle aspiration in an
immunosuppressed patient. Clin Inf Dis 1997;25:745 -6. (Corresponding author)
8.
Chen MF, Wang CS, Jan YY, Jeng LB, Hwang TL, Chen SC, Chao TC, Chen HM, Wang CC,
Lee WC, Yeh TS and Lo YF. Results of pancreatico- duodenectomy for periampullary carcinoma
and analysis of prognostic factors for survival. Hanyu F and Takasaki K eds
“Pancreatoduodenectomy” Springer- Verlag Tokyo, 1997:425-32.
9.
Yeh TS, Jan YY, Jeng LB, et al. Pyogenic liver abscess in patients with malignancy. A report of
52 cases treated at a single institute. Arch Surg 1998; 133:242-5.
10. Jan YY, Yeh TS, Chen MF. Cholangiocarcinoma presenting as pyogenic liver abscess. Is its
outcome influenced by concomitant hepatolithiasis. Am J Gastroenterol 1998;93:253-5.
11. Yeh TS, Jan YY, Chao TC, et al. Refractory pancreatitis secondary to ruptured hepatocellular
carcinoma into the common bile duct. Dig Dis Sci 1998;43:21-5.
12. Yeh TS, Jan YY, Jeng LB, et al. Hepatocellular carcinoma presenting as pyogenic liver abscess:
characteristics, diagnosis, and management. Clin Inf Dis 1998;26:1224-6.
13. Yeh TS, Jan YY, Wang CS, LB Jeng, et al. A multidisciplinary approach to major bile duct injury
following laparoscopic cholecystectomy. Journal of the Society of Laparoendoscopic Surgeons
(JSLS) 1998;2:147-51.
14. Lin SY, Tsang NM, Tsai CS, Chen WC, Tseng CK, Jeng LB, Jan YY, Yeh TS, Wang CS, Wang
JY, Hung JH. Intraoperative radiation therapy: the preliminary experience in Chang Gung
Memorial Hospital. Therapeutic Radiology and Oncology 1998;5:73-80.
15. Yeh TS, Jan YY, Tseng JH, et al. Value of magnetic resonance cholangio- pancreatography in
demonstrating major bile duct injury following laparoscopic cholecystectomy. Br J Surg
1999;86:181-4.
16. Yeh TS, Chen TC, Hsieh LL, et al. Hepatocellular carcinoma complicated with coexisting
hepatolithiasis. Pitfalls of the diagnosis and management. Dig Dis Sci 1998;43:2483-8.
17. Yang JM, Hwang MJ, Yeh TS. Preparation of poly(acrylic acid) modified polyurethane
membrane for biomaterial by UV radiation without degassing. J Biomed Materials Res
1999;45:133-9.
18. Wang CS, Chao TC, Yeh TS, Tsao KC, Sun CF. DNA flow cytometry and its clinicopathologic
correlation in resectable gastric cancer patients. 3rd International Gastric Cancer Congress
1999:495-9.
Page 37
19. Chen MF, Jan YY, Jeng LB, Hwang TL, Wang CS, Chen SC, Chao TC, Chen HM, Lee WC, Yeh
TS, Lo YF. Intrahepatic cholangiocarcinoma in Taiwan. J HPB Surg 1999;6:136-41
20. Yeh TS, Jan YY, Chen MF. Obstructive jaundice caused by biliary tuberculosis. Spectrum of the
diagnosis and management. Gastrointest Endosc 1999;50:105- 8.
21. 李承鴻, 陳邦基, 葉大森, Clinical experience with the peritoneovenous shunt for intractable
ascites.中華民國消化系醫學會雜誌 2000;16:140-8.
22. Yeh TS, Cheng AJ, Chen TC, et al. Telomerase activity is a useful marker to distinguish
malignant pancreatic cystic tumors from benign neoplasms and pseudocysts. J Surg Res1999;
87:171-7.
23. Yeh TS, Jan YY, Tseng JH, et al. Malignant perihilar biliary obstruction: MRCP findings. Am J
Gastroenterol 2000;95: 432-40.
24. Chen MF, Jan YY, Hwang TL, Jeng LB, Yeh TS. The impact of concomitant hepatolithiasis on
patients with peripheral cholangiocarcinoma. Dig Dis Sci 2000; 45:312-6.
25. Yeh TS, Chen TC, Chen MF. Dedifferentiation of human hepatocellular carcinoma upregulates
telomerase and Ki-67 expression. Arch Surg 2000;135: 1334-1339.
26. Yeh TS, Jan YY, Chen MF. Video-assisted endoscopic thyroidectomy. Am J Surg 2000;180:82-5.
27. Yang HR, Yeh TS, Jan YY, Chen MF, Hepatocellular carcinoma presenting with gastrointestinal
bleeding. Chang Gung Med J. 2001;34:198-202
28. Yeh TS, Jan YY, Chao TC, et al. Refractory pancreatitis secondary to ruptured hepatocellular
carcinoma into the common bile duct. Dig Di Sci 2001;46:1029- 33.
29. Harada K, Zen Y, Kanemori Y, Chen TC, Chen MF, Yeh TS, Jan YY, Masuda S, Nimura Y,
Takasawa S, Okamoto H, Nakanuma Y. Human REG I gene is up- regulated in intrahepatic
cholangiocarcinoma and its precursor lesions. Hepatology 2001;33:1036-42.
30. Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, Chiu CT, Kuo TT, Kamiya J, Oda K,
Hamaguchi M, Ohno Y, Hsieh LL, Nimura Y. Intraductal papillary neoplasia of the liver
associated with hepatolithiasis. Hepatology 2001;34:651-8.
31. Chen TC, Ng KF, Jeng LB, Yeh TS, Chen CM. Aspirin-related hepatotoxicity in a child after
liver transplant. Dig Dis Sci 2001;46:486-8.
32. Tseng JH, Hung CF, Ng KK, Wan YL, Yeh TS, Chiu CT. Icteric-type hepatoma: magnetic
resonance imaging and magnetic resonance cholangiographic features. Abdominal imaging.
2001;26:171-7.
33. Yeh TS, Jan YY, Chiu CT, et al. Characterisation of oestrogen receptor, progesterone receptor,
trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and
pancreatic ductal adenocarcinoma. Gut, 2002;51:712-6.
Page 38
34. Chen YC, Yeh TS, Tseng JH, Huang SF, Lin DY. Hepatic hydatid cysts with superinfection in a
non-endemic area in Taiwan. Am J Trop Med Hygiene, 2002; 67:524-7.
35. Shimonishi T, Zen Y, Chen TC, Chen MF, Jan YY, Yeh TS, Nimura Y, Nakanuma Y. Increasing
expression of gastrointestinal phenotypes and p53 along with histologic progression of
intraductal papillary neoplasia of the liver. Human pathology, 2002;33:503-11.
36. Yeh TS, Jan YY, Tang JH, et al. Laparoscopic distal pancreatectomy. Formos J Surg 2002;
35:253-256.
37. Kokuryo T, Yamamoto T, Oda K, Kamiya J, Nimura Y, Senga T, Yasuda Y, Ohno Y, Nakanuma Y,
Chen MF, Jan YY, Yeh TS, Chiu CT, Hsieh LL and Hamaguchi M. Profiling of gene expression
associated with hepatolithiasis by complementary DNA expression array. International journal of
oncology, 2003; 22:175-9.
38. Yang HR, Yeh TS, Jan YY, Chen MF. Laparoscopic resection of malignant gastric polyp-with a
particular emphasis on localization by laparoscopic ultrasonography. J of Laparoendosc Adv A
2003;13: 117-9.
39. Yang HR, Jan YY, Huang SF, Yeh TS, Tseng JH, Chen MF. Laparoscopic cholecystectomy for
gallbladder lymphangiomas. Surg Endos 2003;17:1676.
40. Sasaki M, Huang SF, Chen FM, Jan YY, Yeh TS, Ishikawa A, Mollenhauer J, Poustka A,
Tsuneyama K, Nimura Y, Oda K, Nakanuma Y. Expression of deleted in malignant brain tumor-1
(DMBT1) molecule in biliary epithelium is augmented in hepatolithiasis: possible participation
in lithogenesis. Dig Dis Sci 2003;48:1234-40.
41. Chiu CT, Yeh TS,* Hsu JC, et al. Expression of Bc1-2 family modulated through p53-dependent
pathway in humam hepatocellular carcinoma. Dig Dis Sci 2003;48 :670-6. (*Corresponding
author)
42. Huang CF, Cheng MH, Chen SH, Wei FC, Chen SC, Lo YF, Yeh TS. et al, Skin-sparing
mastectomy with immediate breast reconstruction using free deep inferior epigastric perforator
flap .中華民國重建整形外科醫學會 2004; 13(4):244 -252.
43. Jan YY, Yeh TS, Yeh CN, et al. Expression of epidermal growth factor receptor, apomucins,
matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma. Appraisal of animal
model for cholangiocarcinoma. Ann Surg 2004;240:89-94
44. Yeh TS, Ho YP, Huang SF, et al. Thalidomide salvages lethal hepatic necroinflammation and
accelerates recovery from cirrhosis in rats. J Hepatology 2004;41:606-12.
45. Huang CF, Cheng MH, Chen SC, Lo YF, Yeh TS, Chen SH, Huang WC, Wei FC. Breast
reconstruction with a muscle-sparing free transverse rectus abdominis myocutaneous flap:
comparison between immediate and delayed group. Chang Gung Med J 2004;27:275-82.
Page 39
46. Yeh CN, Jan YY, Yeh TS, et al. Hepatic resection of the intraductal papillary type of peripheral
cholangiocarcinoma. Ann Surg Oncol 2004;11:606-11.
47. Yeh CN, Jan YY, Yeh TS, et al. Endo-GIA for ligation of dilated cystic duct during laparoscopic
cholecystectomy. An alternative, novel, and easy method. Journal of Laparoentoscopic &
Advanced surgical Techniques 2004;14:153-7
48. Chan KM, Yeh TS, Yu MC, et al. Gallbladder carcinoma with biliary invasion: clinical analysis
of the difference from nonbiliary invasion. World J Surg 2005; 29:72-5.
49. Chu PH, Jung SM, Yeh TS, et al. MUC1, MUC2 and MUC5AC expression in cardiac myxoma.
Virchows Arch 2005;446:52-5.
50. Chu PH, Jung SM, Yeh CH, Yeh TS, Wang CL. Mucin gene expression in cardiac myxoma. Int J
Clin Prac 2004;58:306-9.
51. Ishikawa A, Sasaki M, Ohira S, Ohta T, Oda K, Nimura Y, Chen MF, Jan YY, Yeh TS, Nakamura
Y. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2
expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Lab Invest
2004;84:629-38.
52. Yeh TS, HoYP, CT Chiu, et al. Aberrant expression of cdx2 homeobox gene in intraductal
papillary-mucinous neoplasm of the pancreas but not in pancreatic ductal adenocarcinoma.
Pancreas 2005:30:233-8.
53. Yeh TS, Tseng JH, Liu NJ, et al. Significance of cellular distribution of ezrin in pancreatic cystic
neoplasms and ductal adenocarcinoma. Arch Surg 2005; 140: 1184 -90.
54. Yeh TS in Book: Focus on Pancreatic cancer research, chapter: “Altered expression of apomucin
profile in mucinous cystic neoplasm and introduced papillary mucin-producing neoplasm of the
pancreas.” Nova Science Publishers, Inc (2005)
55. Yeh TS, Tseng JH, MD, Chen TC, et al. Characterization of intraductal growth type intrahepatic
cholangiocarcinoma and its precursor. Hepatology 2005; 42: 657-64.
56. Hsieh SY, Chen WY, Yeh TS, et al. High-frequency Alu-mediated genomic
recombination/deletion within the caspase-activated DNase gene in human hepatoma. Oncogene
2005:29;24:6584-9.
57. Chen KM, Yeh TS, Tseng JH, et al. Clinicopathological analysis of cystic duct carcinoma.
Hepatogastroenterology. 2005;52:691-4.
58. Jan YY, Yeh CN, Yeh TS et al. Clinicopathological factors predicting long-term overall survival
after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005:29:894-8.
59. Jan YY, Yeh CN, Yeh TS, Prognostic analysis of surgical treatment of peripheral
cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J
Page 40
Gastroenterol 2005;11:1779-84.
60. Tanimura Y, Kokuryo T, Tsunoda N, Yamazaki Y, Oda K, Nimura Y, Naing Mon N, Huang P,
Nakanuma Y, Chen MF, Jan YY, Yeh TS, et al. Tumor necrosis factor alpha promotes
invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Letter
2005;219:205-13.
61. Zen Y, Harada K, Sasaki M, Chen TC, Chen MF, Yeh TS, et al. Intrahepatic cholangiocarcinoma
escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of
cyclin D1. Lab Inves 2005;85:572-81
62. Yeh TS, Tseng JH, Chiu CT, et al. Cholangiographic spectrum of intraductal
papillary mucinous neoplasm of the bile ducts. Ann Surg 2006;244:248-53.
63. Chang KW, Yang PY, Lai HY, Yeh TS, Chen TC, Yeh CT. Identification of a novel actin isoform
in hepatocellular carcinoma. Hepatol Res 2006; 36(1): 33-39
64. Chan KM, Yeh TS, Jan YY, et al. Laparoscopic cholecystectomy for early gallbladder carcinoma:
long term outcome in comparison with conventional open cholecystectomy. Surg Endosc
2006;20:1867-71.
65. Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, Huang SF, Nimura Y, Nakanuma Y.
Different expression patterns of mucin core proteins and cytokeratins during intrahepatic
cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm
of the bile duct-an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol
2006;44;350-8.
66. Liu EH, Chen MF, Yeh TS*, et al. A useful model to audit liver resolution from cirrhosis in rats
using functional proteomics. J Surg Res 2007;138:214-23. (*Corresponding author)
67. Liu MS, Yang PY, Yeh TS*. Sonic hedgehog signaling pathway in pancreatic cystic neoplasms
and ductal adenocarcinoma. Pancreas 2007;34:340-6. (*Corresponding author)
68. Yeh CT, Chen TC, Chang ML, Hsu CW, Yeh TS, et al. Identification of NV-F virus DNA in
hepatocellular carcinoma. J Med Virol 2007;79:92-6.
69. Yeh TS, Ho YP, Jan YY, et al. Efficacy of color sonography and harmonic scalpel in laparoscopic
management of multiple/lobulated liver cysts and abscesses. Hepatogastroenterology.
2007;54:485-8.
70. Lieu KH, Liao LM, Yeh TS*, et al. Thalidomide attenuates tumor growth and preserves
fast-twitch skeletal muscle fibers of cholangiocarcinoma rats. Surgery 2008;143:375-83.
(*Corresponding author)
71. Chiu CT, Chiang JM, Yeh TS*, et al. Clinicopathological analysis of colorectal cancer liver
metastasis and intrahepatic cholangiocarcinoma- Are they just apples and oranges? Dig Liver Dis.
Page 41
2008;40:749-54. (*Corresponding author)
72. Momiyama M, Wakai K, Oda K, Kamiya J, Ohno Y, Hamaguchi M, Nakanuma Y, Hsieh LL, Yeh
TS, et al. Lifestyle risk factors for intrahepatic stone: Findings from a case-control study in an
endemic area, Taiwan. J Gastroenterol Hepatol. 2008; 23(7 Pt 1):1075-81
73. Yeh TS, Liu KH, Su MY, et al. Laparoscopy-assisted bowel surgery in an era of double-balloon
enteroscopy: from inside to outside. Surg Endosc 2009;23:739- 44.
74. Lin KJ, Liao CH, Hsiao IT, Yen TC, Chen TC, Yeh TS*. Improved hepatocyte function of
future liver remnant of cirrhotic rats after portal vein ligation: a bonus other than volume shifting.
Surgery 2009;145:202-11. (*Corresponding author)
75. Hsu JT, Chen HM, Liao CH, Yeh CN, Yeh TS, et al. Clinicopathologic Features and Predictors
for Survival of Mucinous and Nonmucinous Appendiceal Adenocarcinoma. Dig Surg.
2008;25:369-75
76. Hsu JT, Chen HM, Wu RC, Yeh CN, Yeh TS, et al. Clinicopathologic features and outcomes
following surgery for pancreatic adenosquamous carcinoma. World J Surg Oncol. 2008; 6:95
77. Lai MW, Huang SF, Lin SM, Chen TC, Lin CY, Yeh CN, Yeh TS, et al. Expression of the
HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical
resection. Hepatol Res. 2009;39(2):164-76
78. Liu YY, Yeh CN, Lee HL, Wang SY, Tsai CY, Lin CC, Chao TC, Yeh TS, et al. Local anesthesia
with ropivacaine for patients undergoing laparoscopic cholecystectomy. World J Gastroenterol
2009; 21;15:2376-80.
79. Liu KH, Yeh TS, et al. Surgical management of gallbladder sarcomatoid carcinoma. World J
Gastroenterol. 2009 21;15:1876 -9.
80. Tseng JH, Ouyang CH, Lin KJ, Yeh TS*. Significance of insulin signaling in liver regeneration
triggered by portal vein ligation. J Surg Res 2011;166:77-86(*Corresponding author)
81. Hsiao IT, Lin KJ, Chang SI, Yen TC, Chen TC, Yeh TS.* Impaired liver regeneration of steatotic
rats after portal vein ligation: particular emphasis on 99mTc-DISIDA scintigraphy and adiponectin
signaling. J Hepatol 2010;52(4)540-9
82. Chakravarty K, Hsu JT, Lin KH, Yeh CN, Yeh TS, et al. Prognosis and feasibility of en-bloc
vascular resection in stage II pancreatic adenocarcinoma. World J Gastroenterol
2010;28;16(8):997-1002
83. Yeh CT, Li SH, Lee RK, Lin MH, Tsai YH, Yeh TS,CD133-positive hepatocellular carcinoma in
an area endemic for hepatitis B virus infection. BMC Cancer 2009;11;9:324
84. Lee CW, Wu RC, Hsu JT, Yeh CN, Yeh TS, et al. Isolated pancreatic metastasis from rectal
cancer: a case report and review of literature.World J Surg Oncol. 2010; 8(1):26.
85. Hsieh SY, Huang SF, Yu MC, Yeh TS, et al. Stathmin1 overexpression associated with polyploidy,
Page 42
tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog.
2010;49;5:476-87.
86. Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin CY, Yeh TS, et al. Hepatitis
B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue
independently predict postoperative survival in hepatocellular carcinoma,
Hepatol
2010;52(6):1922-33
87. Liu CC, Jung SM, Orlandi A, Yeh TS, et al. The Fas-mediated apoptotic pathway in cardiac
myxoma. Int J Surg Pathol. 2010;18(6):493-8.
88. Sung CM, Hsu CM, Hsu JT, Yeh TS, et al. Predictive factors for lymph node metastasis in early
gastric cancer.World J Gastroenterol. 2010;7;16(41):5252-6.
89. Pu SJ, Liu MS, Yeh TS. Pyogenic liver abscess in older patients: comparison with younger
patients.J Am Geriatr Soc. 2010;58(6):1216-8.
90. Chen TH, Lin WP, Su MY, Hsu CM, Chiu CT, Chen PC, Kong MS, Lai MW, Yeh TS.
Balloon-Assisted Enteroscopy with Prophylactic Polypectomy for Peutz-Jeghers Syndrome:
Experience in Taiwan .Dig Dis Sci. 2010 Nov 18.
91. Chiu CT, Kuo CJ, Yeh TS, et al. Early Signet Ring Cell Gastric Cancer. Dig Dis Sci. 2010 Nov
21.
92. Cheng CT, Tsai CY, Hsu JT, Vinayak R, Liu KH, Yeh CN, Yeh TS, et al. Aggressive Surgical
Approach for Patients with T4 Gastric Carcinoma: Promise or Myth? Ann Surg Oncol. 2011 Jan
11
Page 43
CURRICULUM VITAE
YEE CHAO, M.D., Ph.D.
(趙 毅)
HOME ADDRESS:6th Fl, 48-4, Tien-Mou West Road Taipei, Taiwan
Tel: 886-2-2872-4468
OFFICE ADDRESS:
201, Sec. 2, Shih-pai Road, Shih-pai, Taipei, 11217, Taiwan, R.O.C.
Division of Chemoradiotherapy, Cancer Center, Taipei-Veterans General
Hospital
Tel: 886-2-28757618
Fax: 886-2-2873-9318
PERSONAL DATA:
Date of Birth: November 29, 1957
Marital Status: Married - 3 Children
CITIZENSHIP:
Republic of China
EDUCATION:
Ph. D., Institute of Clinical Medicine,
National Yang-Ming University, 1994-1999
Bachelor of Medical Science,
Kaohsiung Medical College, 1976-1983
POST-GRADUATE
TRAINING:
Resident in Internal Medicine, Veterans General Hospital-Taipei,
1985-1988
Chief Resident in Division of Gastroenterology, Department of
Internal Medicine, Veterans General Hospital-Taipei, 1988-90
Attending Physician in Gastroenterology, Veterans General HospitalTaipei, 1990-1998
Chief, Division of Chemoradiotherapy, Cancer Center, Veterans General
Hospital-Taipei, 1998BOARD
CERTIFICATION: National Medical Board, 1983
Board of Internal Medicine; The Society of Internal Medicine, R.O.C.,
1988
Board of Gastroenterologist, The Gastroenterological Society. R.O.C.
1990
Board of Clinical Oncology of the Taiwan Clinical Oncology Society
2005
ACADEMIC
APPOINTMENT: Clinical Teaching Assistant, National Yang-Ming Medical College,
1985-1989
Clinical Teaching Assistant, National Defense Medical College,
Page 44
1985-1989
Clinical Lecturer in Medicine, National Yang-Ming Medical College,
1989-1991
Lecturer in Medicine, National Yang-Ming Medical College, 19911995
Lecturer in Medicine, National Yang-Ming University, 1995-1996
Associate Professor in Medicine, National Yang-Ming University,
1996-2003
Professor in Medicine, National Yang-Ming University, 2003MILITARY SERVICE: Medical Officer, R.O.C., Air Force, 1983-1984
EDITORIAL
APPOINTMENTS:
Assistant Editor, Clinical Medicine, 1988-1989
Executive Editor, Clinical Medicine, 1989-1990
Editor, Clinical Medicine, 1990
Assistant Editor, Chinese Medical Journal (Taipei), 1991-1993
Editor, Journal of the Chinese Medical Association 2009MEMBERSHIP: Formosa Medical Association, R.O.C., 1986The Society of Internal Medicine, R.O.C., 1988The Gastroenterological Society, R.O.C., 1990Chinese Medical Association, R.O.C., 1991HONOR:
American Society of Clinical Onclolgy, 2002Best Intern Merit Citation, Mackay Memorial Hospital, 1983
Clinical Teaching Merit Citation, Veterans General Hospital-Taipei,
1994
Best Educational Research Publication Merit Citation, Veterans General
Hospital-Taipei, 1999
Clinical Teaching Merit Citation, Veterans General Hospital-Taipei,
2001
Excellent Research Thesis Award, Taiwan Clinical Oncology Association,
2011
Excellent Poster Award No. 1, The Joint Conference of The
Gastroenterological Society of Taiwan and The Digestive Endoscopy
Society of Taiwan, 2011
PUBLICATIONS OF Dr. Yee Chao ( 趙
1.
毅 醫 師 著 作 發 表 )
Chao Y, Lee FY, Tsai YT, Lin HC, Chang TT, Wang SS, Wu JC, Lai KH, Lee SD, Lo KJ. Muscle
cramps in liver cirrhosis. Chinese J Gastroenterol 1989;6:163- 9.
Page 45
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Chen HT, Wang SS, Lu CW, Lee FY, Chao Y, Tsai YT, Lee SD, Lai KH, Wu SL, Lo KJ. Spontaneous
bacterial peritonitis --- with emphasis on predisposing and prognostic factors. Chinese J
Gastroenterol 1990;7:144-9.
Chao Y, Wang SS, Ng WW, Lee SD. Garlic impaction in the lower esophageal (Schatzki) ring.
Chinese J Gastroenterol 1991;8:179-81.
Chao Y, Wong WW, Liu CY, Wang SS, Lee SD. Gastric Kaposi's sarcoma in patient with acquired
immunodeficiency syndrome. Chinese J Gastroenterol 1991;8: 182-5.
Lee FY, Lee SD, Tsai YT, Lai KH, Chao Y, Lin HC, Wang SS, Lo KJ. A randomized controlled trial
of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol 1991;12:236-40.
[SCI]
Chang TT, Lee FY, Tsai YT, Lai KH, Chao Y, Hsia HC, Lin HC, Wang SS, Lee SD, Lo KJ. A
randomized controlled study of low-dose and high-dose terlipressin in the control of acute
esophageal variceal hemorrhage. J Gastroenterol Hepatol 1991;6:481-4. [SCI]
Chao Y, Wang SS, Lin HC, Wang WS, Tsay SH, Yu TJ, Lee SD. Idiopathic portal hypertension: a
case report. Chin Med J 1992;50:65-8.
Hwu CM, Chao Y, Wang YJ, Su CH, Tsay SH, Hwang JI, Lee SD. Papillary cystic neoplasm of the
pancreas: case report and literature review. J Intern Med ROC 1992;3:138-42.
Chen CC, Wang SS, Chao Y, Lu CW, Lee SD, Tsai YT, Lo KJ. C-reactive protein and lactate
dehydrogenase isoenzymes in the assessment of the prognosis of acute pancreatitis. J Gastroenterol
Hepatol 1992;7:363-6. [SCI]
Hsia HC, Lin HC, Lee FY, Tsai YT, Lee SD, Meng HC, Chao Y, Wang SS, Lo KJ. Changes of
hepatic and systemic hemodynamics following somatostatin administration in patients with hepatitis
B - related cirrhosis. J Gastroenterol Hepatol 1993; 8:15-20. [SCI]
Chao Y, Wang SS, Lee FY, Lin HC, Lo GH, Tsai YT, Lee SD. Measurement of intravariceal pressure
by fine needle direct puncture in HBsAg-positive cirrhotic patients: the effect of vasopressin. J
Gastroenterol Hepatol 1993;8:157-60. [SCI]
Chao Y, Wang SS, Lee MY, Chen CJ, Chang FY, Wong WW, Lui CY, Lee SD. Endoscopic
examination in patients with acquired immunodeficiency syndrome: Taiwan experience. Chin Med J
1993;52:77-80.
Chao Y, Lin HC, Lee FY, Wang SS, Tsai YT, Hsia HC, Lin WJ, Lee SD, Lo KJ. Hepatic
hemodynamic features in patients with esophageal or gastric varices. J Hepatol 1993;19:85-9. [SCI]
Lin RS, Chao Y, Wang SS, Tsay SH, Chiang JH, Lee SD. Prehepatic portal hypertension after biliary
surgery: report of a case. Chinese J Gastroenterol 1993;10:235-241.
Yih JS, Chao Y, Chen YK, Chang KM, Lee SD, Hu HW. Nonbacterial thrombotic endocarditis and
cerebral embolism in a patient with cholangiocarcinoma. Chin Med J 1993;51:238-240.
Wang SS, Lu CW, Chao Y, Lee MY, Lin HC, Lee SD, Tsai YT, Chen CC, Lo KJ. Malignancy-related
ascites: a diagnostic pitfall of spontaneous bacterial peritonitis by ascitic fluid polymorphonuclear
cell count. J Hepatol 1994;20:79-84. [SCI]
Chao Y, Wang SS, Lee SD, Shiao GM, Chang HI, Chang SC. Effect of large- volume paracentesis on
pulmonary function in patients with cirrhosis and tense ascites. J Hepatol 1994;20:101-105. [SCI]
Wang SS, Lu CW, Chao Y, Lee MY, Lin HC, Lee SD, Tsai YT, Chen CC, Lo KJ. Malignant-related
ascites: a diagnostic pitfall of spontaneous bacterial peritonitis by ascitic fluid polymorphonuclear
cell count. J Hepatol 1994;20:79-84. [SCI]
Chen CC, Wang SS, Chao Y, Chen SJ, Lee SD, Wu SL, Jeng FS, Lo KJ. Serum pancreas-specific
protein in acute pancreatitis: its clinical utility in comparison with serum amylase. Scand J
Gastroenterol 1994;29:87-90. [SCI]
Lee MY, Wang SS, Lu CW, Chao Y, Lee FY, Wu SL, Lee SD, Tsai YT, Lo KJ. Diagnostic parameters
for spontaneous bacterial peritonitis in hepatitis B-related cirrhosis: comparison of ascitic fluid
polymorphonuclear cell count, lactate and pH values. Chin Med J 1994;53:71-76.
Page 46
21. Chen SJ, Wang SS, Lu CW, Chao Y, Lee FY, Lee SD, Wu SL, Cherng KL, Lo KJ. Clinical value of
tumor markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites. J
Gastroenterol Hepatol 1994;9:396-400. [SCI]
22. Wang SS, Lu CW, Chao Y, Lee FY, Chen TW, Lin HC, Lee SD, Tsai YT, Lo KJ. Total paracentesis in
non-alcoholic cirrhotics with massive ascites: Mid-term effects on systemic and hepatic
hemodynamics and renal function. J Gastroenterol Hepatol 1994;9:592-596. [SCI]
23. Chan WK, Wu CW, Lin TH, Chi KH, Chao Y, Huang YS, Wu MF, Chen YM, Liu M, Whang-Peng J,
Lee SD, Lui WY. Cisplatin, 5-fluorouracil (5FU), and Leucovorin (LV) in refractory gastric
carcinoma. Therapeut Radiol Oncol 1994;3:255-262.
24. Lu CW, Chao Y, Wang SS, Lee FY, Lee SD. Comparison between esophageal variceal pressure and
portal pressure in HBsAg-positive cirrhotics. Chinese J Gastroenterol 1995;12:166-173.
25. Wong YJ, Chao Y, Wang SS, Chen CC, Tsay SH, Chiang JH, Lee SD. Hepatic angiosarcoma: report
of a case. Chinese J Gastroenterol 1995;12:208-215.
26. Tong KJ, Chao Y, Wang SS, Lee SD. Clinical significance of isolated gastric varices among Chinese
patients. Chin Med J 1995;56:166-172. [correspondence]
27. Chen YM, Whang-Peng J, Liu JM, Chao Y, Lai CR, Wang SY, Perng RP. Leukemoid reaction
resulting from multiple cytokine production in metastatic mucoepidermoid carcinoma with central
necrosis. Jpn J Clin Oncol 1995;25:168-172. [SCI]
28. Chao Y, Chan WK, Huang YS, Teng HC, Wang SS, Lui WY, Whang-Peng J, Lee SD. Phase II study
of flutamide in the treatment of hepatocellular carcinoma. Cancer 1996;77:635-639. [SCI]
29. Huang YS, Chan CY, Wu JC, Pai CH, Chao Y, Lee SD. Serum levels of interleukin-8 in alcoholic
liver disease: relationship with disease stage, biochemical parameters and survival. J Hepatol 1996;
24:377-384. [SCI]
30. Wang SS, Lee FY, Chao Y, Chen CC, Lin HY, Wu SL, Lee SD. Clinical significance of complements
in ascitic diseases: elevated complement levels disapproving the liver disease origin. Proc National
Science Council, ROC 1996;20:51-57.
31. Liu JM, Chen YM, Chao Y, Liu TW, Chou CM, Chen LT, Yu WL, Whang-Peng J. Paclitaxel-induced
severe neuropathy in patients with previous radiotherapy to the head and neck region. J Natl Cancer
Inst 1996;88:1000-1001. [SCI]
32. Wang SS, Lu RH, Lee FY, Chao Y, Huang YS, Chen CC, Lee SD. Utility of lentil lectin affinity of
a-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 1996;25:166-171. [SCI]
33. Weng YJ, Wang SS, Yang WG, Chao Y, Lai CR, Lee SD. Carcinoid tumors of the gastrointestinal
tract in Taiwan Chinese: an analysis of 50 cases. Chin Med J 1996;58:247-251.
34. Wang SS, Chen CC, Chao Y, Wu SL, Lee FY, Lin HC, Kong CW, Tsai YT, Lee SD. Sequential
hemodynamic changes for large volume paracentesis in post-hepatitic cirrhotic patients with massive
ascites. Proc National Science Council, ROC 1996;220:65-70.
35. Huang TS, Shu CH, Shih YL, Huang HC, Su YC, Chao Y, Yang WK, Whang-Peng J. Protein
tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new
homolog of etoposide. Cancer Lett. 110 (1-2):77-85, 1996 Dec 20. [SCI]
36. Wang SS, Lee FY, Wu SL, Hwu CM, Chien CH, Lee SD, Tsai YT, Chao Y, Chen CC, Wang PS.
Effects of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in
carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997;26:1128-34. [SCI]
37. Chao Y, Chan WK, Wang SS, Lai KH, Chi CW, Lin CY, Chan A, Whang-Peng J, Lui WY, Lee SD.
Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol
Hepatol 1997; 12:277-281. [SCI]
38. Hung HC, Chao Y, Huang HC, Wang SS, Chang FY, Lee SD, King KL, Li FY. Hepatoid
adenocarcinoma of the stomach with liver metastasis: report of a case. Gastroenterol J Taiwan
1997;14:223-228. [correspondence]
39. Chen CY, Lu CL, Huang YS, Tam TN, Chao Y, Chang FY, Lee SD. Ageing remains one of the risk
Page 47
factors to develop gallstone disease in current Taiwan society. Age and Ageing 1998;27:437-441.
[SCI]
40. Chi KH, Chao Y, Chan WK, Lo SS, Chen SY, Yen SH, Chen KY, Wu CW, Lee SD, Lui WY. Weekly
etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced
gastric cancer. Brit J Cancer 1998;71:1984-88. [SCI]
41. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, Lee SD, Huang TS. Overexpression of
cyclin A but not Skp 2 correlates with the tumor relapse of human hepatoceullular carcinoma. Cancer
Res 1998;58:985-990. [SCI]
42. Chao Y, Chan WK, Birkhofer MJ, Hu OYP, Wang SS, Huang YS, Liu M, Whang-Penng J, Chi KH,
Lee SD. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular
carcinoma patients. Brit J Cancer 1998;78:34-39. [SCI]
43. Wei SJ, Chao Y, Hung YM, Lin WC, Yang DM, Shih UL, Ch’ang LY, Peng-Whang J, Yang WK. Sand G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells
transduced with herpes simplex virus thymidine kinase. Exp Cell Res 1998;241:66-75. [SCI]
44. Yang WG, Wang SS, Lee FY, Chao Y, Chen CC, Chang FY, Chiang JH, Tsay SH, Su CH, Yang YH,
Lee SD. Severe colonic complications in acute pancreatitis. Chin Med J (Taipei) 1998;61:59-64.
45. Hung HC, Huang YS, Lin CC, Chao Y, Chi KW, Yen SH, Chang FY. Radioatherapy in the treatment
of duodenal bleeding due to hepatocellular carcinoma invasion. J Gastroenterol Hepatol
1998;13:1143-1145. [correspondence] [SCI]
46. Hung HC, Chen WC, Chao Y, Hou MC, Lin HC, Chang FY, Lee SD. Klebsiella pneumoniae
panophthalmitis: A possible complication of endoscopic variceal injection sclerotherapy. Am J
Gastroentrol 1998;98:2603-2604. [SCI]
47. Ho CH, Chau WK, Chao Y, Lee SD, King KL, Wu CW, Liu SM. Diagnostic and prognostic value
of plasma fibrinolytic markers in hepatocellular carcinoma. Advances in Therapy 1998;15:98-105.
[SCI]
48. Huang HC, Hung HC, Li CP, Chao Y, Huang YS, Lio CY, Chang FY. Cholestatic pruritis: current
concepts in pathogenesis and therapeutic directions. J Intern Med Taiwan 1998;9:7-11.(Chinese)
[correspondence]
49. Ho CH, Chao Y, Lee SD, Chau WK, Wu CW, Liu SM. Diagnostic and prognostic values of
plasma levels of fribrinolytic markers in gastric cancer. Thrombosis Research 1998;91:23-27.
[SCI]
50. Hung HC, Huang HC, Huang YS, Chao Y, Teng HC, Chang FY, Lee SD. Effectiveness of
ondansetron on treatment of cholestatic pruritus in patients with advanced hepatocellular
carcinoma. J Intern Med Taiwan 1998;9:70-75. [correspondence]
51. Liu JM, Chen YM, Chao Y, Liu SM, Tiu CM, Wu HW, chiou TC, Hsieh RK, Chen LT,
Whang-Peng J. Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown
primary site (CUPS) in Taiwan, a region with a high prevalence of endemic viral infections. Jpn J
Clin Oncol 1998;28:431-435. [SCI]
52. Whang-Peng J, Chao Y. Clinical trials of HCC in Taiwan. Hepato-Gatroenterology
1998;45:1937-1943. [SCI]
53. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, Lee SD. Serum levels of cytokines
in hepatitis C-related liver disease: a longitudinal study. Chin Med J (Taipei) 1999;62;327-333.
54. Wang K, Huang YS, Deng JF, Yang CC, Ger I, Tsai WJ, Wu JC, Chao Y, Chang FY, Lee SD.
Characteristics and risk factors of acetaminophen-induced hepatitis in Taiwan. Chin Med J (Taipei)
1999;62:369-375.
55. Wei SJ, Chao Y, Shih YL, Yang DM, Hung YM, Yang WK. Involvement of Fas (CD95/APO-1)
and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with
Herpes simplex virus thymidine kinase. Gene Therapy 1999;6:420-431. [SCI]
56. Chao Y, Shih YL, Cheng SJ, Wei SJ, Chi KH, Yeh SH, Lee SD, Yang WK. Increased survival of
Page 48
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
hepatoma-bearing mice by gene therapy using granulocyte-macrophage colony-stimulating factor
(GM-CSF) transduced tumor cell vaccine in combination with Bacillus Calmette-Guerin (BCG).
Chin Med J (Taipei) 1999;62:682-689. [correspondence]
Chao Y, Shih YL, Cheng SJ, Lee SD, Huang TS. Inhibition of DNA synthesis by down regulation
of cyclin A but not Skp 2 overexpression in human hepatocellular carcinoma cells. Cancer Letter
1999 ;139:1-6. [correspondence] [SCI]
Huang TS, Lee CC, Chao Y, Shu CH, Chen LT, Chen LL, Chen MH, Yuan CC, Whang-Peng J. A
novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in
killing refractory cancer cells. Pharmaceutical Research 1999;16:997-1002. [SCI]
Huang YS, Wu JC, Chan CY, Chao Y, Chamg FY, Lee SD. Circulating intercellular adhesion
molecule-1 in chronic liver disease and hepatocellular carcinoma. Chin Med J (Taipei)
1999;62:487-495.
Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, Lui MC, Yeo W, Chak K, Johnston A,
Johnson P. A multi-center randomized phase II study of nolatrexed versus doxorubicin in
treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemotherapy &
Pharmacology 1999;44:307-11. [SCI]
Tsang YW, Kong SL, Yen SH, ChaoY, Chi KH. 3D-Conformal radiotherapy of unresectable and
unembolizable advanced hepatoma-a pilot study. Therapeut Radiol Oncol 1999;6:253-60
Chen CY, Chau GY, Yen SH, Hsieh YH, Chao Y, Chi KW, Li CP, Chang FY, Lee SD.
Life-threatening hemorrhage from a sternal metastatic hepatocellular carcinoma. J Gastroenterol
Hepatol 2000 15;684-687. [correspondence] [SCI]
Wang SS, LeeFY, Chan CC, Lu RH, Chao Y, Lin HC, Wu SL, Tsai YT, Lee SD. Sequential
changes of plasma cytokine and endotoxin levels in cirrhotic patients with bacterial infection.
Clinical Science 2000;98:419-425. [SCI]
Chao Y, Teng HC, Hung HC, King KL, Li CP, Chi KH, Yen SS, Chang FY. Successful initial
treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil, and leucovorin
chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
Jpn J Clin Oncol 2000;30:122-125 [correspondence] [SCI]
Liu JM, Wu HW, Chen WS, Lin WC, Chao Y, Lui WY, Whang-Peng J. Integration of
computer-assembled digital images and text data as evidence for the oncological record. J Digital
Imaging 2000;13:55-59. [SCI]
Chang SS, Huang YS, Chao Y, Li AFY, Chi KW, Yen SH, Wang SS, Chang FY, Lee SD. Gastric
adenocarcinoma with distant cutaneous metastasis : report of a case. Gastroenterol J Taiwan
2000;17:144-147. [correspondence]
Chen CP, Chao Y, Li CP, Lai MY, Chi KH, Yen SH, Chang FY, Lee SD. Radiotherapy is effective
in the treatment of hepatocellular carcinoma with right atrium invasion-report of a case. Therapeut
Radio Oncol 2000;7: 91-96. [correspondence]
Chen CP, Chao Y, Li CP, Lee RC, Tsay SH, Chi KW, Yen SH, Chang FY, Lee SD. Concurrent
chemoradiation is effective in the treatment of alpha-fetoprotein producing acinar cell carcinoma
of the pancreas : report of a case. Pancreas 2001;22:326-329 [correspondence] [SCI]
Huang TS, Shu CH, Chao Y, Chen SN, Chen LL. Activation of MAD2 checkprotein and
persistence of cyclin B1/CDC2 activity associate with paclitaxel-induced apoptosis in human
nasopharyngeal carcinoma cells. Apoptosis 2000;5:235-241. [SCI]
Shu CH, Cheng H, Lirng JF, Chang FC, Chao Y, Chi KW, Yen SH. Salvage surgery for recurrent
nasopharyngeal carcinoma. Laryngoscope 2000;110:1483-1488. [SCI]
Chi KW, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT. Phase II trial
of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma.
Oncology 2001;60:110-15. [SCI]
Chi KW, Wang HE, Chen FD, Chao Y, Liu RS, Chou SL. Wang YS, Yen SH. Precinical
Page 49
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
evaluation of locoregional delivery of radiolabeled iododexsyuridine and thymidylate synthase
inhibitor in a hepatoma model. J Nucl Med 2001;42:345-51. [SCI]
Fang YR, Huang YS, Wu JC, Chao Y, Tsay SH, Chan CY, Chang FY, Lee SD. An unusual
cutaneous metastasis from hepatocellular carcinoma. Chi Med J (Taipei) 2001;64:253-57.
Huang TS, Shu CH, Chao Y, Chen LT. Evaluation of GL331 in combination with paclitaxel:
GL331's interference with paclitaxel-induced cell cycle perturbation and apoptosis. Anti-Cancer
Drugs 2001;12:259-266. [SCI]
Chang SS, Luo JC, Chao Y, Chao JY, Chi KH, Wang SS, Chang FY, LeeSD, Yen SH. The clinical
features and prognsotic factors of hepatocellular carcinoma patients with spinal metastasis. Eur J
Gastroenterol 2001:13:1341-1345. [SCI]
Chang SS, Lu CL, Chao JY, Chao Y, Yen AH, Wang SS, Chang FY, Lee SD. Unchanging trend of
adenocarcinoma of the esophagus and gastric cardia in Taiwan. Dig Dis Sci 2002;47:735-740.
[SCI]
Chao Y, Liu JM, Li AFY, Perng CL, Tiu CM, King KL, Chen LT, Lin WC, Lan C, Whang-Peng J.
Palliative MEFLEP therapy in advanced pancreatic cancer-excellent response in a patient with
Her-2 neu amplification. Pancreas 25:e10-14, 2002 [SCI]
Chang SL, Chung PL, Lee RC, Chang FY, Lee SD, Yen SH, Chao Y. Calcification of liver
metastases in a colon cancer patient following chemotherapy with 5-fluorouracil: a case report.
Chin J Radiol 2002;27:73-77.
Liu JM, Chen LT, Chao Y, Li AFY, Wu CW, Liu TS, Shiah HS, Chang JY, Chen JD, Wu HW, Lin
WC, Lan C, Whang-Peng J. Phase II and pharmacokinetic study of GL331 in previously treated
Chinese gastric cancer patients. Cancer Chemother Pharmacol 2002;49:425-428. [SCI]
Tsi CJ, Chao Y, Chen CW, Lin WW. Aurintricarboxylic acid protects against cell death caused by
lipopolysaccharide in macrophages by decreasing inducible nitric-oxide synthase induction via
IkB kinase, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase
inhibition. Molecular Pharmacology 2002;62:90-101 [SCI]
Chen CW, Chao Y, Chang YH, Hsu MJ, Lin WW. Inhibition of cytokine-induced JAK-STAT
signalling pathways by an endonuclease inhibitor aurintricarboxylic acid. Br J Pharmacol.
2002;137:1011-20. [SCI]
Lee MY, Li CP, Lee RC, Wang LW, Chao Y. Gastric adenocarcinoma with Sister Mary Joseph's
nodule successfully treated with combined chemoradiation. J Gastroenterol Hepatol.
2003;18:114-5. [SCI]
Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor and
angiogenin in patients with hepatocellular carcinoma. Annals of Surgical Oncology
2003;10:255-262. [SCI]
Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD, Hung MC. Adenovirus type 5 EIA sensitizes
hepatocellular carcinoma cells to gemcitabine. Cancer Research 2003; 63: 6229-36. [SCI]
Huang YS, Chern HD, Wu JC, Chao Y, Huang YH, Chang FY, Lee SD. Polymorphism of the
N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma.
Am J Gastroenterology. 2003;98:1417-22. [SCI].
Wu CY, Lee DD, Chen CC, Li CP, Chen CL, Wang WJ, Chao Y, Chang FY. Hepatocellular
carcinoma with an unusual cutaneous metastasis: report of a case. Gastroenterol J Taiwan
2003;153:24-29.
Li CP, Chao Y, Chi KH, Chan WK, Ten HC, Lee RC, Chang FY, Lee SD, Yen SH. Concurrent
chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus
5-fluorouracil, a randomized controlled study. Int J Radiation Oncology Biol Phys 2003;57:98-104.
[SCI]
Li CP, Lee FY, Hwang SJ, Lu RH, Lee WP, Chao Y, Wang SS, Chang FY, Whang-Peng J, Lee SD.
Page 50
Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and
basic fibroblast growth factor. World J Gastroenterol 2003;9:2832-2835. [SCI]
89. Li CP, Chao Y, Yen SH. In response to Dr. Crane: Role of concurrent gemcitabine-based
chemoradiation and regional nodal irradiation in the treatment of locally advanced pancreatic
cancer. . Int J Radiation Oncology Biol Phys 2004;58:1009-1010. [SCI]
90. Chang YH, Chao Y, Hsieh SL, and Lin WW. Mechanism of LIGHT/Interferon-g-induced cell
death in HT-29 cells. J Cellular Biochem 2004, 93(6):1188-202. [SC I]
91. Li CP, Huang TS, Chao Y. Chang FY. Whang-Peng J. Lee SD. Advantages of assaying
telomerase activity in ascites for diagnosis of digestive tract malignancies. World Journal of
Gastroenterology. 10(17):2468-71, 2004
92. Chao Y. Yeh KH. Chang CJ. Chen LT. Chao TY. Wu MF. Chang CS. Chang JY. Chung
CY. Kao WY. Hsieh RK. Cheng AL. Phase II study of weekly oxaliplatin and 24-h infusion of
high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. British
Journal of Cancer. 2004;91(3):453-8.
93. Li CP. Chao Y. Intraarterial chemotherapy: another choice for unresectable advanced
hepatocellular carcinoma?[comment]. Journal of the Chinese Medical Association:
JCMA. 2004;67(12):595-6.
94. Wang LW. Yang SH. Lin JK. Lin TC. Chan WK. Chen WS. Wang HS. Jiang JK. Lee RC. Li AF.
Chao Y. Chi KH. Yen SH. Pre-operative chemoradiotherapy with oral tegafur-uracil and
leucovorin for rectal cancer. J Surgical Oncology. 2005;89(4):256-63.
95. Chi KH. Liu SJ. Li CP. Kuo HP. Wang YS. Chao Y. Hsieh SL. Combination of conformal
radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory
hepatoma. Journal of Immunotherapy. 2005;28(2):129-35.
96. Hsu MJ, Chao Y, Chang YH, Ho FM, Huang Huang YL , Luh TY, Chen CP, Lin WW. Cell
apoptosis induced by a synthetic carbazole compound LCY-2-CHO is mediated through activation
of caspase and mitochondrial pathways. Biochemical Pharmacology 2005; 70: 102–112
97. Chang YH, Hsieh SL, Chao Y, Chou YJ, Lin WW. Proinflammatory effects of LIGHT through
HVEM and LTbR interactions in cultured human umbilical vein endothelial cells. Journal of
Biomedical Science 2005;12: 363–375.
98. Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH,
Whang-Peng J. Alfa-fetoprotein response predicts survival benefits of thalidomide in advanced
hepatocellular carcinoma. Aliment Pharmacol Ther. 2005:22:217-226.
99. Chen CY, Chao Y, Chang FY, Chien EJ, Lee SD, Doong ML. Intracisternal des-acyl ghrelin
inhibits food intake and non-nutrient gastric emptying in conscious rats. Intern J Molecular
Medicine 2005;16:695-699.
100.Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, Majlis A, Assadourian S,
Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or
without fluorouracil in patients with untreated advanced gastric or gastroesoophageal
adenocarcinoma. J Clin Oncol 23(24):5660-5667, 2005.
101.Fu YH, Chao Y, Hsia CY, Li CP, Lee RC, Lee WP, Yuan JN, Tsay SH, Chi KH, Yen SH, Lui WY.
A successful treatment with repeated surgery and adjuvant combination chemotherapy on a case of
advanced undifferentiated embryonal sarcoma of liver. J Cancer Molecules 1(1) :53-57, 2005.
102.Lee WP, Tai DI, Lan KH, Li AFY,, Hsu JC, Lin EJ, Lin YP, Sheu ML, Li CP, Chang FY, Chao Y,
Yen SH, Lee SD. The -251T allele of the interleukin-8 promoter is associated with increased risk
of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res
11:6431-6437, 2005.
103.Lai MY, Yang SP, Chao Y, Lee PC, LeeSD. Fever with acute renal failure due to body
massage-induced rhabdomyolysis. Nephrol Dial Transplant 2006;21:233-234.
104.Shiah HS, Chao Y, Chen LT, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YH,
Page 51
Whang-Peng J, Liu TW. Phase I and pharmacokinetic study of oral thalidomide in patients with
advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006; 21(3):531-6. [SCI]
105.Chao Y, Li CP, Chao TY, Su WC, Hsieh RK, Wu MF, Yeh KH, Kao WY, Chen LT, Cheng AL. An
open, multi-center, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and
leucovorin in patients with advanced gastric cancer. British Journal of Cancer. 2006;
95;159-163.,2006
106.Cutsem EV, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodriguez A, Fodor
M, Chao Y, Voznyi E, Reese ML, and Ajani FA. Docetaxel cisplatin 5-fluorouracil v Cisplatin
5-fluorouracil as First-line Therapy for Advanced Gastric Cancer: A Multicenter, Randomized
Phase III Study. J Clin Oncol. 2006 Nov 1;24(31):4991-7.
107.Chau GY, Liu WY, Tsay SH, Chao Y, King KL, Wu CW. Postresetional adjuvant intraportal
chemotherapy in patients with hepatocellular carcinoma: a case-control study. Ann Surg Oncol
2006;1-6.
108.Su RY, Chao Y, Chen TY, Huang DY, Lin WW. 5-Aminoimidazole-4-carboxamide riboside
sensitizesTRAIL- and TNFA-induced cytotoxicity in colon cancer cells through AMP-activated
protein kinase signaling. Mol Cancer Ther 2007;6(5):1562–71]
109.Jaffer A. Ajani, Vladimir M. Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla,
Corrado Boni, Adriano Rodrigues, Miguel Fodor, Chao Y, Edouard Voznyi, Lucile Awad, Eric
Van Cutsem Quality of life with docetaxel plus cisplatin and fluorouracil compared with
cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal
adenocarcinoma: the V-325 Study Group.J Clin Oncol. 2007 Aug 1;25(22):3210-6. [SCI]
110.Jaffer A. Ajani, Vladimir M. Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla,
Corrado Boni, Adriano Rodrigues, Miguel Fodor, Chao Y, Edouard Voznyi, Cindy Marabotti, Eric
Van Cutsem Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with
cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer
adenocarcinoma: the V-325 Study Group.J Clin Oncol. 2007 Aug 1;25(22):3205-9. [SCI]
111.Su JM, Lai XM, Lan KH, Li CP, Chao Y, Chang FY, Lee SD, Lee WP. X protein of hepatitis B
virus functions as a transcriptional corepressor on the human telomerase promoter. Hepatology.
2007; 46(2):402-13.
112.Li CP, Chao Y, Chen LT, Lee RC, Lee WP, Yuan JN, Yen SH, Lee SD Fever after transcatheter
arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scand
J Gastroenterol 2008; 1-8 [SCI]
113.Yuan JN, Chao Y, Lee WP, Li CP, Lee RC, Chang FY, Yen SH, Lee SD, Whang-Peng J
Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients
with advanced hepatocellular carcinoma. Med Oncol 2008; 25: 201-6 [SCI]
114.Huang PI, Chao Y, Li CP, Lee RC, Chi KH, Shiau CY, Wang LW, Yen SH
Efficacy and factors
affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced
pancreatic cancer. Int J Radiat Oncol Biol Phys 2009 1;73(1):159-65. [SCI]
115.Tsai MC, Chao Y, Lee CL, Chen YA, Lu YY, Yang JN. Sick sinus syndrome and acute tumor lysis
syndrome after low-dose thalidomide therapy in recurrent hepatocellular carcinoma: a case report.
J Intern Med Taiwan 2008; 19:536-541.
116.Chen LT, Shiah HS, Chao Y, Chang JY, Cheng LT, Whang‐Peng J. a‐ fetoprotein response in
advanced HCC receiving cytostatic agent JCO.2009.23.8311 [SCI]
117.Mok T, Yang TS, Chao Y, Wang CH, Liu MC, Kang YK, Kang WK, Kim JS, Wang YJ, Leung T.
Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian
patients with inoperable hepatocellular carcinoma. Asia-Pacific JCO 2009;5:95-100.
118.Tang CP, Wang YW, Shiau YT, Lee RC, Lan KH, Chao Y. Gastropericardial fistula and candida
albicans pericarditis: a rare complication of gastric adenocarcinoma treated with radiation and
Page 52
chemotherapy. J Chin Med Assoc 2009 ;72(7):374-8.
119.Chao Y, Li CP. Current treatment of gastric cancer-Taiwan experience. Proceeding of 2nd
Japan-Taiwan Joint Symposium on Medical Oncology. 2009; p47-50. [correspondence]
120.Chen JS, Chao Y, Yang TS, Chou WC, Chen LT, Lee KD, Lin YC. A phase II trial of biweekly
oxaliplatin with simplified schedule of 48-hour infusion of high-dose 5-fluorouracil and
leucovorin for advanced biliary tract carcinoma. Cancer Chemother Pharmacol 2009
2009 ;65(1):151-7 [SCI]
121.Kuo SC, Chao Y, Luo JC, Lee KC, Wu CW, Li AFY, Lee RC, Li CP. Primary small cell carcinoma
of the stomach successfully treated with cisplatin and etoposide. J Chin Med Assoc
2009;72(11):598–602
122.Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP,
Shen LJ, Linn C. A phase I/II and pharmacogenomic study of pemetrexed plus cisplatin in patients
with unresectable, advanced gastric carcinoma. Anticancer Drugs. 2010 Sep;21(8):777-84. [SCI]
123.Cheng JS, Chao Y, Hsieh RK, Cheng AL, Cheng PM, Chiou TJ, Chao TY, Yeh KH, Chen LT,
Whang-Peng J. A Phase II and Pharmacokinetic Study of First Line S-1 for Advanced Gastric
Cancer in Taiwan. Cancer Chemother Pharmacol. 2010 Aug 17. [Epub ahead of print]. [SCI]
124.Yang KC, Chao Y, Luo JC, Kuo JY, Lee RC, Li AF, Li CP. The unusual presentation of gastric
adenocarcinoma as a testicular mass: a favorable response to docetaxel and Cisplatin plus oral
tegafur/uracil and leucovorin. J Chin Med Assoc. 2010 Feb;73(2):88-92.
125.Li CP, Chen JS, Chen LT, Yen CJ, Lee KD, Su WP, Lin PC, Lu CH, Tsai HJ, Chao Y. A phase II
study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line
chemotherapy in patients with locally advanced or metastatic gastric cancer. Br J Cancer. 2010
Oct 5. [Epub ahead of print][correspondence] [SCI]
126.Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA,
Wang-Peng J, Chen PJ, Chen LT. A randomised phase II study of pegylated arginine deiminase
(ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer. 2010 Sep
28;103(7):954-60. [SCI]
127.Huang SH, Chao Y, Wu YY, Luo JC, Kao CH, Yen SH, Li CP. Concurrence of UGT1A
polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with
metastatic colon cancer. Tumori 2010 [in press] [SCI]
Page 53
Kelvin Kun-Chih Tsai, MD, PhD
Birthday: 01/31/1968
Citizenship: Taiwan
E-mail: kkctsai@gmail.com
EDUCATION
Degree and fields
Dates
M.D., Medicine
1986-1993 Taipei Medical University, Taiwan
Institution
Ph.D., Genetics and Complex 2001-2005 Harvard University,Graduate School of
Diseases
Arts and Sciences, MA, USA (with Z.M.
Yuan)
Post-doctoral Fellow, Cancer 2005-2006 University of Pennsylvania,Institute for
Biology& Tissue Engineering
Medicine&Engineering, PA, USA (with
V.M. Weaver)
Post-doctoral Fellow, Cancer 2006-2007 University of California, San Francisco,
Biology& Tissue Engineering
Department of Surgery, CA, USA (with
V.M. Weaver)
CLINICAL AND ACADEMIC APPOINTMENTS
Resident, Department of Medicine, Taipei Veterans General Hospital, Taiwan (1993-1996).
Chief Resident, Division of Gastroenterology, Department of Medicine, Taipei Veterans General
Hospital, Taiwan (1996-1998).
Clinical Fellow, Division of Critical Care, Department of Medicine, Taipei Veterans General Hospital,
Taiwan(1998-2000).
Attending Physician, Division of Critical Care, Department of Medicine, Taipei Veterans General
Hospital, Taiwan (2000-2001).
Lecturer, NationalYang-MingUniversitySchool of Medicine, Taiwan (2000 to 2002).
Research Assistant, Department of Genetics and Complex Diseases, HarvardUniversitySchool of
Public Health, USA (2002-2005).
Assistant Professor of Medicine, Taipei Medical University School of Medicine, Taiwan
(2007-present).
Attending Physician and Assistant Investigator, National Institute of Cancer Research, National Health
Research Institute, Taiwan (2008-present).
HONORS AND PROFESSIONAL ACTIVITIES
Award
1. Recipient and pre-doctoral fellow, Ruth L. Kirschstein National Research Service Award
(NRSA), Roadmap Training Program, National Institute of Health, USA(2005).
2. Harvard Presidential Scholar, Harvard University, USA (2004-2005).
3. Recipient, Glenn/AFAR scholarship, American Federation for Aging Research, USA (2004).
4. Recipient, Government Scholarship for Studying Abroad, Ministry of Education, Taiwan
(2001-2003)
5. Recipient, Scholarship of the Ivy Association for Cultural and Educational Exchange, Taiwan
(2001).
6. Outstanding Young Researcher, National Science Council, Taiwan (2000).
7. Research Thesis Prize, Taipei Veterans General Hospital, Taiwan (1999).
Membership
Page 54






Board Certified, TaiwanSociety of Internal Medicine (1996 to present).
Board Certified, The Gastroenterology Society of Taiwan (1999 to present).
Board Certified, The Digestive Endoscopy Society of Taiwan (1999 to present).
Board Certified, Society of Emergency and Critical Care Medicine, Taiwan (2000 to present).
The Oxygen Society, CA, USA (1999-2001).
The American Society for Cell Biology (2006 to present).
PRINCIPAL AREAS OF RESEARCH INTEREST




Epigenetic pathways in tumor progression, drug resistance and metastasis.
Cell response to stress and death inductions in different microenvironmental contexts.
Systemic profiling of tumor environmentsand tissue architectures.
Development of three-dimensional tissue-based models and assays in drug development and
personalized medicine.
PUBLICATIONS
Journal articles
1.
Li CR, Su JJ, Chan TS, Chu PY, Lee MT, Li CF, Chang CC, Chuu CP, Chen LT, Shen KH, Chu
JM, Yeh JJ, Weaver VM, Tsai KK (corresponding). A core molecular program of glandular
structural differentiation identifies cancer patients with good prognosis (Submitted).
2. Su JJ, Li CR, Chu PY, Lee MT, Tan KT, Uen YH, Li CF, Wu CH, Liu MS, Chan TS, Chang CC,
Kuo LK, Chang KY, Tsai KK (corresponding). A senescent stroma predicts disease progression
in treated breast cancer patients (under revision in Clin. Cancer Res.).
3. Tsai KK, Chatterjee C, Werner ME, Mian IS, Nuth M, Lakins JN, Tobias J, Weaver VM. The
third dimension drives N-CoR2-dependent death resistance (under revision).
4. Tsai, KK, Stuart J, Chuang YY, and Yuan ZM. Low-dose radiation-induced senescent stromal
fibroblasts render nearby breast cancer cells radioresistant. Radiat. Res. 172:306-313 (2009).
5. Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M,
Feldman MD, Boudreau NJ, Welm AL, Tsai KK, Weber BL, Weaver VM. HoxA9 regulates
BRCA1 expression to modulate mammary tissue growth and survival. J. Clin. Invest.
120:1535-50 (2010).
6. Tuan TC, Hsu TG, Fong MC, Hsu CF, Tsai KK, Lee CY, Kong CW. Deleterious effects of
short-term, high-intensity exercise on immune function: evidence from leukocyte mitochondrial
alterations and apoptosis. Br. J. Sports Med. 42:11-15 (2007).
7. Stuart JR, Kawai H, Tsai KK, Chuang EY, Yuan ZM. c-Abl regulates early growth response
protein (EGR1) in response to oxidative stress. Oncogene24:8085-8092 (2005).
8. Tsai KK, Chuang YY, Little J, Yuan ZM. Cellular mechanisms for low-dose ionizing
radiation-induced perturbation of the breast tissue microenvironment. Cancer Res. 65:6734-6744
(2005).
9. Kong CW, Huang CH, Hsu TG, Tsai KK, Hsu CF, Huang MC, Chen LC. Leukocyte
mitochondrial alterations after cardiac surgery involving cardiopulmonary bypass: clinical
correlations. Shock 21:315-319 (2004).
10. Tsai KK, Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer
Res.63:3418-3424 (2003).
11. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damage-induced MDMX
degradation is mediated by MDM2. J. Biol. Chem.278, 45946-45953 (2003).
12. Hsu TG, Hsu KM, Kong CW, Lu FJ, Cheng H, Tsai K(corresponding). Leukocyte mitochondria
alterations after aerobic exercise in trained human subjects.Med Sci Sports Exerc.34:438-42
(2002).
Page 55
13. Kong CW, Hsu TG, Lu FJ, Chan WL, Tsai K(corresponding). Leukocyte mitochondria
depolarization and apoptosis in advanced heart failure: clinical correlations and effect of therapy.
J. Am. Coll.Cardiol.38:1693-1700 (2001).
14. Tsai K, Hsu TG, Lu FJ, Hsu CF, Liu TY, Kong CW. Age-related changes in the mitochondrial
depolarization induced by oxidative injury in human peripheral blood leukocytes. Free Radic.
Res. 35:395-403 (2001).
15. Tsai K, Hsu TG, Hsu KM, Cheng H, Liu TY, Hsu CF, Kong CW. Oxidative DNA damage in
human peripheral leukocytes induced by massive aerobic exercise. Free Radic. Biol. Med.
31:1465-1472 (2001).
16. Tsai K, Hsu TG, Kong CW, Lin KC, Lu FJ. Is the plasma peroxyl-radical scavenging capacity
protective in systemic inflammatory disorders in humans? Free Radic. Biol. Med. 28:926-933
(2000).
17. Kong CW, Tsai K, Chin JH, Chan WL, Hong CY. Magnolol attenuates peroxidative damage and
improves survival of rats with sepsis. Shock 13, 24-28 (2000).
18. Tsai K, Wang SS, Chen TS, Kong CW, Change FY, Lee SD, Lu FJ. Oxidative stress: an
important phenomenon with pathogenetic significance in the progression of acute pancreatitis.
Gut 42, 850-855 (1998).
Patents
1. Weaver VM, Tsai KK. Novel methods for predicting and treating tumors resistant to drug,
immunotherapy, and radiation. U.S. Patent Application No. 023070-189710US (2009).
Conference & proceeding papers
1. Tsai KK, Weaver VM, Su JJ, Lee MT. A core transcriptional program associated with structural
organization predicts prognosis of pancreatic cancer. Molecular Medicine Tri-Conference,
Cambridge Healthtech Institute, San Francisco, CA, USA (2011).
2. Su JJ, Li CR, Lee MT, Chu PY, Weaver VM, Tsai KK. Disease progression of prostate and
pancreatic cancers relates to a core gene expression profile associated with glandular
differentiation. The 50th Annual Meeting of the American Society for Cell Biology, Philadelphia,
PA, USA (2010).
3. Lee MT, Su JJ, Li CR, Chu PY, Liu MS, Tan KT, Chiang JH, Tsai KK. Gene expression
signatures associated with protracted stromal responses to therapeutically relevant cytotoxic
stimuli predict breast cancer chemoresponsiveness. Fourth AACR International Conference on
Molecular Diagnostics in Cancer Therapeutic Development, Denver, CO, USA (2010).
4. Su JJ, Li CR, Lee MT, Chu PY, Weaver VM, Tsai KK. A gene expression signature associated
with structural differentiation of prostate acini predicts postoperative recurrence of prostate
cancer. Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic
Development, Denver, CO, USA (2010).
5. Tsai, KK, Su, JJ, Chu, PY, Lakins JN, and Weaver VM. Nuclear co-repressor 2 represses
mammary branching morphogenesis and local tumor invasion through epigenetic regulation of
fibronectin. The 49th Annual Meeting of the American Society for Cell Biology, San Diego, CA,
USA (2009).
6. Tsai KK, Mian IS, Lakins JN, Weaver VM. N-CoR2-related genomic predictors of therapeutic
resistance and survival in breast cancer. Asian Oncology Summit, Singapore (2009).
7. Tsai KK, Chu PY, Lakins JN, Weaver VM. Pleiotropic effects of nuclear co-repressor 2 (N-CoR2)
on breast cancer progression. The 48th Annual Meeting of the American Society for Cell Biology,
San Francisco, USA (2008).
8. Zahir N, Leight JL, Lakins JN, Alston-Mills B, Tsai KK, Weaver VM. Regulation of JNK
activity by matrix stiffness mediates apoptosis induction in a mammary epithelium. The 46th
Annual Meeting of the American Society for Cell Biology, San Diego, USA (2006).
Page 56
9.
Tsai KK, Chatterjee C, Lakins JN, Weaver VM. The SMRT way to resist death. The 46th Annual
Meeting of the American Society for Cell Biology, San Diego, USA (2006).
10. Tsai KK, Hsu TG, Kong CW, Lu FJ. Mitochondria alterations of peripheral blood leukocytes
after marathon race. Poster presentation, The 2000 Satellite Symposium on Oxidative Stress and
Atherosclerosis, Oslo, Norway(2000).
Other publications
1. Tsai KK, Weaver VM. Conference report, Third Annual Tissue Models in Therapeutic
Developments Conference. The Investigational Drugs Database, Thomson Scientific Ltd (2006).
2. Tsai KK. Heterotypic cell interactions between stress-induced prematurely senescent mammary
stroma and neighboring epithelial cells in aging and breast cancer. Doctoral thesis, Genetics and
Complex Diseases, Biological Sciences in Public Health program, Graduate School of Arts and
Sciences, Harvard University, USA (2005).
PRESENTATIONS
1. Invited speaker, “Disease Progression of Pancreatic Cancers Relates to a Core Gene Expression
Profile Associated with Glandular Differentiation.”The 14th Annual Meeting of the Taiwan
Cooperative Oncology Group, Taipei, Taiwan (2010).
2. Invited speaker, “Molecular Dissection of Signaling Pathways Involved in Treatment
Refractoriness of Pancreatic Cancer Using Integrated Bioengineering and Genomic Profiling
Approaches.”The Second Japan-Taiwan Joint Symposium on Medical Oncology, Taipei,
Taiwan (2009).
3. Invited speaker, “Overcoming Treatment Refractoriness of Pancreatic Cancer: Do We Find the
Real Culprit?” The Second International Conference for the Treatment of Pancreatic
Cancer, Tainan, Taiwan (2009).
4. Invited speaker, “Three Dimensional Dissection of Therapeutic Resistance in Breast Cancer.”The
6th Timberline Symposium: “3D Tissue Biology: Human Stem Cells, Cancer and the
Microenvironment”, Mt. Hood, Oregon, USA (2008).
5. Minisymposium speaker, “The Third Dimension Drives N-CoR2-dependent Death
Resistance.”The 47th Annual Meeting of the American Society for Cell Biology, Washington,
DC, USA (2007).
6. Invited speaker, “Tissue Architecture Linked to Epigenetic Control of Therapeutic
Response.”Fourth Annual Stem Cell and 3D Models for Therapeutic Screening, Boston, MA,
USA (2007).
7. Invited speaker, “Three Dimensional Dissection of Tumor Microenvironment and Therapeutic
Response.”National Health Research Institute, Taiwan(2006).
Page 57
Curriculum Vitae
Name： John Wang
Gender： Male
Medical License: 醫字 010107
Present︰
Director, Department of Pathology and Medical Laboratories, VGHTC
From July 2007 to now. E-mail: shengw@vghtc.gov.tw
Past：
Director, Department of Pathology, VGHTC
From Mar 2004 to July 2007
Chief, Section of Medical Laboratories, Veterans Hospital Chia-Yi
From Dec 1998 to Mar 2004
Director, Department of Pathology, HuLian Army General Hospital
From Dec 1996 to Dec 1998
Chief, Section of Medical Laboratories, 817 Army Hospital Taipei
From Jan 1993 to Dec 1996
Pathologist, Department of Pathology, Trisevice General Hospital Taipei
From Jan 1988 to Jan 1993
Acadamic：
Associate Professor, Chung Shan Medical University (Part time)
From July 2004 to now
Associate Professor, HungKuang University (Part time)
From July 2005 to now
Education：Medicine , National Defence Medical School
Bachelor degree
Aug 1974 to July 1981
Institute of Pathology, National Defence Medical School Master degree
July 1985
Institute of Biomedicine, National Defence Medical School PhD degree
July 1993
1.
2.
3.
4.
Aug 1989 to
Synchronous renal cell carcinoma and clear cell hepatocellular carcinoma mimicking
metastatic disease. Pathol Res Pract. 2010 May 206: 342-345 Hou TC, Wu CC, Yang CR, Wang J. (SCI:
Impact factor 1.219 Pathology 52/71).
No synergistic effect of mesenchymal stem cells and exercise on functional recovery following
sciatic nerve transection. Funct Neurol. 2010 Jan-Mar; 25(1):33-43. Wang J, Yang CC, Chen SC, Hsieh
YL. (SCI: Impact factor 1.019 Neuroscience 202/230)
Fequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking
female lung cancer in Taiwan. Cancer Lett. 2006 Apr 8:235(1):18-25. Wang J, Cheng YW, Wu
DW, Chen JT, Chen CY, Chou MC, Lee H. (SCI: Impact factor 3.277 oncology 48/127)
Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway Is Associated with
Poor Relapse-Free Survival in Early-Stage Human Papillomavirus-Associated
Lung Cancer. Clin Cancer Res. 2011 Apr 1;17(7): 1895-1905. Epub 2011 Feb 16. Wu DW, Liu WS, Wang J,
(SCI: Impact factor 6.747 Oncology 16/166)
Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular
carcinoma. Histopathology. 2011 Mar 14.1365-2559 Ko BS, Chang TC, Hsu C, Chen YC, Shen TL, Chen SC,
Wang J, Wu KK, Jan YJ, Liou JY. (SCI: Impact factor 3.855 Pathology 12/71)
Chen CY, Cheng YW, Lee H.
5.
Aug 1983 to
Page 58
6.
Osteosarcoma arising in a long-standing uterine leiomyoma: a case report and
literature review. Int J Surg Pathol. 2011 Feb 19(1):99-103. Wang RC, Wen MC, Wang J, Ho SC, Jan YJ.
(SCI: Impact factor 0.912 Pathology
7.
62/71)
Paxillin predicts survival and relapse in non-small cell lung cancer by
microRNA-218 targeting. Cancer Res. 2010 Dec 15;70(24):10392-401 Wu DW , Cheng YW, Wang J,
Chen CY, Lee H.
(SCI: Impact factor 7.543 Oncology 13/166)
8. The learning curve for reducing complications of robotic-assisted laparoscopic radical
prostatectomy by a single surgeon. BJU Int. 2010 Nov 2. Ou YC, Yang CR, Wang J, Yang CK,
Cheng CL, Patel VR, Tewari AK. (SCI: Impact factor 2.865 Urology and Nephrology 15/63)
9. Involvement of 14-3-3γ overexpression in extrahepatic metastasis of hepatocellular
carcinoma. Hum Pathol. 2010 Sep 24. Ko BS, Lai IR, Chang TC, Liu TA, Chen SC, Wang J, Jan YJ, Liou JY. (SCI:
Impact factor 3.332 pathology 17/68)
10.
Primary appendiceal precursor B lymphoblastic lymphoma with peculiar
morphology mimicking diffuse large B cell lymphoma. Pathol Int. 2010 Oct
60(10):690-693. Wang RC, Jan YJ, Wen MC, Wang J, Hsieh PP. (SCI:
Impact factor 1.521 Pathology 43/71)
11. Cilostazol ameliorates nephropathy in type 1 diabetic rats involving
improvement in oxidative stress and regulation of tgf-Beta and NF-kappaB.
Biosci Biotechnol Biochem. 2010 Jul 23; 74(7):1355-61. Epub 2010 Jul 7. Lee WC, Chen HC, Wang CY, Lin PY, Ou TT,
Chen CC, Wen MC, Wang J, Lee HJ. (SCI: Impact factor 1.326 BIOTECHNOLOGY & APPLIED
MICROBIOLOGY 100/150)
12. Robotic-assisted laparoscopic radical prostatectomy: learning curve of first 100 cases. Int J Urol.
2010 Jul 17(7):635-40. Ou YC, Yang CR, Wang J, Cheng CL, Patel VR..
(SCI: Impact factor 1.158 UROLOGY
& NEPHROLOGY 46/63)
13. Primary gastric tuberculosis. Endoscopy. 2009;41 Suppl 2:E327-8. Epub 2009 Nov 17. Liu PF, Chang CS, Wang
J, Wu CC, Yeh HZ. (SCI: Impact factor 6.091 Gastroenterology and hepatology 7/55)
14. Liquid-based cytology in diagnosing nasopharyngeal carcinoma. Am J Rhinol Allergy. 2009 Aug
23(4):422-5. Jan YJ, Chen SJ, Wang J, Jiang RS. (SCI: Impact factor 1.553
OTORHINOLARYNGOLOGY 11/31)
15. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg.
2009 Sep 96(9):1049-57. Wu CC, Cheng SB, Yeh DC, Wang J, P'eng FK. (SCI: Impact factor 4.921 Surgery
4/148)
16. Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse
survival in hepatocellular carcinoma. Hum Pathol. 2009 Oct 40 (10): 1384-1390. Jan YJ, Ko BS, Hsu C,
Chang TC, Chen SC, Wang J, Liou JY. (SCI: Impact factor 3.332 pathology 17/68)
17. Comparison of Robotic-assisted versus Retropubic Radical Prostatectomy Performed by a Single
Surgeon. Anticancer Res. 2009 May 29(5):1637-42. Ou YC, Yang CR, Wang J, Cheng CL, Patel VR.
(SCI: Impact factor 1.390 oncology 119/141)
18. Unsuspected prostate cancer after cystoprostatectomy: a comparison between two periods in taiwan. J
Formos Med Assoc. 2009 May 108(5):409-13. Li JR, Yang CR, Wang J, Ou YC, Ho HC, Cheng CL. (SCI:
Impact factor 0.640 MEDICINE, GENERAL & INTERNAL 83/107)
19. A 32-year-old man with a fourth ventricular mass. Brain Pathol. 2009 Apr;19(2):333-6. Lee FY, Jan YJ,
Wen MC, Li MC, Wang J, Wen-Hsien C. (SCI: Impact factor 5.576 CLINICAL NEUROLOGY 11/156;
NEUROSCIENCES 28/219; PATHOLOGY 3/68)
20. Early adenocarcinoma originating in submucosal gland of thoracic esophagus presenting as submucosal
tumor. Endoscopy. 2008 Sep;40 Suppl 2:E237-8. Epub 2008 Nov 7. Wang SW, Chang CS, Wang J, Yeh
HZ. (SCI: Impact factor 6.091 Gastroenterology and hepatology 7/55)
21. Signet-ring stromal tumor of the testis: a case report and literature review. Hum Pathol. 2009 Apr
40(4):584-7. Kuo CY, Wen MC, Wang J, Jan YJ. (SCI: Impact factor 3.332 pathology 17/68)
22. Association of O(6)-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation with
p53 Mutation Occurrence in Non-Small Cell Lung Cancer with Different Histology, Gender, and
Smoking Status. Ann Surg Oncol. 2008 Nov 15 (11):3272-3277. Wu JY, Wang J, Lai JC, Cheng
YW, Yeh KT, Wu TC, Chen CY, Lee H. (SCI: Impact factor 3.898 oncology 45/141)
23. Developing a Rabbit Model of Rhinogenic Chronic Rhinosinusitis. Laryngoscope. 2008
Page 59
Jun;118(6):1076-1081.Liang KL, Jiang RS, Wang J, Shiao JY, Su MC, Hsin CH, Lin JF. (SCI:
Impact factor 1.877 MEDICINE, RESEARCH & EXPERIMENTAL 50/82; OTORHINOLARYNGOLOGY
6/31)
24. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53
inactivation. Cancer Res. 2007 Nov 15 67(22):10686-93.Cheng YW, Wu MF, Wang J, Yeh KT,
Goan YG, Chiou HL, Chen CY, Lee H. (SCI: Impact factor 7.672 ONCOLOGY 8/132)
25. Central neurocytoma: A clinical, radiological and pathological study of nine cases. Clin Neurol
Neurosurg. 2008 Feb 110(2):129-36. Chen CL, Shen CC, Wang J, Lu CH, Lee HT. (SCI:
Impact factor 1.323 CLINICAL NEUROLOGY 115/156; SURGERY 80/148 )
26. Polyomavirus nephropathy in renal allograft: prevalence and correlation of histology with graft
failure. Nephrology (Carlton). 2007 Dec 12(6):615-9. Wen MC, Lian JD, Chang HR, Shu KH,
Wu MJ, Chen CH, Jan YJ, Wang J, Chang D. (SCI: Impact factor 1.241 UROLOGY &
NEPHROLOGY 41/55)
27. Epithelioid angiosarcoma arising in a deep-seated plexiform schwannoma: a case report and
literature review. Hum Pathol. 2007 Jul 38(7):1096-101. Lee FY, Wen MC, Wang J. (SCI:
Impact factor 3.034 PATHOLOGY 16/66)
28. Thyroid involvement in rosai-dorfman disease. Thyroid. 2007 May 17(5):471-6. Lee FY, Jan YJ,
Chou G, Wang J, Wang CC. (SCI: Impact factor 2.692 ENDOCRINOLOGY & METABOLISM 42/92)
29. Synchronous gastric gastrointestinal stromal tumor and signet-ring cell adenocarcinoma: a case
report. Int J Surg Pathol. 2007 Oct 15(4):397-400. Lee FY, Jan YJ, Wang J, Yu CC, Wu CC.
(SCI: Impact factor 1.078 pathology 54/66)
30. Spinal atypical teratoid/rhabdoid tumor in a 7-year-old boy. Neuropathology. 2007 Apr
27(2):139-44. Yang CS, Jan YJ, Wang J, Shen CC, Chen CC, Chen M. (SCI: Impact
factor1.326 CLINICAL NEUROLOGY 99/146; NEUROSCIENCES 164/211; PATHOLOGY 47/66)
31.
Esophageal metastasis from occult lung cancer.
73(6):327-30.
32.
J Chin Med Assoc. 2010 Jun;
Hsu PK, Shai SE, Wang J, Hsu CP.
Combined primary neuroendocrine carcinoma and hepatocellular carcinoma of the liver. J
Chin Med Assoc. 2009 Aug;72(8):430-3. Yang CS, Wen MC, Jan YJ, Wang J, Wu CC.
33. Malignant Desmoplastic Type Mesothelioma Mimicking a Fibrous Pseudotumor of the Tunica Vaginalis:
A Case Report and Literature Review. The Open Pathology Journal, 2009, 3, 1-3. Fang-Yi Lee, Mei-Chin
Wen, John Wang and Chun-Kai Tseng.
34. Robotic-assisted radical prostatectomy by a single surgeon in Taiwan: experience
with the initial 30 cases. Journal of Robotic Surgery. 2008 sep 9: 2(3): 173-179. Yen-Chuan Ou,
Chi-Rei Yang, John Wang, Chen-Li Cheng and Vipul R. Patel
35. Primary lymphohistiocytic variant of anaplastic large cell lymphoma of the stomach. J Chin Med
Assoc. 2007 Feb 70(2):71-5 Yang CS, Chou G, Jan YJ, Wang J, Yeh DC, Teng CL..
36. Gastrointestinal stromal tumors: computed tomographic features and prediction of malignant risk
from computed tomographic imaging. J Chin Med Assoc. 2007 Sep 70(9):367-73. Yang TH,
Hwang JI, Yang MS, Hung SW, Chan SW, Wang J, Tyan YS.
Page 60
CURRICULUM VITAE
Chin-Yuan Tzen, MD, PhD
Chairman, Department of Pathology & Laboratory Medicine, Cathay General Hospital, Taipei, Taiwan
Professor, College of Medicine, Fu Jen Catholic University
President, Taiwanese Society of Molecular Medicine
Office Address:
Department of Pathology & Laboratory Medicine
Cathay General Hospital
280 Renai Road, Section 4
Taipei, Taiwan
Tel: (+886) 2-2690-7965 ext 2519
e-mail: jeffbucknell@gmail.com
Education: Kaohsiung Medical College, Taiwan
MD in Medicine, 1981
Mayo Graduate School, Mayo Clinic, Rochester, MN
Ph.D. in Experimental Pathology, 1989
Certificate, Licenses & Membership:
The American Board of Pathology (96-572)
Tennessee Medical License (No. MD28109)
Iowa Medical License (No. 30492)
College of American Pathologists (No. M-0704117)
The International Society of Urological Pathology
Taiwan Society of Pathology
Taiwanese Society of Molecular Medicine
Professional Experience:
1989-1997 Assistant Professor, Department of Pathology, University of Tennessee,
Memphis, Tennessee, USA
1997-2001 Senior Pathologist, Department of Pathology, Mackay Memorial Hospital
1999-2009 Director of Cancer Research, Department of Medical Research, Mackay
Memorial Hospital, Taipei, Taiwan
2001-2009 Chairman, Department of Pathology, Mackay Memorial Hospital, Taipei,
Taiwan
2001-2009 Interstitial Review Board, Mackay Memorial Hospital, Taipei, Taiwan
2001-2009 IRB, Mackay Memorial Hospital
2005-2008 Director of Microbiology Research, Department of Medical Research, Mackay
Memorial Hospital, Taipei, Taiwan
2009-present Chairman, Department of Pathology and Laboratory Medicine, Cathay General
Hospital
2009-present Director, Section of Molecular Medicine, Cathay General Hospital
2009-present Professor, College of Medicine, Fu Jen Catholic University
Invited lectures (selected):
1. The diagnostic standard of GIST in Taiwan (Bo’ao, Hainan Island, China; February 19, 2004)
2. View of a Pathologist – Management of a GIST Patient (JW Marriott Phuket Resort and SPA,
Phuket, Thailand; May 5, 2004)
3. Evolving Role of Molecularly Targeted Therapy (Malaysian Oncological Society; Plenary
Session; Hotel Istana, Kuala Lumpur, Malaysian; October 1, 2004)
4. Target Therapy without an apparent target: Can Imatinib be used in CD117-negative GIST?
(Malaysian Oncological Society; Evening Symposium; Hotel Istana, Kuala Lumpur, Malaysian;
October 1, 2004)
5. Recent findings and new insights in gastrointestinal stromal tumor (China Society of Pathology;
Oversea Chinese Hotel, Guangzhou, China; Dec.23, 2004)
Page 61
6. GIST in Asia Pacific and current issues in diagnosis (1st Meeting of the Asia Pacific GI
Molecular Target Therapy Group; JW Marriott Hotel, Shanghai, China; January 21, 2005)
7. GIST/NET: where do we stand? (GI Forum; Hong Kong Society of Clinical Oncology and Hong
Kong College of Radiologists; Grand Hyatt, Hong Kong; July 7, 2005)
8. GIST- where do we stand? (Pan Asia Pacific Oncology Summit, Prince Hotel, Chiba, Japan; July
9, 2005）
9. INTUIT Workshop, GIST-NET: from Diagnosis to Therapy (Regal International East Asia Hotel;
Shanghai, China; August 20, 2005)
10. Molecular Basis and Clinical Implication of GIST (Optimizing Medical Management of GIST in
the Imatinib Era; The Regent Singapore, Singapore; November 11, 2006)
11. Updates on Gastrointestinal Stromal Tumors (The College of Pathologists, Academy of Medicine
of Malaysia; PJ Hilton, Petaling Jaya, Malaysia; April 15, 2007)
12. Pathology of GIST (Rare Gastrointestinal Tumors Symposium; Intercontinental Dubai Festival
City, Dubai; Jun 13, 2008)
13. Pathology of NET (Rare Gastrointestinal Tumors Symposium; Intercontinental Dubai Festival
City, Dubai; Jun 14, 2008)
14. Insights into the pathophysiology of GIST and current issues in diagnosis (Novartis Oncology
Asia Pacific Summit 2008, Phuket Island, Thailand, July 12, 2008)
15. Molecular Basis and Pathological Diagnosis of Gastrointestinal stromal tumor (Gastrointestinal
System Pathology; Antalya, Turkey; Oct 26, 2008 )
16. Clinical implications of primary and secondary mutations in GIST and pathologic risk
stratification of GIST (2008 Korean GIST, Multidisciplinary Symposium; Seoul, Nov 29, 2008)
17. Molecular motif as a common language in neuroendocrine tumor (NET Pathology Summit,
National Cancer Institute; Fontainebleau Hotel, Miami Beach, Florida, USA; Feb. 7-8, 2009)
18. Concept and Diagnosis of Neuroendocrine Tumors (Indonesian Pathologist Society; Cipto
Mangunkusumo Hospital, Jakarta; Mar. 14, 2009)
19. Recent update of GIST diagnostics (Indonesian Pathologist Society; Cipto Mangunkusumo
Hospital, Jakarta; Mar. 14, 2009)
20. Pathology of gastroenteropancreatic neuroendocrine tumours - Forging a common language
(Asia Oncology Summit, The Lancet Oncology and Singapore Society of Oncology; Suntec
Singapore; Apr. 4, 2009)
21. Addressing current unmet needs in the classification of neuroendocrine tumor (Westin Paris,
Paris; November 7, 2009)
22. Diagnostic approach to NETs (Meeting of minds excellence in NET pathology; Swissotel The
Bosphorus, Istanbul, Turkey; June 19, 2010)
23. Classification of NETs (Meeting of minds excellence in NET pathology; Swissotel The
Bosphorus, Istanbul, Turkey; June 19, 2010)
24. Grading, Staging, and Classification of NET (Selective Target, Tailored Therapy in Oncology;
JW Marriott Hotel Hong Kong; July 11, 2010)
25. Pathology of GIST and Stratification for Management (GIST & NET: A multidisciplinary
Journey; Hilton Hotel, Kuala Lumpur, Malaysia; August 8, 2010)
26. Grading, staging, classification, and biomarker of NET (GIST & NET: A multidisciplinary
Journey; Hilton Hotel, Kuala Lumpur, Malaysia; August 8, 2010)
27. Pathologic, molecular, and clinical aspects of GIST (Malaysia Society of Pathology; Le Meridien
Hotel, Kuala Lumpur, Malaysia; December 13, 2010)
28. Pathologic, molecular, and clinical aspects of NET (Malaysia Society of Pathology; Le Meridien
Hotel, Kuala Lumpur, Malaysia; December 14, 2010)
29. Diagnosis and Classification of NET (Chengdu, China; March 25, 2011)
30. NET Pathological Assessment (Beijing, China; April 1, 2011)
31. Case Sharing and Comments on NET (April 2; Shanghai, China)
32. NET Pathological Assessment (Shanghai, China; April 2, 2011)
33. Update of International Classification in GIST (9th International Gastric Cancer Congress; April
21; Seoul, Korea)
Page 62
34. What's new for GIST: current update in pathology (May 24, APIAP, Taiwan)
35. NET & GIST Pathology Masterclass (Hyatt Hotel; June 16-17; Taipei, Taiwan)
36. Pathology of GIST (November 18; Seoul, Korea)
Selected Publications from 135 papers:
1. Liu C-L, Huang M-J, Lin S-C, Ghang K-M, and Tzen C-Y: Neo-adjuvant ST1571 therapy for
high-risk gastrointestinal stromal tumour. ANZ J Surg 74:289-290, 2004
2. Cheng S-P, Huang M-J, Yang T-L, Tzen C-Y, Liu C-L, Liu T-P, and Hsiao S-C:
Neurofibromatosis with gastrointestinal stromal tumors: insights into the association. Dig Dis Sci
49:1165-1169, 2004
3. Wang S-M, Chiang R-A, and Tzen C-Y, Cheng S-P, Liu T-P: Spontaneous rupture of recurrent
gastrointestinal stromal tumor associated with neurofibromatosis type 1. J Chin Med Assoc 68:
538-541, 2005
4. Tzen C-Y* and Mau B-L: Analysis of CD117-Negative Gastrointestinal Stromal Tumors. World
J Gastroenterol 11:1052-1055, 2005
5. Lin S-C, Liu C-L, Wang T-I, Chang W-S, Tzen C-Y, and Huang M-J: Clinical implications of Ckit
gene mutation in patients with large gastrointestinal stromal tumors. J Gastroenterol Hepatol
21:1604-1608, 2006
6. Tzen C-Y, Wang J-H, Huang Y-J, Wang M-N, Lin P-C, Lai G-L, Wu C-Y, and Tzen C-Y*:
Incidence of Gastrointestinal Stromal Tumor: A Retrospective Study Based on
Immunohistochemical and Mutational Analyses. Dig Dis Sci 52:792-797, 2007
7. Tzen C-Y*, Wang M-N, and Mau B-L: Spectrum and Prognostication of KIT and PDGFRA
Mutation in Gastrointestinal Stromal Tumors. Eur J Surg Oncol 34:563-568, 2008
8. Lim K-H, Huang M-J, Chen L-T, Wang T-E, Liu C-L, Chang C-S, Liu M-C, Hsieh R-K, and
Tzen C-Y*: Molecular analysis of secondary kinase mutations in imatinib-resistant
gastrointestinal stromal tumors. Med Oncol 25:207-213, 2008
9. Chou C-C, Chou M-J, and Tzen C-Y*: Prediction of KIT mutation in gastrointestinal stromal
tumors by the immunoprofile of the tumor cells. J Formos Med Assoc 109:25-31, 2010
10. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M,
Kulke M, Lloyd RV, Moran C, Moss SF, Oberg K, O’Toole D, Rindi G, Robert ME, Suster S,
Tang LH, Tzen C-Y, Washington MK, Wiedenmann B, and Yao J: Pathologic Reporting of
Neuroendocrine Tumors: Application of the Delphic consensus process to the development of a
minimum pathologic data set. Am J Surg Pathol 34:300-313, 2010
Page 63
Curriculum Vitae
Name: 沈延盛 Yan-Shen Shan MD, PhD
Gender: Male
Birth Date: Mar 17, 1963
Address: 138, Sheng-Li Road, Tainan, Taiwan
Tel: 886-6-2353535 ext 5181
Fax: 886-6-2766676
E-mail: ysshan@mail.ncku.edu.tw
Education:
Visiting Scholar of University of Pennsylvenia and Thomas
Jefferson University Hospital, USA
2006.11-2007.9
PhD of Clinical Medicine
1998.9-2004.6
School of Medicine
1988.9-1993.6
National Cheng Kung University
Rehabilitation Medicine
1981.9-1985.6
School of Medicine, National Taiwan University
Residency Training Department of Surgery
1993.7-1998.7
National Cheng Kung University Hospital
Faculty
Department of Surgery
1998.8~
National Cheng Kung University Hospital
Assistant professor
2002.8~2008.7
Associate professor
2008.8~
Associate professor of Institute of Clinical Medicine
2010.8~
Chief of Division of Trauma
2010.8~
Professional Membership
Formosa Association of Surgery
Society of Digestive Surgery, R.O.C.
Taiwan Pancreas Society
Society of Endoscopic Surgery, Taiwan (Instructor Surgeon)
Society of Transplantation, R.O.C.
Society of Breast Surgery, R.O.C.
Formosa Association for the Surgery of Trauma
International Hepato-Pancreato-Biliary Association (M2527)
International Association of Surgeon and Gastrpenterologists
The Society for Surgeon of the Alimentary Tract, USA
Bibliography: (*: correspondence)
1. Yan-Shen Shan*, Da-Ming Yang, Jenq-Chang Lee, Pin-Wen Lin. Mutations of the DPC4/
Smad4 Gene in Ampullary Carcinoma. (Submitted, post presented in 2005 DDW).
2. Yan-Shen Shan*, Hui-Ling Dong, Chin-Wong Chen, Chang-Ni Lin, Yi-Ling Chen, Da-Bin
Hsieh, Pin-Wen Lin. Loss of Gelsolin Expression by Epigenetic Alteration Related with
Progression of Gastric Cancer. (submitted)
3. Ying-Jui Chao, Yan-Shen Shan*, Pin-Wen Lin. A Simple Bag for Specimen Removal at
Micro-laparoscopic Cholecystectomy. (submitted)
4. Yan-Shen Shan*, Kai-Hsi Hsu, Edgar D Sy, Pin-Wen Lin. Indicators for Gastric Acid Reducing
Surgery in Perforated Peptic Ulcer in HP Era. (Submitted)
5. Hsin-Hsien Yu, Yan-Shen Shan*. Duodenal-jejunal Bypass Can Reduce Non-alcoholic
Steatohepatitis via Modulation of Insulin Sensitivity and Activity of Hepatic Stellate Cells.
(Submitted)
6. Hsin-Hsien Yu, Ta-Ming Yang, Yan-Shen Shan*, Pin-Wen Lin. Zinc Deficiency in Patients
Page 64
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Received Pancreatoduodenectomy is Associated with Pancreatic Exocrine Insufficiency (World
J Surgery 2011 accepted).
Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin
PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT. Induction
Chemotherapy with Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by
Concomitant Chemoradiotherapy in Patients with Locally Advanced Pancreatic Cancer: A
Taiwan Cooperative Oncology Group Phase II Study. Int J Radiat Oncol Biol Phys. 2011 Mar
21.
Chee-Hwee Lee, Yu-Shan Yen, Yan-Shen Shan*, Pin-Wen Lin. Follicular Dendritic Cell
Tumor of Hepatic Involvement: A Case Report and Collective Review. Gastroenterology
Research 2010;3(3):139-143
Shau-Chieh Lin, Yan-Shen Shan*, Pin-Wen Lin. Adequate Preoperative Preoperative Biliary
Drainage Is the Determinative to Decrease Postoperative Infectious Complications after
Pancreaticoduodenectomy. HepatoGastroenterology 2010; 57 (101): 698-705.
Hsu HP, Shan YS, Lai MD, Lin PW. Osteopontin-positive infiltrating tumor-associated
macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther. 2010 Jul; 10
(2):144-54.
Yan-Shen Shan, Jung-Hua Fang, Ming-Derg Lai, Meng-Chi Yen, Pin-Wen Lin, Hui-Ping Hsu,
Chian-Yun Lin, Yi-Ling Chen. Establishment of an orthotopic transplantable gastric cancer
animal model for studying the immunological effects of new cancer therapeutic modules. Mol
Carcinogenesis 2010 Aug 24 (on line)
Kai-Hsi Hsu, Hung-Wen Tsai, Pin-Wen Lin, Yun-Shang Hsu, Yan-Shen Shan*, and Pei-Jung
Lu*. Clinical Implication and Mitotic Effect of CD44 Cleavage in Relation to
Osteopontin/CD44 Interaction and Dysregulated Cell Cycle Protein in Gastrointestinal Stromal
Tumor. Ann Surg Oncol 2010;17(8): 2199-212 .
Kai-Hsi Hsu, Hung-Wen Tsai, Pin-Wen Lin, Yun-Shang Hsu, Pei-Jung Lu*, and Yan-Shen
Shan*. Osteopontin Expression is an Independent Adverse Prognostic Factor in Resectable
Gastrointestinal Stromal Tumor and its Interaction with CD44 Promotes Tumor Proliferation.
Ann Surg Oncol 2010; 17(11):3043-52.
Hui-Ping Hsu, Yan-Shen Shan, Pin-Wen Lin, Ying-Tai Jin, Ming-Derg Lai. Loss of E-Cadherin
and -Catenin is Correlated with Prognosis of Ampullary Neoplasms. J Surg Oncol 2010 Apr 1;
101(5):356-62.
Hsin-Hsien Yu, Yan-Shen Shan*, Pin-Wen Lin. Effect of Pancreatoduodenectomy on the
Course of Hepatic Steatosis World J Surg 2010; 34(9):2122-7.
Yan-Shen Shan; Roberto Zuchini; Hung-Wen Tsai; Pin-Wen Lin; Gwo-Bin Lee; Xi-Zhang Lin.
Bloodless Liver Resection Using Needle Arrays under Alternating Electromagnetic Fields. Surg
Innovation 2010; 17(2): 95-100.
Po-Lin Chen, Hsin-Chun Lee, Yan-Shen Shan, Nai-Ying Ko, Nan-Yao Lee, Chia-Ming
Chang,Chi-Jung Wu, Ching-Chi Lee. Respiratory failure and acalculous cholecystitis in a
patient with AIDS and disseminated tuberculosis: masking effect of fluoroquinolone
monotherapy and immune restoration syndrome. IJID 2009 Jul; 13 (4):e165-8. (SCI)
Yan-Shen Shan*. Delayed gastric emptying after pylorus preserving pancreaticoduodenectomy.
Formosan J Surg 2008; 41 (6): 251~256.
Sy ED, Chen MD, Yang YJ, Shan YS. Obscure gastrointestinal bleeding due to Meckel's
diverticulum: unusual capsule endoscopic finding as polyp-like lesion. Endoscopy. 2008 Aug;
40 Suppl 2:E203. (SCI)
Tsai HM, Shan YS, Lin PW, Lin XZ, Chen CY. Clinical and imaging characteristics relating to
surgical outcomes of perforated appendicitis. Hepatogastroenterology. 2008 Jan-Feb; 55(81):
127-32. (SCI)
Yan-Shen Shan *, Shu-Fen Huang, Ying-Hsiang Wu, Ai-Wen Kao, Pin-Wen Lin. The variable
of clinical state and side effect of administration Venolipid MCT/LCT 20% through All-in-one
Page 65
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
System after upper abdominal surgery. A Prospective, Randomized Controlled Trial. CN &
e-SPEN; Vol 3/4 pp e135-e141. DOI information: 10.1016/j.eclnm.2008.04.004. (SCI)
Yi-Ling Chen, Jung-Hua Fang, Ming-Derg Lai, Yan-Shen Shan*. CD4+CD25+ Regulatory T
cells In Regional Lymph Nodes Suppress Local Immunity to Help Tumor Growth in
Benzo[a]pyrene-induced Forestomach Carcinoma. World J Gastroenterology 2008; 14 (Oct.):
5797-5809.
Su CC, Lin YP, Cheng YJ, Huang JY, Chuang WJ, Shan YS, Yang BC. Phosphatidylinositol
3-kinase/akt activation by integrin-tumor matrix interaction suppresses fas-mediated apoptosis
in T cells. J Immunol. 2007 Oct 1;179 (7): 4589-97.
Hui-Ping Hsu, Ta-Ming Yang, Yu-Hsiang Hsieh, Yan-Shen Shan*, Pin-Wen Lin. Predictors of
Recurrence after Pancreaticoduodenectomy in Ampullary Cancer: Comparison between Non-,
Early, and Late-recurrence. J Formos Med Assoc. 2007 Jun; 106 (6): 432-443.
Yan-Shen Shan*, Pin-Wen Lin. A Phase I Study of Combination of Intravenous Gemcitabine,
Oxaliplatin, and 5-FU with Daily Oral Thalidomide (GOFT) in Metastatic/ Locally Advanced
Pancreatic Carcinoma Patients. HepatoGastroenterology 2007; 54: 2141-2145.
Yao-Chou Lee, Yan-Shen Shan*, Pin-Wen Lin. Successful Surgical Decompression in the
Patients of Pancreatic Intraductal Papillary Mucinous Neoplasm. HepatoGastroenterology 2007;
54: 2395-2397.
Hsin-Hsien Yu, Yan-Shen Shan*, Pin-Wen Lin. Zinc Deficiency with Acrodermatitis
Enteropathica Eruption after Pancreaticoduodenectomy. J Formos Med Assoc. 2007; 106(10):
864-868.
Kai-Hsi Hsu, Hong-Wen Tsai, Yan-Shen Shan*, Pin-Wen Lin. The significance of CD44
expression in gastrointestinal stromal tumor in relation to disease progression and survival.
World J Surgery 2007 Jul; 31(7): 1438-1444.
Kai-Hsi Hsu, Ta-Ming Yang, Yan-Shen Shan*, Pin-Wen Lin. Tumor Size is a Major
Determinant of Recurrence in Resectable GIST. Am J Surg 2007 Aug; 194(2): 148-52.
Yan-Shen Shan, Yu-Hsiang Hsieh, Wei-Jen Yao, Mei-Ling Tsai, Pin-Wen Lin.
Impaired Emptying Function of the Retained Distal Stomach caused Delayed Gastric Emptying
after Pylorus-Preserving Pancreaticoduodenectomy. World J Surg, 2007 Aug; 31(8):1606-1615.
Yan-Shen Shan, Yu-Hsiang Hsieh, Pin-Wen Lin. Telomerase Activity in Tumor and Remnant
Liver as Predictor for Recurrence and Survival in Hepatocellular Carcinoma after Resection.
World J Surg 2007 May; 31(5):1121-1128.
Hui-Ping Hsu, Ta-Ming Yang, Yu-Hsiang Hsieh, Yan-Shen Shan*, Pin-Wen Lin. Predictors of
Patterns of failure after Pancreaticoduodenectomy in Ampullary Cancer. Ann Surg Oncol; 2007;
14 (1): 50-60.
Jen-Pin Chuang, Yan-Shen Shan*, Ray-Mo Lin, Pin-Wen Lin, Po-Chang Lee. Acuqired
superior mesentery artery syndrome following surgery for kyphosis-case report. Formosan J
Surg 2006; 39 (5): 256-260.
E.D. Sy, YS. Shan, YR. Yang, HM Tsai, CH. Lin. Hirschsprung’s Disease, a Rare Precipitating
Factor in Neonatal Perforated Meckel’s Diverticulum. J Ped Surg 2006; 41 (7): 1319-1321.
(SCI).
Hui-Ping Hsu, Yan-Shen Shan*, Yu-Hsiang Hsieh, Edgar D. Sy, Pin-Wen Lin. The Impact of
Etiologic Factors, APACHE II and POSSUM Scores in the Management and Clinical Outcome
of Acute Intestinal Ischemic Disorders. Would J Surg 2006; 30(12):2152-2162. ( with invited
comments) (SCI)
Hong-Ming Tsai, Yan-Shen Shan, Pin-Wen Lin, Xi-Zhang Lin, Chiung-Yu Chen. Clinical
Analysis of the Predictive Factors for Recurrent Appendicitis after Initial Non-operative
Treatment of Perforated Appendicitis. Am J Surg 2006; 192: 311-316. (SCI)
Yan-Shen Shan, Edgar D. Sy, Shan-Tair Wang, Jenq-Chang Lee, Pin-Wen Lin. Early
presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery.
World J Surg 2006; 30(1, Jan): 119-26. (SCI)
Page 66
38. Yan-Shen Shan, Edgar D. Sy, Mei-ling Tsai, Li-Ying Tang, P-Shirley Li, Pin-Wen Lin.
Somatostatin Prophylaxis after Pylorus-Preserving Pancreaticoduodenectomy Increases
Delayed Gastric Emptying and Reduces Plasma Motilin. World J Surg 2005; 29: 1319-24. (SCI)
39. Wen-Tsung Huang, Kun-Chao Chang, Yan-Shen Shan, Chao-Jung Tsao, Jenq-Chang Lee.
Successful initial treatment with weekly 24-hour infusion of 5-fluorouracil and leucoverin in a
rectal cancer patient with disseminated intravascular coagulation. HepatoGastroenterology 2005;
52: 1436-1439. (SCI)
40. Pin-Wen Lin, Yan-Shen Shan, Yih-Jih Lin, Chung-Jye Hung. Pancreaticoduodenectomy for
pancreatic head cancer：PPPD versus Whipple procedure. HepatoGastroenterogy 2005; 52:
1601-1604. (SCI)
41. Yan-Shen Shan, Edgar D. Sy, Nan-Tsing Chiu, Mai-Ling Tsai, Pin-Wen Lin. Reconsideration
of delayed gastric emptying in pancreaticoduodenectomy. World J Surg 2005: 29: 873-9. (with
expert’s comments). (SCI)
42. Shen-Shin Chang, Yan-Shen Shan, Yih-Jyh Lin, Yun-Sheng Tai, Pin-Wen Lin. A Review of
Obturator Hernia and a Proposed Algorithm for the Diagnosis and Treatment. World J Surg
2005; 29: 450-454. (SCI)
43. Yan-Shen Shan, Yu-Hsiang Hsieh, Edgar D Sy, Nan-Tsing Chiu, Pin-Wen Lin. The Influence of
Spleen Size on Liver Regeneration after Major Hepatectomy in Normal and Early Cirrhotic
Liver. Liver International 2005; 25: 1-5. (SCI)
44. Kuo-Ting Lee, Yan-Shen Shan*, Shin-Tai Wang, Pin-Wen Lin. Verres needle decompression of
distended gallbladder to facilitate laparoscopic cholecystectomy in acute cholecystitis: A
prospective study. HepatoGastroenteroly 2005; 52: 1388-1392 . (SCI)
45. Wen Chieh Chen, Guan-Yu Chen, Shaw-Jenq Tsai, Pei-Wen Wang, Hamm-Ming Sheu,
Yen-Sheng Shen (Yan-Shen Shan), Fen-Fen Chen. Mild cutaneous manifestation in two young
women with extraordinary hyperandrogenemia. Dermatology 2005; 210: 49-52 (DOI:
10.1159/000081484). (SCI)
46. Chao-Han Lai, Yan-Shen Shan*, Edgar D. Sy, Yu-Hsiang Hsieh, Hung-Wen Tsai, Shan-Tair
Wang, Jenq-Chang Lee, Pin-Wen Lin. The significance of CD44 expression in gastrointestinal
neuroendocrine tumors. HepatoGastroenterology 2005; 52: 1071-1076. (SCI)
47. Hui-Ping Hsu, Yan-Shen Shan*, Edgar D. Sy, Pin-Wen Lin. Acute Mesentery Venous Ischemia
in Patients with Warfarin – warfarin therapy may perplex the diagnosis of intestinal vascular
complication. Formosan J Surg 2005; 38 (1): 13-19.
48. Yan-Shen Shan, Edgar D. Sy, Hui-Ling Tung, Mei-Ling Tsai, Pin-Wen Lin. Reduction of
intrinsic inhibitory enteric neurons in the antropyloric area in PPPD patients with delayed
gastric emptying. HepatoGastroenterology 2005; 52: 1375-1382. (SCI)
49. C-L Ho, S-C Pan, J-W Lee, H-Y Chiu, Yan-Shen Shan. Splenic-cutaneous fistula in
melioidosis. A case report. J Plastic Surg Association, ROC 2005; 14: 148-152.
50. Yan-Shen Shan, Chia-Rei Yen, Chao-Jung Taso, Pin-Wen Lin. Regulatory CD4+CD25+ T cells
in peripheral and tumors from patients with gastric carcinoma. A preliminary report. J
Gastrointestinal Surg. 2004; Vol. 8, No. 7S: 129A. (SCI)
51. Hui-Ping Hsu, Yan-Shen Shan*, Yu-Hsiang Hsieh, Mei-Ling Tsai, Nan-Tsing Chiu, Pin-Wen
Lin. Intragastric Distribution of Meal in Patients with or without Delayed Gastric Emptying
after Pylorus-Preserving Pancreaticoduodenectomy. J Gastrointestinal Surg. 2004; Vol. 8, No.
7S: 82A. (SCI)
52. Edgar D Sy, Yan-Shen Shan, Chyi-Her Lin, Pin-Wen Lin. Immature Intrinsic Nerve
Innervations of Pyloric Muscle in Idiopathic Hypertrophic Pyloric Stenosis (Equal distribution)
J Formos Med Assoc. 2004; 103: 558-61. (SCI)
53. Yan-Shen Shan, Yu-Hsiang Hsieh, Edgar D Sy, Pin-Wen Lin. Delayed Gastric Emptying After
Pylorus-Preserving Pancreaticoduodenectomy: An Analysis of 63 Consecutive Patients. J
Formos Med Assoc 2004; 103: 767-72. (SCI)
54. Yan-Shen Shan, Hui-Ping Hsu, Yu-Hsiang Hsieh, Edgar D. Sy, Jenq-Chang Lee, Pin-Wen Lin.
Page 67
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
The significance of intraoperative peritoneal fungus culture in perforated peptic ulcer. Br. J.
Surg. 2003: 90; 1215-1219. (SCI: 2003 surgery portion 2nd journal)
Yan-Shen Shan, Jeng-Chag Lee, Nan-Haw Chow, et al. Immunohistochemical microvessel
count is not a reliable prognostic predictor in colorectal carcinoma. Hepatogastoenterology 2003;
50: 1316-1320. (SCI)
Yan-Shen Shan, Edgar D. Sy, Pin-Wen Lin. Somatostatin in the prevention of pancreatic stump
related morbidity following elective pancreaticoduodenectomy in high risk patients after
excluded surgical factor. A prospective, randomized, double blind, controlled clinical trial.
World J. Surg. 2003; 27: 709-14. (SCI)
Kuan-Wei Lai, Chiao-Hsiung Chung, Chin-Chung Tseng, Yan-Shen Shan. Fatal pancreatitis
secondary to iatrogenic intramural duodenal hematoma: report of a case. Gastroenterol J Taiwan
2003; 20: 9-14.
Edgar D. Sy, Yan-Shen Shan, Hong-Ming Tsai, Chyi-Her Lin. Meckel`s diverticulum
associated with ileal volvulus in a neonate. Ped. Surg. Internat. 2002; 18: 529-31. (SCI)
Yan-Shen Shan, Edgar D Sy, Pin-Wen Lin. Nonsurgical treatment for the main pancreatic duct
transection with pseudocyst in blunt abdominal injury. Pancreas 2002; 25: 210-15. (SCI; Formal
journal of International society of pancreas)
Yan-Shen Shan, Jing-Jou Yan, Edgar D Sy, Ying-Tai Jin, Jeng-Chang Lee. Nested polymerase
chain reaction in the diagnosis of negative Ziehl-Neelsen stained mycobacterium tuberculosis
fistula in ano: report of four cases. Dis. Colon Rectum 2002; 45: 1685-8. (Treatment guideline
for anal tuberculosis on the Johns Hopkins Hospital Website)
Yan-Shen Shan, Edgar D Sy, Hong-Ming Tsai, et al. Annular pancreas with obstructive
jaundice. Beware of underlying neoplasms. Pancreas 2002; 25 (3): 314-6. (SCI; Formal journal
of International society of pancreas)
M-J Chen, Y-S Tai, Y-C Chang, Yan-Shen Shan, Y-J Lin, P-W Lin. Percutaneous transhepatic
gallbladder drainage following laparoscopic cholecystectomy for acute cholecystitis. Formosa J
Surg 2002; 35: 82-86.
Yan-Shen Shan, Edgar D. Sy, Nan-Chin Chow, Mei-Lin Tsai, Pin-Wen Lin. Dysfunction of the
distal stomach causes different presentation of delayed gastric emptying between conventional
and pylorus-preserving pancreaticoduodenectomy. J HBP Surg. 2002; 9 (suppl 1): 240.
Shen-Shin Chang, Yan-Shen Shan*, Huei-Ling Dung, Li-Ying Tang, Edgar D Sy, Pin-Wen Lin,
Mei-Ling Tsai. Somatostatin inhibits antral motility via activation of neuronal nitric oxide
synthase. J HBP Surg. 2002; 9 (suppl 1): 250.
Tsung-Ching Chou, Yan-Shen Shan, Edgar D Sy, Pin-Wen Lin. Somatostatin promotes the
incidence of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy. J HBP
Surg. 2002; 9 (suppl 1): 253*.
T-L Lin, C-R Wang, M-F Liu, P-C Chen, Yan-Shen Shan, Y-T Jin, C-H Chien. Multiple colonic
ulcers caused by Churg-Strauss syndrome in a 15-year-old girl. Clin Rheumatology 2001; 20:
362-364. (SCI)
Yan-Shen Shan, Po-Chang Lee, Edgar D.Sy et al. Fibrosing cholestatic hepatitis possibly
related to persistent parvovirus B19 infection in a renal transplant recipient. Nephrol Dialysis
Transplant. 2001; 16: 2420-2422. (SCI)
Yan-Shen Shan, Edgar D. Sy, Po-Chang Lee, et al. Polycystic Kidney as a cadeveric donor. Is it
appropriate? Nephrol Dialysis Transplant. 2001; 16: 410-411. (SCI; With expert’s comments)
Edgar D Sy, Chun-Hung Lin, Yan-Shen Shan, et al. Chyloperitoneum: A postoperative
complication after repair of tracheoesophageal fistula. J Pediatr. Surg. 2001; 36: E1. (SCI)
Edgar D Sy, Chun-Shung Liu, Shin-Ming Huang, Yan-Shen Shan. Cecal perforation presenting
as abdominal-wall necrotizing fascitis. Pediatr. Surg. Int. 2001; 17: 215-217. (SCI)
Yan-Shen Shan, Shen-Shing Chang, Pin-Wen Lin. Somatostatin in the prevention of surgical
complications following elective pancreaticoduodenectomy. A prospective, randomized,
controlled trial. J. HBP Surg. 2001; 8 suppl 1: 31.
Page 68
72. Yan-Shen Shan, Edgar D.Sy, Pin-Wen Lin. Chronic hemosuccus pancreaticus. A rare
complication of pancreatic microcystic adenoma successfully treated with Whipple`s procedure.
Pancreas 2000; 20:416-418. (SCI; Formal journal of International society of pancreas)
73. Yan-Shen Shan, Edgar D.Sy, Pin-Wen Lin. Surgical resection of isolated pancreatic
tuberculosis presenting as obstructive jaundice. Pancreas 2000; 21:100-101. (SCI; Formal
journal of International society of pancreas)
74. Shin-Min Huang, Yan-Shen Shan*, Edgar D. Sy, Pin-Wen Lin. Superior mesentery artery
syndrome in post-spinal cord injury masquerading as peptic ulcer disease. Formosan J
Surg.2000; Vol33, No.5: 229-33.
75. Yan-Shen Shan, Edgar D.Sy, Chau-Jen Cheng.Duodenal obstruction secondary to phytobezoar
in a child. Surgically removed Via gastrostomy. Formosan J Surgery 1999; 32: 28-32.
76. Yan-Shen Shan, Jeng-Chang Lee, Pin-Wen Lin, I-H Su, Hsiao-Bai Yang. A rare abdominal
actinomycetoma mimicking invasive colon carcinoma-a case report. J Surg Assoc ROC 1996;
29: 244-8.
77. Yan-Shen Shan, Chung-Jye Hung, Pin-Wen Lin. Intestinal obstruction by gastrohepatic hernia
with reentry into the greater peritoneal cavity. Report of a case with review of the literature. J
Surg Assoc ROC 1996; 29: 353-7.
78. Pin-Wen Lin, Yan-Shen Shan. Portal hemodynamics and humoral factors involved in a portal
hypertensive rabbit model. Proceedings of the National Science Council, Part B: Life Sciences
1995; 19: P240-5. (SCI)
79. Pin-Wen Lin, Yan-Shen Shan. Deprivation of portal blood flow causes delaying in liver
regeneration. J Surg Assoc ROC 1995; 28: P427-33.
80. Pin-Wen Lin, Yan-Shen Shan. Effects of octreotide on the hemodynamics and glucagon level
in portal hypertensive rabbits. J Formosan Med Assoc 1994; 93: 668-72. (SCI)
81. Pin-Wen Lin, Yan-Shen Shan. Effects of splenectomy and splenic artery ligation on the portal
pressure in the portal hypertensive rats. J Surg Res 1992; 53: 621-4. (SCI)
82. Pin-Wen Lin, Yan-Shen Shan. Effects of splenectomy in experimental rats with short- and
long-term portal hypertension. J Formosan Med Assoc 1992; 91: 687-90. (SCI)
83. 沈延盛, 陳永榮. 腹部癲癇.當代醫學 1992 Aug; 226: 678-82.
84. Pin-Wen Lin, Yan-Shen Shan. Effects of splenectomy on pressure in portal hypertensive rats. J
Surg Assoc ROC 1990; 23: 208-12. (外科醫學會年度最佳論文, Annual best paper of Surgical
Association of ROC).
Page 69
葉坤輝
臺大醫院 腫瘤醫學部化學治療科 科主任
臺大醫學院 腫瘤醫學研究所 副教授
葉坤輝醫師，公元 1989 年於臺灣大學醫學院醫學系畢業，之後於母校附設醫院接受完整
的內科學與腫瘤內科學訓練，1995 年起於腫瘤醫學部擔任主治醫師，同時期並在母校臨床醫學
研究所研修博士學位，1998 年獲頒醫學哲學博士學位。1998 至 2000 年間，在美國耶魯大學
醫學院遺傳系從事癌症細胞周期調控相關之博士後研究。2000 年返院服務，2001 至 2006 年 8
月期間，專案教研服務於與臺大教學研究合作之亞東紀念醫院，擔任內科部主任兼醫學研究部
主任，內科系醫務副院長兼教學研究副院長等職務。2006 年 6 月亞東醫院升格為醫學中心，2006
年 9 月葉醫師返母院述職，並應聘母校副教授教職，2009 年 8 月葉醫師擔任化學治療科主任職
務，持續進行腫瘤醫學相關之研究、教學、與臨床工作。
葉醫師積極規劃並參與許多癌症治療之國際與國內臨床試驗，並進行癌症基礎與相關轉譯
研究，目前已發表研究結果於 80 餘篇國際知名期刊中，內容涵蓋胃癌、胃黏膜相關惡性淋巴
瘤(MALToma)、結腸癌、肝癌、食道癌與乳癌等領域。葉醫師積極參加各種國際與國內醫學會，
如 美國臨床腫瘤學會(ASCO)、美國癌症研究學會(AACR)、歐洲腫瘤內科學會(ESMO)、歐洲
癌症研究學會(EACR)、臺灣醫學會、內科醫學會、癌症醫學會等。受邀為英國癌症雜誌(Br J
Cancer)、Clinica Chimica Acta、Asia-Pacific J Clin Oncol、臺灣醫學會雜誌(JFMA)等 SCI
期刊審查委員。
Page 70
CURRICULUM VITAE
NAME: Jen-Shi Chen (陳仁熙)
SEX: Male
BIRTH DATE: November 1, 1958.
BIRTH PLACE: Taipei, Taiwan
CITIZENSHIP: Taiwan
HOME ADDRESS & TEL NO.: 2F 18, Lane 165, Dung Hwa North Road, Taipei, Taiwan. Tel:
+886-2-25467983
OFFICE ADDRESS & TEL NO.: Division of Hematology-Oncology, Department of Internal
Medicine, Chang Gung Memorial Hospital, 199 Tung-Hwa North Road, Taipei, Taiwan. Tel:
+886-3-328-1200 ext. 8825, Fax: +886-3-3278211
E-mail: js1101@adm.cgmh.org.tw
fong0301@ms18.hinet.net
TAIWAN PERMANENT REGISTRATION NO.: B100131xxx
LANGUAGE: Chinese, English
SPOUSE: Su-Fen Fong (Birth Date: March 1, 1962)
CHILDREN: An-Hsin Chen (Birth Date: August 14, 1989)
An-Ting Chen (Birth Date: June 13, 1991)
EDUCATION: 1977-1984, Bachelor of Medicine, China Medical College,
Taichung, Taiwan
POST-GRADUATE EDUCATION:
June 1983 - May 1984 Intern, Chang Gung Memorial Hospital (CGMH)
July 1984 - May 1986 Military service
July 1986 - June 1989 Resident, Department of Internal Medicine, CGMH
July 1989 - June 1991 Clinical Fellow, Division of Medical Oncology,
Department of Internal Medicine, CGMH
March 1995 - June 1995 Observer, Medical Oncology, MD Anderson Cancer
Center, Houston, USA
ACADEMIC APPOINTMENT:
Aug. 1993 - Oct. 2003
Nov. 2003 - present
March 2006 - present
2006-2009
Clinical lecturer, Chang Gung University.
Assistant Professor, Chang Gung University.
兼任老師 臺大護理學系暨研究所臨床護理師學程暨學
分班
長庚大學護理研究所碩士論文指導
Page 71
EMPLOYMENT RECORD:
July 1991 - present
Attending Physician,
Division of Hematology/Oncology
Department of Internal Medicine, CGMH.
July 1999 – 2010
Assistant Professor,
Division of Hematology/Oncology,
Department of Internal Medicine, CGMH.
2011
Associate Professor
Division of Hematology/Oncology,
Department of Internal Medicine, CGMH.
BOARD CERTIFICATION:
1990 Board of Internal Medicine, Taiwan, ROC.
1991 Board of Medical Oncology, Taiwan, ROC.
2005 Board of Clinical Oncology, Taiwan of Clinical Oncology Society (License No: 18)
License: Taiwan License No: 012334
Professional Affiliations:
American Society of Clinical Oncology.
European Society of Medical Oncology.
Taiwan Society of Internal Medicine.
The Chinese Oncology Society.
理事: May, 2001 to 2005.
出版委員會主任委員: Aug, 2003 to June, 2005
監事: July, 2005 to 2007
Hematology Society of ROC.
The Formonsan Association of Medicine.
The Society of Palliative Medicine and Hospice of Taiwan.
Taiwan Society of Pancreas.
Commiteeman, Committee of gastric cancer, Taiwan Co-operative Oncology Group. (TCOG)
Commiteeman, Committee of pancreatic cancer, Taiwan Co-operative Oncology Group. (TCOG)
Taiwan Society of Cancer Palliative Medicine, 監事 2004 to 2008
Taiwan Society of Cancer Palliative Medicine, 理事 2008 to 2010; 2010 -2012
Taiwan Cooperative Oncology Group(TCOG) 資料及安全監督委員會委員, 2009 至今
Taiwan Cooperative Oncology Group(TCOG) 計畫審查委員 2011 to 2012
The Chinese Oncology Society. 理事: May, 2011 to 2013.
Research Interest:
Clinical trial for Gastrointestinal Cancer & Quality of life.
Research Projects:
NSC86-2314-B255-002, 1997, Co-investigator:
A validation of different clinical response criteria for gastric cancer with weekly
high-dose 5-fluorouracil and leucovorin 24-hr continous therapy.
Page 72
NSC-87-2314-B182-112, 1998 Co-investigator:
The impact of chemotherapy protocols and exercise program on the clinical
indicator for patients with gastric cancer.
NSC-89-2320-B-182-044, 1999 Co-investigator:
Nursing interventions for cancer fatigue: outcome measure and clinical
Utilization.
SMRP134, Principle Investigator, Feb 1999 to August 2002:
Open label, randomized multicenter phase II/III study of docetaxel in
combination with Cisplatin (CDDP)or Docetaxel in combination with
5-Fluorouracil(5-FU) and CDDP compared to combination of CDDP and 5-FU
in patients with metastatic or locally recurrent gastric cancer previously
untreated with chemotherapy for advanced disease.
SMRP89-85, Principle investigator, Oct 2000 to Sep 2002:
The efficacy and safety of Tegafur-Uracil (UFUR) plus leucovorin in the
treatment of advanced biliary tract cancer.
XMRP049, Principle investigator, Jan 2001 to March 2002
Efficacy and safety study of PNU-93914 (liposome encapsulated paclitaxel) in
patients with advanced gastric cancer previous exposed to chemotherapy.
XMRP049, Principle investigator, Dec 2001 to Dec 2006
Phase I/II study of Oxaliplatin (Oxalip) with oral tegafu-uracil (UFUR) and
leucovorin in patients with advanced gastric cancer.
XMRP115, Principle investigator, Dec 2001 to Dec 2005.
A randomized phase III trial of Alimta + Gemzar vs Gemzar monotherapy in
chemonaive patients with local advanced and metastatic pancreatic cancer.
XMRP214, Principle investigator, Jan, 2003 to JUL 2005.
Doulble-blind, palcebo-controlled, randomixed phase III trial of oral
thalidomide in advanced hepatocellualr carcionma with poor liver reserve
XMRP298, Principle investigator, Feb, 2004 to Dec 2006.
A phase II efficacy and safety of intravenous Endotcarin in patients with advanced gastric
cancer that has been progressed or recurred after prior fluoropyrimidine-based
chemotherapy
XMRP297, Principle investigator, Feb, 2004 to Dec 2006.
Phase I/II study od Alimta and Cisplatin in patients with advanced gastric cancer.
T2202 (Taiwan Cooperative Oncology Group), Principle investigator, closed
Double-blind, Placebo-controlled, Randomized Phase Ⅲ Trail of Oral Thalidmide in
Advanced Hepatocellular Carcinoma with Poor Liver Reserve
T1204 (Taiwan Cooperative Oncology Group), Principle investigator, closed
Page 73
每週靜脈注射 Gemcitabine 及 24 小時高劑量 5-FU/Leicovorin 以治療進行性或
轉移性膽道系統癌
國健局安寧共同照護研究計劃協同主持人和長庚紀念醫院林口總院聯絡人,
Macrh 1, 2004 to July 2006
XMRPG340102, Principle investigator, Sep 2005 to Dec 2006.
An randomized, double blind, placebo controlled, multicentre phase III trial to evaluate
the efficacy and safety of adding Bevacizumab to gemcitabine and erlotinib in patients
with metastatic pancreatic cance
XMRPG350082, Principle investigator, Feb, 2006 to 2007.
以 S-1 為第一線化學治療局部進展性或轉移性胃癌之藥物動力學及第二期臨床
研究
XMRPG350301 Principle investigator, June 2006 to July 2008
以 SU011248 治療曾經接受過化學治療後，疾病復發或惡化之轉移或晚期胃癌病人.
XMRPG350482 Principle investigator, Feb 2007 to 2008
A Phase II Study of Irinotecan (Irinoâ) in Combination with Cisplatin as Second Line
Chemotherapy in Patients with Metastatic or Locally Advanced Gastric Cancer.
XMRPG360191 Principle investigator, April 2007 to 2008
A Phase II Study of Weekly Eloxatin Combined with Taxotere as First-Line Treatment in
Patients with Advanced Gastric Cancer
XMRPG360741 Principle investigator, Nov 2007 to present
第三期隨機雙盲臨床試驗以 Sunitnib 或安慰劑治療逐漸惡化胰臟內分泌瘤
XMRPG370531 Principle investigator,
以 RAD001 10mg/d 加上最佳支持性照護 v.s 安慰劑加上最佳支持性照護作為晚期胰
臟神經內分泌腫瘤. [ IRB NO.97-0232A ]
T3207 (Taiwan Cooperative Oncology Group), Principle investigator
A Randomized Phase III Study of Adjuvant Gemcitabine versus Gemcitabine Plus Concurrent
Chemoradiation in Pancreatic Cancer Underwent Curative Intent (R0 / R1) Resection
XMRPG390061 Principle investigator Jan 2010 to present
Ixabepilone 第二階段研究：用於先前的化療以 Fluoropyrimidine 為主之患有無法切除或轉
移胃癌. [IRB NO. 98-2415A]
XMRPG370711 Principle investigator
Gemcitabine 或 TS-1 或 Gemcitabine 合併 TS-1 治療局部進展性或轉移性胰臟癌之隨機分組
第三期臨床試驗 [ IRB NO.97-1185A] 2008/12/1 to 2009/11/30
XMRPG380352
Principle investigator, May 2009 to present
Page 74
NC-6004 合併使用 Gemcitabine 化學治療模式在局部晚期及轉移性胰臟癌病患於亞洲國家
之臨床一、二期試驗 [ IRB NO.97-2084A]
XMRPG380332 Principle investigator, May 2010 to present
一項隨機分配、開放性、多中心、第Ⅲ期臨床試驗，在無法切除或轉移性胃腸道期質瘤(GIST)
成人病患 [ IRB NO.97-2349A3 ]
XMRPG380382 Principle investigator, July 2010 to present
EXPAND (Erbitux 併用 Xeloda 與 cisplatin，用於治療晚期胃癌)開放標示、隨機分配、對
照、多試驗中心 [ IRB NO.97-0469A ]
XMRPG380582 Principle investigator, July 2009 to present
BIBW2992 開放性臨床二期研究，用以治療經基因預篩選確定有 EGFR 與／或 HER2 基因
擴增（gene amplification）於食道癌 胃癌 膽道癌及膀胱癌晚期病人 [ IRB NO.98-0555A ]
XMRPG370432 XMRPG380582 Principle investigator, July 2009 to present
一項以 Lapatinib(GW572016)併用每週一次 Paclitaxel，與每週一次 Paclitaxel 單方，作為
ErbB2 陽性晚期胃癌
NSC 96-2314-B-182-029-MY2. Co-investigator:
Impact of caregiving on bereavement outcome for family caregivers of terminally ill cancer
patients.
NSC 98-2314-B-182-052 2009, 08-2010, 07. Co-investigator:
The impact of “self-perceived burden to others” and “posttraumatic growth” on quality of life
for terminally ill cancer patients.
NSC 99 - 2628 - B - 182 - 031 - MY2. 2010, 08-2012, 07, Co-investigator:
A continued study of the impact of “self-perceived burden to others” and “posttraumatic
growth” on quality of life for terminally ill cancer patients.
DOH96-HP-1510 2007/10 至 2008/10 Co-investigator:
利用健保資料分析癌症病人非因疾病末期死亡估算之可行性分析
BIBLIOGRAPHY:
Publications:
1. Chen JS, Wang JM, Liaw CC, Ng KT, Ho YS: Klinefelter‘s syndrome associated with mediastinal
germ cell tumor: report of a case. J Chinese Oncol Soc 6: 21-25, 1990
2. Kiu MC, Hsueh S, Ng SH, Chen JS: Elevated serum CA-125 in tuberculous peritonitis: report of
a case. J Formos Med Assoc 93: 816-818, 1994
3. Huang JS, Liaw CC, Chen JS, Fang KM, Yen CL, Lai GM: Combinant chemotherapy with a
modified schedule of etoposide, adriamycin and cisplatin (EAP) regimen for advanced gastric
adenocarcinoma. J Chinese Oncol Soc 10: 12-21, 1994
4. Chen JS, Liaw CC, Wang HM, Tsai MH, Hao SP, Hsueh S: Osteosarcoma of jaw: the experience
of Chang Gung Memorial Hospital. Chang Gung Med J 18: 260-265, 1995
Page 75
5. Kiu MC, Chang CN, Cheng WC, Lin TK, Wong CW, Tang SG, Leung WM, Chen JS, Lai GM et
al: Combination chemotherapy with carmustine and cisplatin before, during, and after
radiotherapy for adult malignant gliomas. J Neuro Oncol 25:215-220, 1995.
6. Wang HM, Wang CH, Chen JS, Chang HK, Kiu MC, Liaw CC, Ng KT, Lai GM: Cisplatin and
5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell
cancer. J Formos Med Assoc 94: 87-94, 1995
7. Ho YS, Hsieh LL, Chen JS, Chang CN, Lee ST, Chiu LL, Chin TY, Cheng SC: p53 gene mutation
in cerebral primitive neuroectodermal tumor in Taiwan. Cancer Lett 1996 Jun 24;104(1):103-113.
8. Wang CH, Wang HM, Chen JS, Chang WJ, Lai GM: Intensive chemotherapy plus recombinant
human granulocyte-colony stimulating factor support for distant metastatic nasopharyngeal
carcinoma. Oncology 54:34-37, 1997
9. Liaw CC, Wang CH, Huang JS, Kiu MC, Chen JS, Chang HK: Serum lactate dehydrogenase level
in patients with nasopharyngeal carcinoma. Acta Oncol 36: 159-164, 1997
10. Cheng YT, Huang CT, Leu HS, Chen JS, Kiu MC: Central nervous system infection due to
clostridium septicum: a case report and literature review. Infection 25: 171-174, 1997
11. Liaw CC, Chuang CK, Chen JS, Chang HK: Gastric cancer with obstructive uropathy: clinical
experience with 17 cases. Chang Gung Med J 20: 286-292, 1997.
12. Chen JS, Lai GM, Hsueh S: Malignant thyroid teratoma of an adult: a long-term survival after
chemotherapy. Am J Clin Oncol 21: 212-214, 1998
13. Chen JS, Jan YY, Lin YC, Wang HM, Chang WC, Liau CT: Weekly 24-hour infusion of
high-dose 5-flurouracil (5-FU) and leucovorin (LV) in patients with biliary tract carcinomas.
Anti-Cancer Drugs 9: 393-397, 1998
14. Liaw CC, Chen JS, Wang CH, Chang HK, Huang JS: Tumor fever in patients with
nasopharyngeal carcinoma: clinical experience of 67 patients. Am J Clin Oncol 21: 422-425, 1998.
15. Chung CM, Chu PH, Chen JS, Hsueh C, Chiang CW: Primary pericardial mesothelioma with
cardiac tamponade and distant metastasis: case report. Chang Gung Med J 21: 498-502, 1998.
16. Liaw CC, Wang HM, Wang CH, Yang TS, Chen JS, Chang HK, Lin YC, Liaw SJ, Yeh CT: Risk
of transient hyperammonemia encephalopathy in cancer patients who received continous infusion
of 5-fluorouracil with the complication of dehydration and infection. Anti-Cancer Drugs 10:
275-281, 1999.
17. Chen JS, Liu HE, Wang CH, Yang TS, Wang MH, Liau CH, Chang WH, Lin YC: Weekly 24-hour
infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced gastric
cancer. Anti-Cancer Drugs, 10: 355-359, 1999.
18. Wang HM, Wang CH, Chen JS, Su CL, Liao CT, Chen IH: The impact of oral submucous fibrosis
on the chemotherapy-induced mucositis for the head and neck cancer in a geographic area in
which betal quid chewing is prevalent. Am J Clin Oncol 22: 485-488. 1999.
19. Lin YC, Liu HE, Wang CH, Wang HM, Yang TS, Liau CT, Chen JS*. Clinical benefit and
response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil
(5-FU) and leucovorin(LV). Anticancer Research 19: 5615-5620, 1999. (SCI；IF= 1.428；Oncology
126/166)
20. Yang TS*, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with
advanced hepatocellular carcinoma. Cancer 89; 750-6, 2000. (SCI；IF= 5.418；Oncology 21/166)
21. Lin YC*, Hsien-Kun Chang, Wang CH, Chen JS, Liaw CC. Single-agent docetaxel in metatstatic
breast cancer patients pretreated with antracyclines and paclitaxel: partial cross-resistance between
paciltaxel and docetaxel. Anti-Cancer Drugs 11; 617-621, 2000. (SCI；IF= 2.230; Pharmcology
and Pharmacy 123/237)
22. Yeow KM*, Wang CH, Liaw CT, Chen JS, KO Wu, PN Wang. The groshong peripheral inserted
central (PIC) catheter: initial experience with ultrasound-guided insertion. 中華民國放射線醫學
會雜誌 24; 61-66, 2000.
Page 76
23. Yeow KM*, Tan CF, Chen JS, Hsueh C. Diagnostic sensitivity of ultrasound-guided needle
biopsy in soft tissue masses about superficial bone lesions. J Ultrasound Med 19: 849-55, 2000.
(SCI；IF= 1.181; Acoustics 12/28)
24. Wang HM*, Wang CH, Liaw CT, Chen JS, Yang TS, Chen IH. Intra-arterial plus intravenous
chemotherapy for advanced bulky Squamous cell carcinoma of buccal mucosa. Anti-Cancer Drugs
12; 331-7, 2001. (SCI；IF= 2.230；Pharmcology and Pharmacy 123/237)
25. Chen JS*, Lin YC, Jan YY, et al. Mitomycin C with weekly 24-hour infusion of high-dose
5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Anti-Cancer Drugs 12; 339-43, 2001. (SCI;IF= 2.230；Pharmcology and Pharmacy 123/237)
26. Lin YC*, Chen JS, et al. Weekly high-dose 5-fluorouraicl, leucovorin and biweekly cisplatin in
patients with advanced gastric cancer. Jpn J Clin Oncol 31(12): 605- 09, 2001. (SCI；IF=1.498;
Oncology 122/166)
27. Pan KY, Lin JL*, Chen JS. Severe reversible bone marrow suppression induced by Selanginella
doederleinii. Clinical Toxicology. 39(6): 637-39, 2001. (SCI；IF=1.46; Toxicology 56/77)
28. Wang SH*, Hsieh CC, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF, Chen PC, Chen JS,
Hsueh S. Resectable gastric cancer: operative and survival analysis. Chang Gung Med J. 25(4):
228-37, 2002.
29. Wang HM*, CH Wang, Chen JS, Chen IH, Liao CT, Chang TCJ. Cisplatin, tegafur and leucovorin:
A moderately effective and minimally toxic outpatient neoadjunant chemotherapy for locally
squamous cell carcinoma of the head and neck. Cancer 94; 2898-95, 2002. (SCI；IF= 5.418；
Oncology 21/166）
30. Yang TS*, Wang JY, Tang R, Hsu KC, Chen JS. Oral uracil/tegafur UFT plus leucovorin as
first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucorvin for
the treatment of metatstatic colorectal cancer. Jpn J Clin Oncol 32(9): 352-357, 2002. (SCI；
IF=1.498; Oncology 122/166)
31. Yang TS*, CH Wang, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the
treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol
2002(13); 1771-78. (SCI；IF= 5.647；Oncology 20/166）
32. Liaw CC*, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete
protection from emesis for womwn during chemotherapy cycles. Am J Clin Oncol 2003 (26):
12-15. (SCI；IF= 2.206; Oncology 91/166）
33. Chen JS*, Lin YC, Wang CH, Liaw CC. Mitomycin with weekly 24-hour infusion of high-dose
5-fluorouracil and leucorvin in patients with advacned gastric cancer. Chang Gung Med J, 2003:
26 (June): 433-39,
34. Lin MH. Chen JS, Chen HH, Su WH*. A phase II trial fo gemcitabine in the treatment of
advcanced bile duct and periampular carcinoma. Chemotherapy, 2003 (49): 154-158. (SCI；IF=
2.028；Pharmcology and Pharmacy 137/237)
35. Chen JS*, Yang TS, Lin YC, Jan YY. A phase II trial of tegafur-uracil and uracil in the treatment
of advanced viliary tarct carcinomas. Jpn J Clin Oncol 2003 ; 33(7): 353-356. (SCI; IF=1.498;
Oncology 122/166)
36. Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hus CH, Liu TY, Li CC, Chen JS, Wu CY, Cheng
AL*. Weekly gencitabine plsu 24-h infusion of high-dose 5-fluorouracil/leucorvin for locally
advanced or metastatic carcinoma of the biliary tract. Brit J Cancer 2004; 90:1715-1719. (SCI；IF=
4.346; Oncology 35/166)
37. Sheen WC, Chen JS, Wang HM, Yang TS, Liaw CC, Lin YC*. A modified low-dose regimen of
mitoxantrone and predisolone in patients with androgrn-independent prostate cancer. Jpn J Clin
Oncol 2004; 34(6): 337-341. (SCI; IF=1.498; Oncology 122/166)
38. Yang TS*. Chang HK. Chen JS. Lin YC. Liau CT. Chang WC. Chemotherapy using
5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an
Page 77
analysis of 63 cases. Journal of Gastroenterology. 39(4):362-9, 2004.
(SCI; IF=2.909; Gastroenterology & Hepatology 20/66)
39. Chen JS*, Huang JS, Yang TS, Lin YC, Wang HM, Liau CT, Rau KM. Phase I dosing-escalating
study of oxalipaltin in combination with oral tegafur-uracil and leucorvin in patients with
advanced gastric cancer. Anti-Cancer Drugs, 2005;16: 47-51. (SCI;IF= 2.230；Pharmacology and
Pharmacy 123/237)
40. CT Liau, Chu NM, Liu HE, Deuson R, Lien J, Chen JS*. Incidence of chemotherapy-induced
nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcome.
Suppotive Care in Cancer, 2005;13(5): 277-286. (SCI;IF= 2.089; Rehabitation 8/33)
41. CC Liaw*, CG Wang, HS Chang, HM Wang, JS Huang, YC Lin, JS Chen. Cisplatin-related
hiccupc: male predominance, induction by desamethasone, and protection against nausea and
vomiting. J of Pain & Symptom Management, 2005; 30 (No 4): 359-366. (SCI;IF=2.423；Health
care service and service 17/69)
42. WC Chou, SM Jung, Chen JS*, Spontaneous intrcranial tumor bleeding from metastatic
heptaocelullar carcinoma: a case report. J. Chinese Oncol Soc 2004; 20 (2): 10-21. (publication on
Oct 26, 2005)
43. YC Lin, HK Chang, Chen JS, HM Wang, TS Yang and CC Liaw. A Phase II randomized study of
two Taxanes and Cisplatin for metastatic breast cancer after anthracycline: A final analysis. Jpn J
Clin Oncol 2007; 37: 23-29. (SCI; IF=1.498; Oncology 122/166)
44. Lin YC*, Chang KH, Shen WC, Chen JS, Wang HM. An open-labeled pahse II tiral of docetaxel
incombination with cisplatin as first-line cytoxic therapy for antracyclin-naïve patinets with
metastatic breast cancer. Anti-Cancer Drugs 2007, 18: 1213-19. (SCI;IF= 2.230；Pharmcology and
Pharmacy 123/237)
45. Chou WC. Lu CH. Lin G. Hong YS. Chen PT. Hsu HC. Chen JS. Yeh KY. Wang HM. Liaw
CC*. Transcutaneous arterial embolization to control massive tumor bleeding in head and neck
cancer: 63 patients' experiences from a single medical center. Supportive Care in Cancer.
15(10):1185-90, 2007 Oct. (SCI;IF= 2.089; Rehabitation 8/33)
46. Chu Z. Chen JS. Liau CT. Wang HM. Lin YC. Yang MH. Chen PM. Gardner ER. Figg WD.
Sparreboom*. A. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered
with cyclosporin A in cancer patients. Anti-Cancer Drugs. 19(3):275-81, 2008 Mar. (SCI; IF=
2.230；Pharmcology and Pharmacy 123/237)
47. Liaw CC, Chen JS *, Chang HK, Huang JS, Yang TS, Liau CT. Symptoms and signs of
port-related infections in oncology patients related to the offending pathogens. Int J of Clinic
Practice 2008; 62: 1193-8. (SCI; IF= 2.245; Medicine, General & Internal 31/132)
48. Hsu HC, Chang HK, Lin YC, Hseu C, Chen JS, Yang TS, Wang HC, Shen YC*. The role of
HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. Chang Gung
Medical J, 2009; 32 (1): 33-41.
49. Tang ST*, Wu SC, Hung YN, Huang EW, Chen JS, Liu TW. Trends in quality of end-of-life care
for Taiwanese cancer patients who died in 2000–2006. Ann Oncol 2009; 20: 343-349 (SCI；IF=
5.647；Oncology 20/166)
50. Chen JS*, Rau KM, Chen YY Huang JS, Yang TS, Lin YC, Liau CT, Lee KD, Su TC, Kao RH. A
multiple-center phase II study of biweekly oxaliplatin and tegafur- uracil/ leucovorin for
chemonaive patients with advanced gastric cancer. Cancer Chemother Pharmacol 2009; 63:
818-825. (SCI;IF= 2.654；Pharmcology and Pharmacy 96/237)
51. Ch'ang HJ, Huang CL, Wang HP, Shiah HS, Chang MC, Jan CM, Chen JS, Tien YW, Hwang TL,
Lin JT, Cheng AL, Whang-Peng J, Chen LT*. Phase II study of biweekly gemcitabine followed by
oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced
pancreatic cancer. Cancer Chemother Pharmacol 2009; 64: 1173-9. (SCI;IF= 2.654；Pharmcology
and Pharmacy 96/237)
Page 78
52. Chen JS*, Chao Y, Yang TS, Chou WC, Chen LT, Lee KD, Lin YC. A phase II trial of biweekly
oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for
advanced biliary tract carcinoma. Cancer Chemother Pharmacol. 2009; 65: 151-57. (SCI;IF=
2.654；Pharmcology and Pharmacy 96/237)
53. Tang ST*, WuSC, Hung YN, Chen JC, Huang EW, Liu TW. Determinants of Aggressive
End-of-Life Care for Taiwanese Cancer Decedents, 2001 to 2006. J Clin Oncol 2009 : 4613-18.
(SCI; IF= 17.793；Oncology 4/166)
54. Chen JS, Wang HM, Wu SC, Liu TW, Hung YN, Tang ST*.A population-based study on the
prevalence and determinants of cardiopulmonary resuscitation in the last month of life for
Taiwanese cancer decedents, 2001-2006. Resuscitation 2009; 80: 1388-93. (SCI; IF= 2.712；
Emergency Medicine 2/19)
55. Liu TW, Chen JS, Wang HM, Wu SC, Hung YN, Tang ST*. Quality of end-of-life care between
medical oncologists and other physician specialists for Taiwanese cancer decedents, 2001-2006.
Oncologist. 2009 Dec; 14 (12):1232-41 (SCI; IF= 6.701；Oncology 17/166)
56. Tang ST*, Huang EW, Liu TW, Wang HM, Chen JS. A population-based study on the
determinants of hospice utilization in the last year of life for Taiwanese cancer decedents,
2001-2006. Psych-Oncology 2010 Jan 29 [Epub ahead of print] (SCI ; IF 2.684, Psychology,
multidisciplinary 16/111).
57. Wu SC, Chen JS, Wang HM, Hung YN, Liu TW, Tang ST. Determinants of ICU care in the last
month of life for Taiwanese cancer decedents, 2001-2006.Chest 2010 Apr 2. [Epub ahead of print]
(SCI; IF= 6.363；Respiratory system 3/43)
58. Bang YJ*, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng
WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A. Phase II study of sunitinib as
second-line treatment for advanced gastric cancer. Invest New Drugs. 2010 May 12. [Epub ahead
of print] (SCI;IF= 3.072；Pharmcology and Pharmacy 72/237)
59. Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP,
Shen LJ, Lin C*. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients
with unresectable, advanced gastric carcinoma. Anti-Cancer Drugs. 2010 Sep, 21 (8):777–784
(SCI;IF= 2.230；Pharmcology and Pharmacy 123/237)
60. Chen JS, Chao Y, Hsieh RK, Cheng AL, Chen PM, Chiou TJ, Chao TY, Yeh KH, Chen LT,
Whang-Peng J*. A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer
in Taiwan. Cancer Chemother Pharmacol. 2010 Aug 17. [Epub ahead of print] (SCI;IF= 2.654；
Pharmcology and Pharmacy 96/237)
61. Liaw CC*, Huang JS, Chen JS, Chang JW, Chang HK, Liau CT. Using vital sign flow sheets can
help to identify neoplastic fever and other possible causes in oncology patients: a retrospective
observational study. J Pain Symptom Manage. 2010 Aug; 40(2):256-65. (SCI;IF=2.423；Health
care service and service 17/69)
62. Tang ST*, Tang WR, Liu TW, Lin CP, Chen JS. What really matters in pain management for
terminally ill cancer patients in Taiwan. Journal of Palliative Care 26:3 / 2010; 151–158.
(SCI;IF= 1.837；Health care service and service 30/69)
63. Tang ST, Huang EW, Liu TW, Wang HM, Rau KM, Chen JS. Aggressive End-of-Life Care
Significantly Influenced Propensity for Hospice Enrollment Within the Last Three Days of Life
for Taiwanese Cancer Decedents. J Pain Symptom Manage. 2010 Sep 7. [Epub ahead of print]
64. Wang LH, Tsai YF, Chen JS, Tsay PK. Intension, needs, and expectations of cancer patients
participating in clinical trials. Cancer Nurs. 2011 Mar-Apr; 34(2):117-23.
65. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P,
Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu
DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic
neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13
Page 79
66. Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin
PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT. Induction
Chemotherapy with Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by
Concomitant Chemoradiotherapy in Patients with Locally Advanced Pancreatic Cancer: A Taiwan
Cooperative Oncology Group Phase II Study. Int J Radiat Oncol Biol Phys. 2011 Mar 21.
[Epub ahead of print]
67. Shen WC, Yang TS, Hsu HS, Chen JS (Correspondence) . A Phase II Study of Irinotecan in
Combination With Cisplatin as Second-line Chemotherapy in Patients with Metastatic or Locally
Advanced Gastric Cancer Chang Gung Medical Journal (accepted, in press) 2011.
68. Chen JS, Chen YY, Huang JS, Yeh KY, Chen PT, Shen WC, Hsu HC, Lin YC, Wang HM. A
multiple-centre phase II study of weekly docetaxel and oxaliplatin as first-line treatment in
patients with advanced gastric cancer. Gastric Cancer (accepted, in press) 2011.
Presentations:
1. Small cell carcinoma of unknown primary. The annual meeting of Chinese Oncology Society,
Taipei, May 1996.
2. Weekly high dose 24-hour infusion 5-FU and Leucovorin in patietns with metastatic
pancreati-biliary tract cancer, The annual meeting of Chinese Oncology Society, Taipei, May
1997.
3. Clinical response, Quality of Life and Clinic Benefit in patients with metastatic gastric cancer
treated with weekly high dose 24-hour infusion 5-FU and Leucovorin.
5th Sino-Japan symposium for cancer treatment: gastric cancer from basic to clinic. Taipei, Oct.
1997. (invited speaker)
4. Weekly high dose 24-hour infusion 5-FU and Leucovorin in patients with metastatic biliary tract
cancer. 4th Asia-Pacific Cancer Conference(APCC), Hong Kong, Nov, 1997.
5. A validation of different clinical response criteria for gastric cancer with weekly high-dose
5-fluorouracil and leucovorin 24-hr continous therapy. 34th annual meeting of American Society
of Clinical Oncology, Los Angeles, May 1998.
6. Cisplatin, tegafur, & leucovorin: An effective, nontoxic, and outpatient neoadjuant chemotherapy
for squamous cell carcinoma of the head and neck. 35th annual meeting of American Society of
Clinical Oncology, Atlanta, May 1999.
7. Mitomycin with 24-hr high-dose of 5-FU & LV in patient with advanced biliary tract cancer.
Annual meeting of Chinese Oncology Society, May 2000.
8. The chemotherapy for advanced gastric cancer- Chang Gung Memorial Hospital experience. 4th
Terry-Fox International Cancer Symposium. Oct 21, 2000. Linkuo, Taiwan.
9. Mitomycin with 24-hr high-dose of 5-FU & LV in patient with advanced gastric cancer. 4th Asia
Society of Clinical Oncology and Annual meeting of Chinese Oncology Society, April 2001.
Taipei, Taiwan.
10. A phase II study of Gemcitabine for patients with advcnaced biliary tract and periampullar vater
cancers. Elly Lilly Local regional Oncology Meeting. Hong Kong, March 9-10, 2002. (invited
speaker)
11. A phase II trial of tegafur-uracil and uracil in the treatment of advanced biliary tarct carcinomas.
The annual meeting of Chinese Oncology Society, Taipei, July, 2003.
12. Phase I dosing-escalating study of oxalipaltin in combination with oral tegafur-uracil / leucorvin in patients
with advanced gastric cancer. Gastrointestenial Cancer symposium by American Society of Clinical
Oncology , San Francisco, Jan 21, 2004.
13. Efficacy and Safety for Phase I/II Study of Biweekly OXA and Tegafur-Uracil /LV for Advanced
Gastric Cancer. The 2005 ISGIO Gastrointinal Oncology Conference, Arlington, Virgina, USA.
July 14, 2005.
14. A Multiple Center Phase II Study of Biweekly Oxaliapltin (OXA) and tegafur- Uracil / Leucorvin
(LV) in Chemonaive Patients With Advanced Gastric Cancer.
Page 80
7th Asian Clinical Oncology Society Annual Meeting, Sep 13-15, 2006. Bejing, China
15. A phase II trial of oxalipaltin with high-dose of 5-FU/LV in the first line treatment of inoperable,
locally advanced or metastatic biliary tract cancer. 14th European Conference of Cancer (ECCO),
Sep 23-27, 2007. Barcelona, Spain.
16. A Pharmacokinetic and Phase II Study of S-1 as First Line Chemotherapy in Patients with Locally
Advanced or Metastatic Gastric Cancer. 2008 Gastrointestinal Cancers Symposium. Jan 25-27,
2008, Orlando, Florida, USA
17. A Phase II Study of Irinotecan (Irinoâ) in Combination with Cisplatin as Second Line
Chemotherapy in Patients with Metastatic or Locally Advanced Gastric Cancer. The 13th Taiwan
Joint Cancer Conference, May 3 –4, 2008. Taipei, Taiwan.
18. A Phase II Study of Weekly Eloxatin Combined with Taxotere as First-Line Treatment in Patients
with Advanced Gastric Cancer: Preliminary Report of Feasibility Analysis. The 13th Taiwan Joint
Cancer Conference, May 3 –4, 2008. Taipei, Taiwan.
19. A Pharmacokinetic and Phase II Study of S-1 as First Line Chemotherapy in Patients with Locally
Advanced or Metastatic Gastric Cancer. Final report (oral report). The 13th Taiwan Joint Cancer
Conference, May 3 , 2008. Taipei, Taiwan.
20. The Role Of Oxaliplatin And Docetaxel in The Treatment Of Advanced Gastric Cancer (invited
speaker). The 13th Taiwan Joint Cancer Conference, May 4 , 2008. Taipei, Taiwan
21. Practice and perspective of chemotherapy for advanced gastric cancer. (invited speaker) Satellite
International Symposium of 81st Annual meeting of Japan Gastric Cancer Association. March 8,
2009, Kyoto, Japan.
22. A Phase II Study of Weekly Eloxatin Combined with Taxotere as First-Line Treatment in Patients
with Advanced Gastric Cancer: 14th Taiwan Joint Cancer Conference, May 3 , 2008. Taipei,
Taiwan. May2- 3 , 2009, Taipei, Taiwan.
23. A Phase II Study of Weekly Eloxatin Combined with Taxotere as First-Line Treatment in Patients
with Advanced Gastric Cancer: ECCO14-34ESMO Sep 20-24, Berlin, German.
24. Management of Malignant Functional Pancreatic Neuroendocrine Tumor with Somatostatin
Analogue. Taiwan Pancreatic Neuroendocrine Tumor meeting, Taipei, Oct. 2009
25. The Chemotherapy in Patient With Biliary Tract Cancer: Experience of Chang Gung Memorial
Hospital. The Japan-Taiwan joint symposium on Medical Oncology. Nov 2009.
26. Octreotide Long-acting Release for Patients with Functional Gastroenteropancreatic
Neuroendocrine Tumors - An Experience in Chang Gung Memorial Hospital. May 2010 Taiwan
Joint Cancer Conference
Honor:
1. The best Chief Residence in 1989-1990 (CGMH).
2. The best chart record of attending physican in Chang Gung Memorial Hospital in 2003.
3. The best paper of The 12th Taiwan Joint Cancer Conference, May , 2007. Taipei, Taiwan
References:
1. Lee-Yung Shih, M.D.
Professor
Division of Hematology-Oncology
Department of Internal Medicine
Chang Gung Memorial Hospital
Taipei, Taiwan.
2. Yi-Yin Jan, MD
Chief & Professor,
Department of General Surgery,
Chang Gung Memorial Hospital.
Taipei, Taiwan.
Page 81
3. Siew -Tzuh Tang, D.N. Sc.,
Professor,
Graduate School of Nursing,
Chang Gung University,
259 Wen-Hwa 1st Road, Kwei-Shan,
Tao-Yuan, Taiwan
4. Chang-Chi Liaw, MD
Clinical Professor
Division of Hematology-Oncology
Department of Internal Medicine
Chang Gung Memorial Hospital
Taipei, Taiwan.
Page 82